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I. Abstract 
 
 
Out of all gynaecological cancers, epithelial ovarian cancer (EOC), a mainly sporadically 
occurring disease affecting postmenopausal women, exhibits the highest fatality-to-case 
ratio. Further research is therefore urgently required to combat the disease. In previous 
studies, our group identified the IgLON protein OPCML to be an important, frequently 
epigenetically inactivated (>80%) tumour suppressor in EOC. On the molecular level, OPCML 
functions by directly interacting with and subsequently endocytotically downregulating a 
broad repertoire of receptor tyrosine kinases (RTKs). 
During this PhD project, the aim was to determine if LSAMP and NEGR1, two further IgLON 
family members, function in a similar manner. Bioinformatic approaches as well as in vitro 
experiments were used to address issues such as sequence similarity, colocalisation or 
interaction; furthermore, overexpression and knockdown clones were generated to 
determine the impact of IgLON presence/absence on cellular characteristics such as RTK 
expression, proliferation or migration. While LSAMP was found to potentially function in a 
similar manner as OPCML in the ovarian cancer cell line SKOV3 by reducing RTK expression, 
proliferation and colony formation, its functions in the ovarian epithelial surface cell line 
OSE-C2 were less clear and require further validation. For NEGR1, a striking downregulation 
of RTKs, including those which had been unaffected by OPCML in previous experiments – 
such as EGFR, HER3 or FGFR2 – was observed in transfected SKOV3 cells. Downregulation 
seemed to occur both via lysosomal and proteasomal pathways, and resulted in substantial 
reduction of cell proliferation and colony formation. 
Overall, these results suggest that the IgLON family could function as a broad regulator of 
RTK expression and function. Since IgLONs are extracellular proteins, they represent 
excellent subjects for drug development as no intracellular delivery or gene therapy is 
necessary. To our knowledge, this is the first report investigating the functional properties 
of LSAMP and NEGR1 in epithelial ovarian cancer. 
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gDNA Genomic DNA 
h Hour(s) 
HER2 Human epidermal growth factor receptor 2, ErbB2 
HGS(C) High-grade serous (carcinoma) 
His Histidine 
HNT Gene encoding human neurotrimin 
IFM Immunofluorescence microscopy 
Ig Immunoglobulin 
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Abbreviation Explanation 
IgCAM Immunoglobulin domain-containing cell adhesion molecule 
IgSF Immunoglobulin superfamily 
IP Intraperitoneal 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
IU International unit 
IV Intravenous 
kb Kilo base pairs 
kDa Kilo dalton 
Kilon Rat homologue of NEGR1 
LAMP 
Limbic system-associated membrane protein; rat and chicken 
homologue of human LSAMP 
L-G L-glutamine 
LMP Low malignant potential 
LOH Loss of heterozygosity 
LSAMP Limbic system-associated membrane protein 
m Milli (as prefix) 
m Metre (as suffix) 
MCS Multiple cloning site 
min Minute(s) 
MW Molecular weight 
n Nano 
NCBI National Center for Biotechnology Information, USA 
NCI National Cancer Institute, USA 
NEGR1 Neuronal growth regulator 1 
Neurotractin Chicken homologue of NEGR1 
nt Nucleotide(s) 
Ntm Rat homologue of human neurotrimin 
o/n Over night 
OBCAM 
Opioid-binding cell adhesion molecule; rat and chicken homologue 
of human OPCML 
OPCML Opioid-binding protein/cell adhesion molecule 
OSE Ovarian surface epithelium 
p Pico (as a prefix for units) 
p Phosphorylated (as a prefix for molecule names) 
P/S Penicillin/Streptomycin 
PBS Phosphate-buffered saline 
PBST Phosphate-buffered saline containing 0.1% Tween®-20 
PCR Polymerase Chain Reaction 
Pen Penicillin 
Puro Puromycin 
qRT-PCR Quantitative real-time PCR 
R Reverse (primer) 
RefSeq Reference sequence according to the NCBI 
RNA Ribonucleic acid 
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Abbreviation Explanation 
rpm Revolutions per minute 
RRSO Risk-reducing salpingo-oophorectomy 
RT Room temperature 
RTK Receptor tyrosine kinase 
S Serum-free medium (not containing FCS) 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
sec Second(s) 
SEER Surveillance, Epidemiology, and End Results Programme of the NCI 
SEM Standard error of the mean 
SH2 Src-homology-2 domain 
Strep Streptomycin 
TBS Tris-buffered saline 
TBST Tris-buffered saline containing 0.1% Tween®-20 
TEMED N,N,N′,N′-Tetramethylethylenediamine 
TKI Tyrosine kinase inhibitor 
Tm Melting temperature 
Trx Thioredoxin 
TSG Tumour suppressor gene 
TVS Transvaginal screening 
V Volt 
VEGF Vascular endothelial growth factor 
VEGFR Vascular endothelial growth factor receptor 
w/v Weight per volume 
X-gal 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside 
Zeo Zeocin 
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1.1) Introduction 
To establish the context of the PhD project, this chapter will firstly provide background 
information on cancer in general and explore the underlying molecular mechanisms that 
lead to the development of the disease. Next, ovarian cancer and its causes, progression 
and treatment will be described in more detail. Thirdly, the key proteins investigated in this 
project will be introduced, namely the IgLON family and selected receptor tyrosine kinases. 
Finally, a summary of previous results on the role of the IgLON family in ovarian cancer will 
be given, leading to the project rationale, aims and hypotheses. 
 
 
 
1.2) Cancer 
1.2.1) Prevalence and Characteristics 
Cancer is one of the most prevalent causes of death worldwide, particularly in more 
developed countries (Figure 1A). Out of the non-communicable diseases, which were 
responsible for 65% of global deaths in 2008, cancer came second (21%), surpassed only by 
cardiovascular diseases (48%), and followed by chronic respiratory diseases (12%) [WHO, 
2012]. As cancer can originate in any part of the body and in different tissue types within 
the same organ, there are several hundred different varieties; worldwide, the most 
prevalent cancer is breast cancer, followed by prostate and lung cancer (Figure 1B). Ovarian 
cancer is at 10th position. 
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Figure 1: Overall cancer incidence worldwide (A) and divided into cancer types (B). 
Age-standardised incidence rates (ASRs) for 148 countries show that cancer is a global problem, particularly in 
more developed countries (A). Worldwide, breast cancer is the most common cancer, followed by prostate 
and lung cancer; lung cancer has the highest mortality rate, followed by breast and stomach cancer (B). ASR: 
age-standardised rate (world) per 100,000 for 2008. Both figures were created using the GLOBOCAN 2008 IARC 
online tool [Ferlay et al., 2010]. Calculation: all cancers except non-melanoma skin cancer, all ages, both sexes. 
  
A) 
B) 
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In 2000, Hanahan and Weinberg defined six characteristic shared by most, if not all, types of 
cancer: self-sufficiency in growth signals, insensitivity to anti-growth signals, tissue invasion 
and metastasis, limitless replicative potential, sustained angiogenesis, and the ability to 
evade apoptosis [Hanahan and Weinberg, 2000]. Since then, several additional “emerging 
hallmarks” (namely deregulation of cellular energetics and evasion of immune destruction) 
and “enabling characteristics” (genome instability and mutation, and tumour-promoting 
inflammation) have been added to the list [Hanahan and Weinberg, 2011]. All of these 
characteristics allow cancer cells to form tumour masses which proliferate in an 
uncontrolled manner and create their own microenvironment which is optimal for growth. 
Continuously growing tumours can cause pressure on nearby body structures (such as 
nerves, blood vessels or organs), invade surrounding tissues, and ultimately spread to other 
parts of the body to form metastases. 
 
1.2.1.1) Classification 
Cancers are classified depending on their tissue of origin, i.e. the tissue type they most 
resemble. Sarcomas are cancers of the connective tissue, such as bone, muscle or fat; 
leukaemias have their origin in the blood; and lymphomas form in the lymphatic system. 
Approximately 85% of all cancer types however originate in epithelial cells; these types of 
cancers are referred to as carcinomas [CRUK, 2012]. Due to the broad spectrum of cancer 
types and localisations, symptoms can be very non-specific and easily mistaken for other 
diseases [ACS, 2012]. 
 
PhD Thesis – Sarah Christen – Imperial College London Introduction 
23 
1.2.2) Causes and Prevention 
Cancer can be caused by various factors, either individually or, more commonly, in 
combination. The percentage of cancers due to external (i.e. non-inherited) factors is 
estimated to be 90-95% [Anand et al., 2008]. 
In a large meta-study, Danaei et al. identified nine potentially modifiable risk factors which 
were estimated to be responsible for 35% of global cancer deaths in 2001: obesity, low fruit 
and vegetable consumption, smoking, alcohol, unsafe sex, urban air pollution, indoor smoke 
from solid fuels used in households, and contaminated injections in health care settings 
[Danaei et al., 2005]. Awareness and avoidance of these and other – often modifiable – risk 
factors, i.e. by eating a healthy and balanced diet or quitting smoking, are hence important 
ways to decrease the risk of cancer. For non-modifiable causes such as inherited gene 
defects, several screening programmes are available for individuals with a family history, 
e.g. for colorectal cancer [Cairns et al., 2010]. 
 
1.2.2.1) Lifestyle Factors 
Various lifestyle-associated factors such as diet, exercise, smoking or alcohol intake can have 
an influence on the individual’s risk to develop cancer. It has been suggested that 30-40% of 
all cancers could be prevented by maintenance of appropriate body weight, diet and 
physical activity alone [Glade, 1999]. 
Choosing a healthy diet is not only important to minimise the intake of potential 
carcinogens, such as unsaturated fatty acids or heterocyclic amines (which are produced 
when cooking meat at high temperatures), but also to maximise the uptake of protective 
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agents such as antioxidants from fruits and vegetables [Greenwald et al., 2001; Anand et al., 
2008]. Furthermore, both diet and physical activity help maintaining a healthy body weight, 
a factor that has frequently been related to cancer risk [Calle et al., 2003; Danaei et al., 
2005; Irigaray et al., 2007; Anand et al., 2008]. However, it is not clear whether an increase 
in body weight itself can cause cancer, or whether ensuing complications, such as diabetes, 
play a more important role [Irigaray et al., 2007; Cohen and Leroith, 2012]. 
Smoking is another crucial factor as it has been estimated to be responsible for 70-87% of all 
deaths from lung cancer [Danaei et al., 2005; Irigaray et al., 2007; Anand et al., 2008]. 
Furthermore, the majority of other cancer types associated with smoking, such as 
oesophageal, stomach or pancreatic cancer, generally have poor outcomes as well; hence, 
smoking remains one of the most important factors in cancer mortality [Danaei et al., 2005; 
Irigaray et al., 2007]. 
Alcohol intake has been found to be responsible for 3.6% of cancer deaths recorded in 2002 
[Boffetta et al., 2006]. While the correlation of alcohol intake and incidence of cancers such 
as liver or breast cancer has been well established, data for other cancers, such as 
pancreatic or colorectal cancer, has been inconsistent [Boffetta and Hashibe, 2006]. 
  
1.2.2.2) Environmental Factors 
Environmental influences include exposure to radiation, chemicals, occupational hazards, or 
air pollution. Data on these factors is generally difficult to obtain and interpret as the 
assessment of exact length or intensity of exposure is challenging. However, it has been 
proposed that radiation alone could be responsible for up to 10% of all cancer cases, while 
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2-10% can attributed to occupational hazards [Belpomme et al., 2007]. 8% of all lung 
cancers were found to be caused by air pollution [Pope et al., 2002]. 
 
1.2.2.3) Infections 
Infection with various microorganisms, particularly viruses, has been associated with cancer. 
Pisani et al. estimated that around 15.6% of global cancer cases in 1990 were due to 
infections, e.g. with human papilloma viruses (HPV), hepatitis viruses (particularly hepatitis 
B virus, HBV), human immunodeficiency virus (HIV), Eppstein-Barr virus (EBV) or Heliobacter 
pylori [Pisani et al., 1997]. The connection of HPV and cervical cancer has been very well 
established, and up to 99.7% of all cervical cancer cases have been reported to be HPV-
positive [Walboomers et al., 1999]. A similarly close connection was found between HBV 
infection and hepatocellular carcinoma, with around 59.6% of liver cancer cases attributable 
to HBV infection [Pisani et al., 1997]. Infections with HIV, EBV and Heliobacter have been 
linked to Kaposi’s sarcoma, Hodgkin’s lymphoma, and gastric cancer, respectively [Pisani et 
al., 1997; Belpomme et al., 2007; Irigaray et al., 2007]. 
In recent years, several vaccinations have been developed successfully; while vaccination 
against HPV types 16 and 18 could prevent up to 70% of cervical cancer cases, vaccination 
against HBV has been shown to significantly reduce the incidence of hepatocellular 
carcinoma [Chang et al., 1997; Villa, 2011]. 
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1.2.2.4) Inherited Factors 
Even though only a small number of cancers are thought to be caused by inherited genetic 
defects, mutations in some genes significantly increase the carrier’s susceptibility. BRCA1 
and BRCA2 (breast cancer susceptibility genes 1 and 2) are two important examples. While 
only 7% of breast cancer cases are estimated to be due to mutated BRCA1/2 genes, several 
studies found the life-time risk of carriers of BRCA1/2 mutations to develop the disease to 
be between 54% and 84% [Easton et al., 1995; Easton et al., 1997; Ford et al., 1998; 
Antoniou et al., 2003]. A 14- to 30-fold increased risk to develop breast cancer compared to 
the general population was observed for carriers of BRCA1 mutations, while the risk was 
increased 11-fold for BRCA2 mutations [Antoniou et al., 2003]. 
 
1.2.3) Molecular Background 
On the molecular level, cancer is a disease caused primarily by alterations in genes which 
regulate cell proliferation and cell death, leading to an imbalance between the two 
processes. Such genetic alterations can range from single nucleotide mutations to changes 
affecting whole chromosomes, and can be caused by any of the factors mentioned above. 
Cancers with only one genetic aberration, such as the chromosome translocation found in 
chronic myelogenous leukaemia, are rare; usually an accumulation of changes is needed, 
explaining the late onset of the majority of cancers [Knudson, 2001]. 
The affected genes can broadly be divided into two categories based on the processes their 
encoded proteins are involved in: oncogenes (which drive cell survival and proliferation) and 
tumour suppressor genes (which inhibit cell survival and proliferation). Both types of genes 
are essential for normal functioning of a cell, but can lead to cancerous properties if altered. 
PhD Thesis – Sarah Christen – Imperial College London Introduction 
27 
1.2.3.1) Oncogenes 
Oncogenes mainly encode proteins involved in signalling processes (such as growth factors 
and their receptors, downstream signalling molecules, or regulators of apoptosis) or in the 
regulation of gene expression (such as chromatin remodelers or transcription factors) 
[Croce, 2008]. Several different mechanisms can lead to enhanced activity of these 
molecules in cancer cells, stemming either from an increase in protein concentration or 
from prolonged stability/activity. Gene duplications, changes in methylation status, or 
chromosomal rearrangement are factors that can upregulate gene expression, while the 
proteins themselves can be modified through mutations which increase their stability or 
activity. 
One example for a well-established oncogene is the HER2 receptor (human epidermal 
growth factor receptor 2), a receptor tyrosine kinase (RTK) that has long been associated 
with several cancers, particularly breast cancer [Moasser, 2007]. HER2 activates signalling 
pathways promoting proliferation and suppressing apoptosis; in normal cells, it is therefore 
tightly regulated [Yarden and Sliwkowski, 2001; Citri et al., 2003]. In cancer cells however, 
HER2 signalling can be strongly upregulated; this is mainly due to overexpression of the 
receptor, while mutations leading to constitutive activity are rare [Kallioniemi et al., 1992; 
Moasser, 2007]. 
 
1.2.3.2) Tumour Suppressor Genes 
Tumour suppressor genes, which have the opposite function of oncogenes, usually encode 
proteins which either downregulate proliferation and/or promote apoptosis, are involved in 
recognition and repair of DNA damage, or represent regulators of cell cycle progression 
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[Sherr, 2004]. Partial or full deletions of genes or chromosomes resulting in loss of gene 
expression, as well as mutations leading to protein inactivity due to frameshifts or 
missense/nonsense mutations, are frequent mechanisms affecting these types of molecules 
[Marshall, 1991]. BRCA1 and BRCA2 (see 1.2.2.4) are examples of tumour suppressor genes; 
both genes encode proteins involved in pathways mediating the repair of DNA double 
strand breaks [Friedenson, 2007]. Another frequently affected gene is TP53 encoding p53, a 
transcription factor which is activated in healthy cells upon cellular stress and regulates a 
range of responses ranging from cell cycle arrest to initiation of apoptosis [Sherr, 2004]. Loss 
of p53 function in cancer cells therefore has a wide range of consequences. 
 
1.2.3.3) Heredity of Oncogenes and Tumour Suppressor Genes 
Inheritance of oncogenes is typically dominant, while tumour suppressor genes follow 
recessive patterns [Knudson, 1971; Levine, 1993]. This is due to the fact that proteins 
encoded by oncogenes are generally upregulated or modified in cancer; therefore, changes 
in only one allele of an oncogene are enough to override wildtype functionality by 
expression of more or functionally altered protein. For tumour suppressor genes however, 
which are often inactivated in the process of carcinogenesis, one “hit” is not enough to 
achieve complete loss of the protein, as the remaining allele will still be able to produce 
wildtype protein. It is therefore commonly seen that one allele is inactivated by a mutation, 
while the second one is deleted, leading to loss of heterozygosity (LOH) and consequently 
absence of wildtype protein [Knudson, 1971; Levine, 1993]. 
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As opposed to modifications in oncogenes, which are usually lethal during foetal 
development, tumour suppressor genes hence play an important role in familial cancers as 
their initial modification does not have immediate consequences, but increases the 
predisposition to  develop the disease [Levine, 1993; Sherr, 2004]. 
There are a few exceptions from these patterns of inheritance, most notably the tumour 
suppressor gene TP53. Depending on the localisation of the mutation, p53 malfunction is 
not inherited in a recessive, but rather a dominant-negative way; this is due to the protein 
functioning as a homotetrameric complex, which already loses its ability to bind to DNA 
even if only one subunit is mutated [Fearon and Vogelstein, 1990; de Vries et al., 2002]. It is 
therefore not surprising that TP53 is involved in a large number of cancers, since only one 
genetic event is needed for inactivation of the whole protein complex. 
 
1.2.4) Development and Progression 
Carcinogenesis is a multistep evolutionary process during which cells accumulate a number 
of genetic changes leading to survival and growth advantages compared to normal somatic 
cells [Fearon and Vogelstein, 1990; Merlo et al., 2006]. Although not all tumours develop 
these characteristics in the same order, there seems to be a preferential sequence which 
differs between early- and late-onset tumours [Spencer et al., 2006]. 
Cancer cells need to be able to survive and proliferate continuously to form tumours; 
however, in order to grow beyond a certain size, the ability to induce angiogenesis becomes 
vital as all cells forming the tumour need to be within 100 µm of a blood vessel in order to 
obtain sufficient supply of oxygen and nutrients [Hanahan and Weinberg, 2000; Spencer et 
al., 2006]. Furthermore, to ensure the availability of physical space to grow, cancer cells 
PhD Thesis – Sarah Christen – Imperial College London Introduction 
30 
must acquire the capability to invade surrounding tissue or metastasise via the blood or 
lymphatic system [Hanahan and Weinberg, 2000; CRUK, 2012]. In the majority of patients, 
these secondary metastatic tumours, which interfere with normal organ function, are 
ultimately the cause of death [Zimm et al., 1981; Hanahan and Weinberg, 2000]. 
 
1.2.5) Treatment and Prognosis 
Surgery, radiotherapy and chemotherapy represent the main types of cancer treatment. 
Which measure (or combination) is chosen for each patient largely depends on the tumour 
type and stage, as well as the patient’s general health. All three factors determine initial 
outcome and further prognosis. 
Locally confined tumours can be tackled surgically or using radiotherapy; residual cells or 
metastases will have to be treated separately. In radiotherapy treatment, ionising radiation 
is used to induce DNA damage and thus initiate apoptosis. This effect is particularly harmful 
to cancer cells due to their reduced capacity to repair DNA errors. However, ionising 
radiation also affects the surrounding tissues, and several studies have shown increased 
rates of late mortality in patients who underwent radiotherapy during childhood [Sigurdson 
et al., 2005; Mertens et al., 2008]. 
Chemotherapy represents a more systemic approach than surgery or radiotherapy as it is 
usually not confined to one area only. Chemotherapeutic agents generally act on cells with 
increased proliferation rates, such as tumour cells; however, healthy cells which divide 
rapidly as well, e.g. hair follicles, bone marrow or the lining of the digestive tract, can also be 
affected. Therefore, alopecia, immunosuppression, and gastrointestinal inflammation are 
frequently observed side effects. 
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Due to these side effects, more recent therapeutic efforts have focused on disruption of 
cancer-specific aspects, such as overexpressed growth factor receptors or deregulated 
hormones. Monoclonal antibodies or small molecule inhibitors which interfere with these 
molecules are typical examples of such targeted therapy approaches. However, since cancer 
cells are characterised by genomic instability, not all cells within the same tumour will have 
the same genetic background; this can prove to be a major difficulty when choosing the 
appropriate means of treatment [Merlo et al., 2006; Croce, 2008]. Biomarker tests which 
can predict suitable treatment and clinical outcome are hence an important factor in cancer 
management [van't Veer and Bernards, 2008]. 
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1.3) Ovarian Cancer 
1.3.1) Anatomy and Function of the Ovaries 
The ovaries are part of the female reproductive system. They contain a woman’s germ cells 
(oocytes) and are connected to the uterus by the fallopian tubes (Figure 2A). During each 
menstrual cycle, a mature oocyte is released from the ovaries and travels through the 
fallopian tubes towards the uterus. If fertilisation occurs during this time, the resulting 
zygote implants in the endometrium, the epithelium covering the uterus; if not, it will be 
expelled during the following menstruation. 
The menstrual cycle is tightly regulated by various hormones: while an increase in luteinising 
hormone (LH) and follicle-stimulating hormone (FSH) before ovulation induces maturation 
of follicles and ovulation itself, presence of progesterone and estrogen after ovulation 
prepare the endometrium for a potential pregnancy. Progesterone and estrogen are 
released by the corpus luteum, which develops from the empty follicle after ovulation. Both 
hormones suppress the production of LH and FSH, and since LH and FSH are necessary to 
maintain the corpus luteum, it eventually degenerates. This results in falling levels of 
progesterone and estrogen, and hence a re-increase in levels of LH and FSH, marking the 
beginning of the next cycle. 
The ovaries mainly contain three different cell types, namely the germ cells within the 
follicles, the stromal cells which make up most of the inner ovarian substance, and the 
surface epithelium cells covering each ovary (Figure 2B). Ovarian cancer is thought to be 
able to arise from all three cell types [Chen et al., 2003b; Romero and Bast, 2012]. 
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Figure 2: Overview of the female reproductive tract (A) and the ovary (B). 
A woman’s ovaries are connected to the uterus by the fallopian tubes (A). Germ cells mature within the 
ovaries (B) and are released during ovulation. Ovaries are made up of three different main tissue types: the 
germ cells, the stroma surrounding them, and the surface epithelium covering the ovary. Figure A was taken 
from [CRUK, 2012], figure B was amended from [Romero and Bast, 2012]. 
 
 
1.3.2) Prevalence and Characteristics of Ovarian Cancer 
Ovarian cancer represents a global problem, particularly in more developed countries 
(Figure 3A). Worldwide, it is the seventh most common cancer in women, and the third 
most common gynaecological cancer after cervical and uterine cancer (Figure 3B). In the UK, 
it is the fifth most common cancer in women and only has a 5-year survival rate of 35% 
[NICE, 2011]. In the United States, the lifetime incidence of ovarian cancer is 1.39% (1 in 72), 
while the lifetime risk of death from ovarian cancer is 1.04% (1 in 96) [Jelovac and 
Armstrong, 2011]. Due to its high mortality rate, ovarian cancer is the most lethal 
gynaecological cancer. 
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Figure 3: Ovarian cancer incidence worldwide (A) and compared to other cancer types in women (B). 
Age-standardised incidence rates (ASRs) for 148 countries show that ovarian cancer is a global problem, 
particularly in more developed countries (A). Worldwide, breast cancer is the most common cancer in females, 
followed by cervical and colorectal cancer (B). Ovarian cancer is at 7
th
 position. ASR: age-standardised rate 
(world) per 100,000 for 2008. Both figures were created using the GLOBOCAN 2008 IARC online tool [Ferlay et 
al., 2010]. Calculation: ovarian cancer, all ages, females only 
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Ovarian cancer mainly affects post-menopausal women around 60 years of age (Figure 4A). 
Its often unspecific symptoms frequently lead to late diagnosis (see 1.3.6) and thus poorer 
prognosis (see 1.3.7). Over the last three decades, mortality rates have only decreased 
marginally (Figure 4B). 
 
       
Figure 4: Ovarian cancer incidence (A) and mortality rates (B). 
Ovarian cancer is rare in young women but peaks at around 60-69 years of age (A). Over the last 34 years, only 
a small reduction in annual mortality rates could be observed (B). Graph A was created based on data for 
32,019 ovarian cancer cases reported to the Surveillance, Epidemiology, and End Results (SEER) Programme of 
the National Cancer Institute (NCI) in the United States between 1988-2001 [Kosary, 2007]. Graph B was 
created using the SEER Fast Stats online tool [SEER, 2012]. Calculation: 1975-2009, age-adjusted, all ages, all 
races. 
 
 
1.3.2.1) Classification 
Ovarian cancer can be divided into different subtypes depending on the tissue of origin; the 
most common subtypes are epithelial, germ cell and stromal cancers (Figure 5A). Stromal 
cancers originate from the connective tissue that forms the ovaries, while germ cell tumours 
develop in the oocytes located within the ovaries [Romero and Bast, 2012]. Around 90% of 
0 
5 
10 
15 
20 
25 
20-29 30-39 40-49 50-59 60-69 70-79 80+ 
In
ci
d
e
n
ce
 [
%
] 
Age [years] 
A) B) 
PhD Thesis – Sarah Christen – Imperial College London Introduction 
36 
ovarian cancers however are thought to be derived from epithelial cells; these cancers will 
be the focus of this project. 
Epithelial ovarian cancer (EOC) can be divided into several further subtypes depending on 
the tumour histology, with each subtype having a distinct gene expression profile [Schwartz 
et al., 2002]. The most common form is serous EOC, which represents almost a third of all 
ovarian cancer cases and has one of the lowest 5-year survival rates (Figure 5). Cells of this 
tumour type strongly resemble the inner lining of the fallopian tube. Endometrioid tumours 
resemble the endometrium, i.e. the epithelial layer covering the uterus; these cancers have 
the most favourable outlook of all EOC subtypes apart from borderline tumours. Mucinous 
neoplasms frequently form the largest observed EOC tumours (median diameter: 18-20 cm), 
but are generally confined to the ovaries [Jelovac and Armstrong, 2011]. They are analogous 
to endocervical glands which secrete mucin. Clear cell tumours are made up of cells 
resembling vaginal rests and contain large amounts of glycogen; patients presenting with 
this subtype often have a history of endometriosis, a condition in which cells of the 
endometrium grow outside the uterine cavity, usually on the peritoneum [Jelovac and 
Armstrong, 2011]. 
Not all EOC tumours develop into malignant, invasive forms: borderline tumours, which are 
mainly of serous histology, only have low malignant potential (LMP) and exhibit the best 5-
year survival rate of all ovarian cancer types (Figure 5B). They do not invade the stroma, and 
only about 10% of tumours are lethal if they reappear after surgery [Romero and Bast, 
2012]. The majority of patients with these tumour types are younger and already diagnosed 
at early stages [Jelovac and Armstrong, 2011]. 
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Figure 5: Incidence (A) and 5-year survival rates (B) for ovarian cancer subtypes. 
Epithelial ovarian cancer (EOC) makes up the majority of ovarian cancer cases (A). Its most prevalent subtype, 
serous EOC, has one of the lowest relative 5-year survival rates (B). Graphs created based on data for 32,019 
ovarian cancer cases reported to the NCI’s SEER Programme between 1988-2001 [Kosary, 2007]. 
 
Low-grade serous, low-grade endometrioid, mucinous, clear cell, and borderline tumours 
are often referred to as type I tumours. Tumours in this group usually exhibit a lesser 
malignant profile, are slower in growth, detected at an earlier stage and therefore confined 
to the ovary, and exhibit a relatively strong genetic stability [Kurman and Shih, 2010; 
Romero and Bast, 2012]. In contrast, type II tumours are detected at more advanced stages, 
grow aggressively, and are genetically unstable. High-grade serous and high-grade 
endometrioid tumours fall into this category, and type II tumours make up about 75% of all 
EOC tumours [Kurman and Shih, 2010]. 
 
1.3.3) Causes and Prevention 
To date, EOC carcinogenesis remains poorly understood. About 5-15% of ovarian cancer 
cases have a familial background, while the large majority occurs spontaneously [Claus et 
al., 1996; Benedet et al., 2000; Romero and Bast, 2012]. The main risk factors for sporadic 
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EOC are advancing age and the number of ovulatory cycles. Early onset of menses, late 
onset of menopause, and low/no parity increase the number of ovulations, putting the 
women in these categories at a higher risk to develop the disease [Benedet et al., 2000; Bast 
et al., 2009; Romero and Bast, 2012]. Oral contraceptives have been found to decrease the 
risk of ovarian cancer, potentially through reducing the number of ovulations: in a large 
meta-study covering data from 45 independent studies involving 23,257 cases and 87,303 
controls, Beral et al. found that the use of oral contraceptives conveyed a significant 
protective effect which could still be detected over 30 years after termination of use [Beral 
et al., 2008]. Furthermore, longer use of oral contraceptives correlated with an increase in 
protection. 
Overall, reproductive or genetic errors seem to be the main causes for EOC development; 
for example, both estrogen and progesterone, which play important roles in the regulation 
of the ovulatory cycle (see 1.3.1), have been associated with EOC [Benedet et al., 2000]. 
While estrogen has been associated with an increased risk of developing the disease, 
progesterone was found to have a protective effect [Ho, 2003]. The use of talc is one of the 
few external factors that has been linked to an increased risk of ovarian cancer; however, 
data has been inconsistent [Muscat and Huncharek, 2008]. 
 
A family history exhibiting an increased frequency of colon, uterine or ovarian cancer can be 
an indication for familial EOC. The accumulation of these types of cancers is termed 
hereditary nonpolyposis colorectal cancer syndrome (HNPCC) and has been associated with 
mutations in several DNA mismatch repair genes such as MSH2 and MSH6 (human mutS 
homologs) [Jelovac and Armstrong, 2011]. Hereditary breast-ovarian cancer syndrome 
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(HBOC), a further category of high-risk family history, is characterised by an increased 
incidence of ovarian and breast cancer, most commonly caused by mutations in BRCA1 and 
BRCA2 (see 1.3.4). 
Women from high-risk families have the option to undergo regular screening comprising of 
blood tests and ultrasound. However, due to the limitations of the currently available early-
detection screening mechanisms (see 1.3.6), carriers of mutations in known susceptibility 
genes should consider prophylactic risk-reducing salpingo-oophorectomy (RRSO; removal of 
the ovaries and fallopian tubes) once childbearing is complete. For carriers of BRCA1/2 
mutations, such procedures have been shown to decrease the risk of ovarian cancer by 80% 
[Finch et al., 2006; Rebbeck et al., 2009]. 
 
1.3.4) Molecular Background 
Similarly to other cancers, the development of ovarian cancer is triggered by incorrect 
activation and deactivation of certain genes. Activation of oncogenes frequently occurs 
through gene amplification, mutation or promoter hypomethylation, while inactivation of 
tumour suppressor genes is often based on loss of heterozygosity or promoter 
hypermethylation. So far, more than 30 oncogenes and tumour suppressor genes involved 
in ovarian cancer have been identified [Bast et al., 2009]. 
The precise genetic alterations differ between tumours of type I and tumours of type II. 
Type I tumours often carry mutations in genes involved in cell growth and proliferation; 
important examples are KRAS (in low-grade serous and mucinous tumours), BRAF (low-
grade serous), PI3KCA (clear cell, low-grade endometrioid), ERBB2 (low-grade serous), 
CTNNB1 (encoding β-catenin; low-grade endometrioid) and PTEN (clear cell,  low-grade 
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endometrioid) [Bast et al., 2009; Karst and Drapkin, 2010; Kurman and Shih, 2010; TCGA, 
2011; Romero and Bast, 2012]. Type II tumours however rarely exhibit these mutations; 
instead, they are often characterised by genetic instability, which is reflected in the fact that 
they frequently harbour mutations in DNA damage signalling and repair genes, mainly TP53 
and BRCA1/2. TP53 mutations have been observed in up to 96% of high-grade serous 
ovarian carcinomas (HGSC), while BRCA1/2 alterations can be found in around 12% of cases 
[Risch et al., 2001; Lakhani et al., 2004; TCGA, 2011]. Carriers of mutations in these 
susceptibility genes have been reported to have at least a 15-fold increased age-specific risk 
of developing ovarian cancer compared to non-carriers, and often show an earlier onset of 
the disease [Claus et al., 1996].  
 
1.3.5) Development and Progression 
As mentioned above, normal ovarian cells have to acquire a number of genetic lesions 
before they become cancerous. However, once a tumour has formed, the cancer cells can 
easily spread in the abdomen and pelvis due to the location of the ovaries within the 
peritoneal cavity; hence, the majority of metastases are found on the peritoneum [Jelovac 
and Armstrong, 2011]. In many patients, growth of cancer cells leads to peritoneal 
irritations and thus accumulation of ascitic fluid [CRUK, 2012]. Distant metastases occur by 
spread of tumour cells via the blood vessels or lymphatic system to the liver, lungs or brain 
[Romero and Bast, 2012].  
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1.3.5.1) Origin of Epithelial Ovarian Cancer 
Conventionally, epithelial ovarian cancer has been thought to arise from the surface 
epithelium (OSE) covering the ovaries. OSE cells are rather primitive, not fully differentiated 
cells of mesothelial origin and express both epithelial and mesenchymal markers [Auersperg 
et al., 2001; Karst and Drapkin, 2010; Kurman and Shih, 2010]. These characteristics 
facilitate tissue remodelling, which is necessary after rupture of the ovarian surface during 
ovulation [Karst and Drapkin, 2010]. One of the most commonly cited theories, the 
“incessant ovulation hypothesis”, states that the trauma of repeated ovulation is 
responsible for the initiation of cancerous growth of OSE cells. During and after ovulation, 
the epithelium is exposed to various external factors such as hormones, cytokines and 
reactive oxygen species (ROS); furthermore, rupture of the epithelium can lead to formation 
of inclusion cysts following repair [Karst and Drapkin, 2010]. All these factors can result in 
DNA damage (through cytokines or ROS, and through increased cell proliferation during 
repair) or deregulated growth of epithelial cells in inclusion cysts (due to the exposure to 
high levels of hormones inside the ovaries), and thus potentially give rise to cancer. The 
subsequent formation of the different histological subtypes of EOC has been suggested to 
be triggered by the hormone-rich milieu of the ovaries [Karst and Drapkin, 2010; Kurman 
and Shih, 2010]. 
Over the past few years however, the alternative “fallopian tube hypothesis” has gained 
more and more importance: it states that the each EOC subtype actually originates from the 
cell type it most resembles (i.e. from the fallopian type in the case of serous EOC), and not 
the ovarian surface epithelium [Berns and Bowtell, 2012]. It has been suggested that the 
precursor cells become entrapped within the ovaries after ovulation; in the case of serous 
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tumours, this is facilitated by the close contact of the ovaries with the fallopian tubes [Karst 
and Drapkin, 2010; Kurman and Shih, 2010; Tone et al., 2012]. For other EOC types, e.g. 
endometrioid or mucinous cancers, retrograde menstruation and endometriosis could lead 
to cells of the endometrium being dislocated towards the ovaries and becoming trapped 
during ovulation [Kurman and Shih, 2010]. Due to the high concentration of growth-
promoting hormones within the ovaries, the entrapped cells could be stimulated to undergo 
abnormal proliferation and tumour formation, particularly if they harbour underlying 
genetic lesions. 
While both hypotheses are in agreement with reports stating that a reduced number of 
ovulatory cycles decreases the risk of ovarian cancer, the “fallopian tube hypothesis” has 
been supported over the “incessant ovulation hypothesis” by several findings: a) risk-
reducing salpingo-oophorectomy rarely revealed OSE abnormalities but rather changes in 
fallopian tube tissue, so-called serous tubal intraepithelial carcinomas (STICs); b) STICs and 
high-grade serous carcinomas carry identical mutations; c) STICs could not be detected in 
women with non-serous EOC; and d) there is a residual risk of 11% to develop peritoneal 
HGSC if only oophorectomy was carried out but the fallopian tubes were left in place [Tone 
et al., 2012]. Removal of the fallopian tubes during prophylactic surgery should therefore be 
considered, particularly as the tubes also function as carriers for endometrial cells in 
endometriosis and are thus involved in the development of other EOC subtypes as well. 
 
1.3.5.2) Stages 
Staging is used to define how far the patient’s cancer has progressed. Four stages have been 
classified by the International Federation of Gynaecology and Obstetrics (FIGO; Table 1). 
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They can be further divided into substages depending on exact tumour location or spread. 
While tumours at stage I are limited to one or both ovaries, tumours at stage IV have spread 
beyond the peritoneal cavity and formed distant metastases. Tumours of stage II-IV are 
referred to as advanced ovarian cancer [NICE, 2011]. 
 
Table 1: FIGO staging of ovarian cancer. 
The main four stages in ovarian cancer progression as categorised by the International Federation of 
Gynaecology and Obstetrics (FIGO). Table amended from [Benedet et al., 2000]. 
Stage Description 
I Tumour confined to ovaries 
II Tumour involves one or both ovaries with pelvic extension 
III Tumour involves one or both ovaries with microscopically confirmed peritoneal metastasis 
outside the pelvis and/or regional lymph nodes metastasis 
IV Distant metastasis beyond the peritoneal cavity 
 
 
1.3.5.3) Grades 
Grading describes the morphological similarity of the tumour cells to their respective normal 
tissue equivalents. Due to the mutations accumulated over time, ovarian cancer cells 
become less differentiated with disease progression: while grade 1 tumours appear 
morphologically well differentiated and bear close resemblance to their respective healthy 
cellular counterparts, grade 2 tumours are only moderately differentiated, while grade 3 
tumours are poorly differentiated [Benedet et al., 2000]. Cancers of higher grades generally 
grow faster than those of lower grades [CRUK, 2012]. 
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1.3.6) Screening and Diagnosis 
Ovarian cancer has frequently been described as the “silent killer” as it is often not detected 
until more advanced stages, which are increasingly difficult to treat (see 1.3.7). However, 
the majority of patients do experience symptoms: only 11% of women with stage I and II, 
and 3% of women with stage III and IV are completely asymptomatic [Goff et al., 2000]. The 
reason for the frequent late diagnosis is therefore more likely due to the fact that most 
symptoms are highly unspecific and could also be caused by other diseases [Goff et al., 
2000]. 
Commonly reported symptoms include abdominal symptoms (77%; especially increased 
abdominal size or pain), gastrointestinal symptoms (70%; unable to eat normally or weight 
loss), pain (58%; back pain or pain during intercourse), constitutional symptoms (50%; 
fatigue), urinary symptoms (34%; urinary incontinence) or pelvic symptoms (26%; vaginal 
bleeding) [Goff et al., 2000]. Several studies have looked into defining algorithms based on 
these and other symptoms that allow easy and early detection of high-risk cases; however, 
the success of these approaches has been varied [Rossing et al., 2010; Hippisley-Cox and 
Coupland, 2012]. 
Particularly abdominal distension, feeling full quickly, pelvic or abdominal pain, and 
increased urinary frequency are symptoms that, if they occur on a regular basis (more than 
12 times a month), are regarded as indicators for ovarian cancer by the National Institute 
for Health and Clinical Excellence [NICE, 2011]. In these cases, measurement of serum levels 
of cancer antigen 125 (CA125) is recommended. For concentrations of >35 IU/ml, 
ultrasound of the abdomen and pelvis should be arranged. Transvaginal ultrasound (TVS) 
can be used to determine size and shape of the ovaries, and patients are referred to 
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specialist multidisciplinary teams if abnormalities are observed. Several studies reported 
this approach to be suitable for diagnosis of ovarian cancer, and repetition of both CA125 
tests and TVS in regular intervals has been shown to reduce false-positives [Menon et al., 
2005; Menon et al., 2009]. 
False-positives are particularly problematic with regards to screening of the general 
population as well as younger, high risk women. Pre-menopausal women often have 
fluctuating levels of CA125 depending on the stage of their menstrual cycle; additionally, 
increases can also be due to other cancers (like pancreatic, breast or liver cancer), non-
malignant conditions such as endometriosis or ovarian cysts, or even pregnancy [Jacobs and 
Menon, 2004; CRUK, 2012]. Furthermore, not all patients present with increased CA125; 
rather, its levels seem to rise over time as only 25% of women have CA125 levels of >35 
IU/ml before diagnosis, while this can be observed in 50% of stage I and >90% stage II-IV 
patients [Jacobs and Menon, 2004]. Additionally, the degree of increase in CA125 also varies 
between EOC tumours types [Jacobs and Menon, 2004]. While rising levels of CA125 
therefore are a good indicator for ongoing tumour growth, particularly in post-menopausal 
women, the value of regular CA125 tests for screening and detection of ovarian cancer at an 
early-stage remains a matter of debate [Jacobs and Menon, 2004; Menon et al., 2005; 
CRUK, 2012]. Due to ovarian cancer being a relatively rare disease, the negative effects of 
surgery in false-positive cases may outweigh the positive effects of detection of true-
positive cases [Jacobs and Menon, 2004]; ultimately, the search for biomarkers or 
biomarker combinations with high sensitivity and specificity is hence still ongoing and crucial 
to reduce the high number of late diagnoses. 
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One of the most comprehensive trials investigating different screening approaches is the 
United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), which initially 
ran from 2001 until 2005 [Menon et al., 2009]. It included 202,638 post-menopausal women 
aged 50-74 years, which were randomly divided into three groups: the first group was 
screened annually using transvaginal ultrasound, while the second group underwent annual 
CA125-testing with second-line transvaginal ultrasound; the third cohort represented a 
control group with no treatment. Both screening approaches demonstrated high sensitivity, 
while specificity was significantly higher in the group undergoing CA125 testing prior to 
ultrasound. Based on their findings, Menon et al. concluded that both approaches are viable 
methods for large-scale screening, and further evaluation is ongoing to determine the effect 
of the different approaches on mortality. 
 
1.3.7) Treatment and Prognosis 
Treatment choice depends on tumour size and spread. Generally, the majority of the 
tumour mass is removed by cytoreductive surgery, while residual cancer cells are treated 
with platinum-based chemotherapy. Radiotherapy is only rarely used, e.g. under 
circumstances that require palliative care. Success of treatment can be monitored by regular 
assessment of CA125 levels, ultrasound, or computed tomography (CT). 
 
1.3.7.1) Surgery 
Prior to surgery, imaging techniques such as CT scans are used to assess the size of the 
tumour, the extent of spread into the peritoneal cavity, and the presence of metastases 
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[Benedet et al., 2000]. In certain cases, neoadjuvant chemotherapy can be applied to reduce 
tumour volume. During surgery, all obvious signs of tumour growth are removed; often this 
includes bilateral salpingo-oophorectomy (removal of both ovaries and fallopian tubes), 
hysterectomy (removal of the uterus) and omentectomy (removal of the omentum) 
[Benedet et al., 2000]. For younger patients who would like to preserve their fertility, a 
unilateral salpingo-oophorectomy can be considered as an alternative, particularly for low-
risk stage I or borderline tumours. During surgery, tissue samples should be taken not only 
of the primary tumour mass, but also from the peritoneal cavity and lymph nodes to assess 
tumour stage, grade and spread. 
The amount of residual disease left after surgery is a major prognostic factor. Optimal 
debulking surgery, leaving tumour masses of <1 cm behind, is associated with significantly 
increased outcome [Benedet et al., 2000; Jelovac and Armstrong, 2011]. As opposed to 
other cancers, it is therefore advised that the majority of ovarian cancer patients should 
undergo surgery if their condition permits such a procedure. 
 
1.3.7.2) Chemotherapy 
The choice of adjuvant chemotherapy following cytoreductive surgery depends on the type 
of ovarian cancer (as assessed in biopsies of samples taken during surgery), its stage and 
grade, the amount of residual disease after surgery, and the patient’s general health. For 
patients with correctly staged borderline tumours or low-risk stage I disease, chemotherapy 
is not generally recommended [NICE, 2011]. For high-risk stage I disease (grade 3 tumours) 
and stages II-IV, first-line treatment usually consists of either carboplatin alone, or a 
combination of carboplatin with paclitaxel. Both drugs induce apoptosis: while carboplatin is 
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a platinum-based DNA-crosslinker, taxane-based paclitaxel interferes with the formation of 
the mitotic spindle [Romero and Bast, 2012]. Standard treatment usually consists of six 3-
week cycles with intravenous drug administration [Romero and Bast, 2012]. Platinum-based 
chemotherapy has been found to be less effective in mucinous and clear cell tumours 
compared to other subtypes [Jelovac and Armstrong, 2011]. 
 
1.3.7.3) Alternative Approaches 
Docetaxel is frequently considered as an alternative to paclitaxel, while cisplatin represents 
an alternative to carboplatin, albeit with a less favourable toxicity profile [Benedet et al., 
2000]. 
Several studies are currently investigating if alterations of the standard treatment lead to 
improved outcome: while the ICON8 trial evaluates if lower doses of chemotherapy in 
shorter intervals (weekly instead of 3-weekly) have a beneficial effect on patient survival, 
the SCOTROC4 trial is investigating if response can be improved by increasing the dose of 
administered chemotherapy from cycle to cycle [CRUK, 2012]. 
Other studies have addressed the question of whether intraperitoneal (IP) drug 
administration is advantageous compared to intravenous (IV) administration since the 
peritoneal cavity is the main site of disease in ovarian cancer. Several studies have showed 
promising results and increased patient survival, possibly due to reduced side effects as IP 
treatment is locally confined [Alberts et al., 1996; Markman et al., 2001; Armstrong et al., 
2006]. However, other studies reported increased toxicity of IP approaches compared to IV; 
hence, intraperitoneal drug administration is currently not recommended outside clinical 
trials [NICE, 2011]. 
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Several alternatives to platinum- and taxane-based approaches are currently under 
investigation, particularly as alternative second-line treatments after relapse (see 1.3.7.4). 
The focus of these approaches usually lies on targeting specific proteins that are 
deregulated in ovarian cancer. One of the most successful drugs so far is bevacizumab, a 
monoclonal antibody which interacts with VEGF-A (vascular endothelial growth factor A), 
thus inhibiting VEGF signalling and consequently angiogenesis [Jelovac and Armstrong, 
2011; Romero and Bast, 2012]. Targeting PARP (Poly (ADP-ribose) polymerase), a molecule 
involved in single-strand DNA repair, has proven particularly useful in carriers of BRCA1/2 
mutations: since absence of BRCA1/2 leads to disrupted double-strand DNA repair, cells in 
these tumours rely heavily on PARP-mediated single-strand DNA repair to overcome 
platinum-induced damage [Jelovac and Armstrong, 2011; Romero and Bast, 2012]. Further 
targeted or hormonal therapies are currently being investigated; however, improvement in 
overall survival to date remains marginal. 
 
1.3.7.4) Relapse, Second-Line Treatment and Drug Resistance 
Even though most patients respond well to first-line treatment, over 70% of women relapse 
[Romero and Bast, 2012]. If relapse occurs more than 6 months after the end of the last 
treatment, patients are considered platinum-sensitive, and carboplatin/paclitaxel is 
generally used as second-line treatment as well, sometimes together with further 
cytoreductive surgery [Jelovac and Armstrong, 2011]. It has been observed that the length 
of the progression-free interval before relapse is a strong determinant of success of 
retreatment, with longer intervals leading to increased response to subsequent second-line 
chemotherapy [Benedet et al., 2000]. However, even though response rates of retreatment 
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can be up to 80%, the length of second remission is generally shorter and recurrent ovarian 
cancer is ultimately incurable [Jelovac and Armstrong, 2011]. 
If tumour progression can be observed during or no more than 6 months after the end of 
the previous chemotherapy, patients are considered platinum-resistant. Under these 
circumstances, further treatment is merely used to increase progression-free and overall 
survival, to minimise symptoms, and to maintain or improve quality of life [Cooke et al., 
2010; Romero and Bast, 2012]. Paclitaxel, docetaxel or alternative drugs (see 1.3.7.3) can be 
used as single agents; however, response rates are substantially lower than in platinum-
sensitive patients [Romero and Bast, 2012]. 
Progression of ovarian cancer after remission can be monitored by CA125 testing and often 
predicted by several months [Rustin et al., 2010]. However, no significant improvement in 
survival could be detected in patients treated as soon as CA125 levels increased compared 
to patients who remained untreated until symptoms became apparent, while quality of life 
deteriorated if treatment was reinitiated early. 
The underlying mechanisms of drug resistance in ovarian cancer remain poorly understood, 
but have been attributed to pre-existing genetic tumour heterogeneity rather than 
evolvement of resistance due to evolutionary pressure during chemotherapy treatment 
[Cooke et al., 2010]. 
 
1.3.7.5) Prognosis 
Four main factors affect the individual patient’s prognosis: cancer subtype, stage, grade, and 
volume of residual disease after surgery [Benedet et al., 2000; Romero and Bast, 2012]. 
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Generally, lower stage, grade and amount of residual disease are associated with improved 
outcome. Patients diagnosed at stage I, when the disease is still confined to the ovaries and 
hence comparably easy to remove during surgery, have a 5-year survival rate of 89.3% 
(Figure 6A). However, this amount drops to only 17.9% at stage IV, when the cancer has 
spread. Unfortunately, only 22.8 % of cases are detected at stage I, while over two thirds of 
patients are diagnosed at stage III or IV. 
Within each stage, patients with moderately or poorly differentiated tumours (i.e. grades 2 
or 3) have substantially decreased 5-year survival rates compared to patients with well 
differentiated (grade 1) tumours (Figure 6B). 
 
  
Figure 6: 5-year survival based on cancer stage (A) and grade (B). 
While more than two thirds of ovarian cancer cases are not diagnosed until stage III and IV, survival rapidly 
decreases with advanced stage (A). Within each stage, moderately and poorly differentiated tumours (grade 2 
and 3) have substantially worse prognoses than well differentiated (grade 1) tumours (B). Graphs created 
based on data for 32,019 ovarian cancer cases reported to the NCI’s SEER Programme between 1988-2001 
[Kosary, 2007]. 
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1.3.8) Outlook 
Despite considerable efforts over the last few decades, ovarian cancer remains the most 
lethal gynaecological cancer. Since this can mainly be attributed to late diagnosis and 
frequent relapse, improved early detection methods and better treatment strategies are 
urgently needed. Due to the heterogeneity of the disease not only between patients but 
even within the same cancer subtype, personalised treatment targeting multiple pathways 
seems to be the most promising approach to increase patient survival. 
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1.4) IgLONs 
The IgLON family consists of four members, OPCML (opioid binding protein/cell adhesion 
molecule-like) [Schofield et al., 1989], neurotrimin [Struyk et al., 1995; Spaltmann and 
Brümmendorf, 1996], LSAMP (limbic system-associated membrane protein) [Levitt, 1984; 
Brümmendorf et al., 1997] and NEGR1 (neuronal growth regulator 1) [Funatsu et al., 1999; 
Marg et al., 1999]. They were initially discovered in rat and chicken (OBCAM, Ntm, LAMP 
and Kilon in rat, respectively; OBCAM, CEPU-1, LAMP and neurotractin in chicken) and later 
found to be present as highly homologous forms in humans as well. Based on the four 
molecules’ similar structure, which is made up of three immunoglobulin (Ig) domains, they 
were termed the IgLON family (for LSAMP, OPCML and neurotrimin; NEGR1 was discovered 
later) [Pimenta et al., 1995]. 
The NCBI gene database (www.ncbi.nlm.nih.gov/gene) however also describes a fifth family 
member termed IgLON5, which is encoded on chromosome 19. The protein has no 
predicted GPI anchor according to the UniProt website (www.uniprot.org/uniprot/A6NGN9), 
although a brief online analysis using PredGPI (http://gpcr.biocomp.unibo.it/ 
predgpi/pred.htm) showed that attachment of a GPI anchor is nonetheless highly likely. 
Overall, sequence similarity of IgLON5 with the other IgLON family members is high (see 
Figure 75, Appendix B), and both the modular structure (containing three Ig domains, see 
section 1.4.1) as well as a high degree of glycosylation are maintained. However, as its 
validity as a true IgLON family member was still disputed at the time this PhD project started 
– Figure 7 shows that IgLON5 is the least related molecule amongst the five proteins – and 
as no publications on IgLON5 could be identified to this day, the protein was not included in 
any further analyses. 
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Figure 7: Phylogram of the IgLON family including IgLON5. 
Phylogram created using ClustalW2. The diagram shows that OPCML and neurotrimin are closely related, as 
are LSAMP and NEGR1. IgLON5 exhibits the greatest difference compared to the other family members. 
 
Cell adhesion molecules (CAMs) can be divided into three subgroups: the integrins, the 
cadherins, and the Ig superfamily (IgSF) [Struyk et al., 1995; Funatsu et al., 1999; Miyata et 
al., 2003]. IgLONs are members of the IgSF (Figure 8), a family found both in invertebrates 
and, at considerably higher numbers, in vertebrates, where they represent one of the 
largest protein groups [Barclay, 2003]. Within the human genome, 765 genes containing Ig 
domains have been identified, encoding proteins such as major histocompatibility complex 
(MHC) class II proteins, various co-receptors (CD4, CD8), receptor tyrosine kinases such as 
PDGFR, or neuronal cell adhesion molecules such as L1 or NCAM [Brümmendorf and 
Lemmon, 2001; Barclay, 2003; Kulahin et al., 2008]. 
 
 
Figure 8: Overview of the family of cell adhesion molecules (CAMs) and its subgroups. 
Within the family of cell adhesion molecules (CAMs), the IgLON family represents a subgroup of the IgCAMs, a 
type of cell adhesion molecules from the Ig superfamily (IgSF). Other IgCAMs include the family of L1-like 
molecules, protein tyrosine phosphatases (PTPs) and various others. Graph created based on [Kamiguchi and 
Lemmon, 2000]. 
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Cell adhesion molecules of the Ig superfamily (IgCAMs) are extracellular proteins made up of 
one or more Ig domains forming linear rod-like molecules, sometimes in combination with 
other structural elements such as fibronectin-III domains [Vaughn and Bjorkman, 1996; 
Aplin et al., 1998]. Typically, these domains are linked to a shorter and more variable 
cytoplasmic tail by a single helical transmembrane segment; however, in recent years an 
increasing number of (particularly neural) IgCAMs has been detected which lack both the 
transmembrane and intracellular regions and are instead connected to the cell surface by a 
glycosylphosphatidylinositol (GPI) anchor [Aplin et al., 1998; Miyata et al., 2003; 
Bombardelli and Cavallaro, 2010]. IgCAMs exhibit varying levels of glycosylation which 
sometimes even differ between species homologues or between foetal and adult forms in 
the same organism [Williams and Barclay, 1988; Barclay, 2003]. 
As the extracellular IgCAM domains do not seem to have any enzymatic activity but instead 
readily associate with other molecules, IgCAMs have mainly been implied in interaction 
processes [Barclay, 2003]. They were found to directly bind to integrins, cadherins, receptor 
tyrosine kinases, cytoskeletal proteins or components of the extracellular matrix 
[Bombardelli and Cavallaro, 2010]. Furthermore, they frequently form homo- or heterophilic 
dimers in both cis (on the same cell) and trans (across different cells) [Cavallaro and 
Christofori, 2004; Zecchini et al., 2011]. 
IgCAMs are expressed in a broad range of cell types such as leukocytes, endothelial or 
epithelial cells, and hence involved in a large spectrum of biological processes, particularly 
within the immune and nervous systems [Williams and Barclay, 1988; Cavallaro and 
Christofori, 2004; Bombardelli and Cavallaro, 2010]. In the immune system, they regulate 
adhesive contacts and cellular trafficking; during brain development, they are responsible 
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for processes such as axon growth and guidance, synapse formation, intercellular adhesion, 
or neuronal migration and fasciculation [Williams and Barclay, 1988; Struyk et al., 1995; 
Aplin et al., 1998; Hachisuka et al., 2000; Reed et al., 2004]. 
IgCAMs can be modified in numerous different ways, thus contributing a large degree of 
plasticity to the processes they are involved in. Transcriptional regulation, oligomerisation, 
endocytosis and recycling, conformational changes, or proteolytic cleavage of the 
ectodomain are frequently observed mechanisms altering IgCAM functioning [Kamiguchi 
and Lemmon, 2000; Brümmendorf and Lemmon, 2001; Piazza et al., 2005]. 
Many of the properties outlined here for IgCAMs in general also apply to the IgLON family in 
particular, and are described in more detail in the following paragraphs. 
 
1.4.1) Protein Structure 
In humans, members of the IgLON protein family have an amino acid (aa) chain length of 
approximately 345 residues (OPCML: 345 aa; neurotrimin: 344 aa; LSAMP: 338 aa; NEGR1: 
354 aa). These primary sequences are highly conserved across species; for example, rat 
LAMP has an amino acid identity of 91% compared with the chicken homologue, and even 
shares over 99% of residues with human LSAMP [Pimenta et al., 1995; Brümmendorf et al., 
1997]. 
The molecular structure of IgLON proteins represents one of the smallest and simplest 
modular conformations found in neural IgCAMs [Hachisuka et al., 2000]. Each molecule is 
made up of three C2-type Ig domains, which are tethered to the outer cell membrane by a 
GPI anchor connected to the C-terminal third domain of the molecule (Figure 9). Ig domains 
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of the C2 type consist of approximately 75-100 amino acid residues and are characterised by 
two cysteines forming a disulfide bond between two antiparallel β-sheets which make up 
one domain [Spaltmann and Brümmendorf, 1996; Vaughn and Bjorkman, 1996]. 
 
     
Figure 9: Structural representation of the four IgLON family members. 
IgLONs are made up of three Ig domains formed by disulfide bonds (S-S). They contain several potential N-
glycosylation sites (black pins) and are anchored to the cell surface via GPI anchors (red arrows). Figure 
adapted from [Itoh et al., 2008]. 
 
Overall, the IgLON peptide chains are mostly hydrophilic, with only a short stretch of slightly 
hydrophobic amino acid residues located at each end of the molecule [Pimenta et al., 1995]. 
Both hydrophobic ends are cleaved off to yield the mature form: the N-terminal stretch 
represents a signal sequence, while the C-terminal end is removed during attachment of the 
GPI anchor [Spaltmann and Brümmendorf, 1996]. Advantages of GPI-mediated membrane 
attachment include increased mobility on the cell surface, facilitated targeting of the 
molecules to specific domains within the membrane, or the possibility of being easily 
cleaved and released from the membrane [Struyk et al., 1995]. 
IgLONs are usually highly glycosylated; depending on the species and precise family 
member, they contain between six and eight potential glycosylation sites, and can exhibit 
various degree of glycosylation depending on factors such as cell type or developmental 
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stage [Pimenta et al., 1995; Spaltmann and Brümmendorf, 1996; Itoh et al., 2008]. 
Considering that the size of a typical carbohydrate chain is almost as large as a single Ig 
domain, glycosylation has a major impact on IgLON molecules and can account for up to 30-
50% of the proteins’ overall molecular masses [Barclay, 2003]. Carbohydrate attachment 
has been reported to serve various purposes; one major aspect is the controlled covering or 
exposing of specific protein surface areas to regulate binding to other molecules and thus 
modify processes such as cell-cell interaction [Barclay, 2003; Itoh et al., 2008]. 
 
1.4.2) Expression 
In the human genome, the IgLON family members are encoded on different chromosomes 
(LSAMP: 3q13.2-q21; NEGR1: 1p31.1) except for HNT (neurotrimin) and OPCML (both are 
located on 11q25, with HNT approx. 80 kb closer to the centromer and in the opposite 
orientation as OPCML) [Sellar et al., 2003; Reed et al., 2007]. All four genes contain at least 
seven exons and are strongly expressed in neuronal cells [Reed et al., 2007]. Here, the 
mature proteins can be present on axons (at presynaptic terminals), dendrites and cell 
bodies during development; however, in the adult brain, they are almost exclusively found 
in postsynaptic sites on dendrites and cell bodies [Miyata et al., 2003; Hashimoto et al., 
2008].  
Previous work on the temporal and spatial expression of IgLON has mainly focussed on rat 
and chick brain. While their individual expression patterns are distinct, strong overlap 
suggesting coordinated expression can be observed in certain areas, such as the cerebral 
cortex and hippocampus [Miyata et al., 2003; McNamee et al., 2011]. While Kilon (NEGR1 in 
humans) frequently showed a broad distribution in rat brain, OPCML is much more 
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regionally restricted [Miyata et al., 2003]. Neurotrimin, which is significantly more abundant 
and wide-spread than OPCML, showed a complementary expression pattern to LSAMP 
[Levitt, 1984; Struyk et al., 1995; Gil et al., 2002]. 
Despite their distinct expression patterns, timing of IgLON expression often overlaps and 
coincides with a period during which the majority of neuronal circuits are formed in the 
developing brain [Hachisuka et al., 2000]. LSAMP expression is particularly profound during 
this time and declines postnatally [Miyata et al., 2003]. Similarly, levels of neurotrimin rise 
gradually during embryonic development and are postnatally reduced to half-maximum 
levels [Struyk et al., 1995]. Expression of Kilon/neurotractin (NEGR1) and OPCML was 
observed to increase slowly during embryonic and postnatal development, and is 
maintained at a constant level in adulthood [Funatsu et al., 1999; Marg et al., 1999; Miyata 
et al., 2003; Schäfer et al., 2005]. 
Several IgLON splice variants have been detected in rat, chicken and humans; however, as 
they commonly do not result in different mature proteins, their roles remains unclear. For 
rat and human OPCML, initially identified peptide isoforms either varied in the 5’ noncoding 
region or the signal sequence, hence resulting in the same mature protein; later, three 
additional minor isoforms were discovered [Struyk et al., 1995; Reed et al., 2007; Cui et al., 
2008]. LSAMP has also been found with modifications of both the N- and the C-terminal end 
in chicken. While N-terminal modifications lead to long and short forms of the signal peptide 
but result in identical mature proteins, C-terminal modifications consist of an additional 12 
amino acids with unknown function inserted between the third Ig domain and the GPI 
anchor [Brümmendorf et al., 1997; Lodge et al., 2000]. Similar N- and C-terminal alterations 
have been found for CEPU-1, the chicken homologue of neurotrimin, with the C-terminal 
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insert consisting of an additional 11 amino acids [Struyk et al., 1995; Spaltmann and 
Brümmendorf, 1996]. Furthermore, a secreted version of CEPU-1, which lacks the GPI 
moiety and exhibits altered biological function, has been described [Lodge et al., 2001]. The 
chicken homologue of NEGR1, neurotractin, was found to exist in a long and short isoform, 
with the short version lacking the third membrane-proximal Ig domain and showing no 
biological activity [Marg et al., 1999].   
 
1.4.3) Functions and Interactions 
Due to their increased expression in the nervous system, IgLONs have mainly been studied 
in neuronal processes where they were found to play an important role in circuit formation 
during development, and in synaptic plasticity during memory and learning processes 
[Hashimoto et al., 2008]. The molecules carry out these roles by selectively promoting or 
inhibiting neurite outgrowth through adhesive interactions, either alone or, preferentially, 
as homo- or heterodimeric complexes termed DigLONs [Lodge et al., 2000; Reed et al., 
2004; Schäfer et al., 2005]. Interestingly, heterodimeric DigLONs can have different effects 
from their respective subunits alone, and seem to be the biologically more important 
conformation with a higher affinity for trans interactions [Reed et al., 2004; Hashimoto et 
al., 2009; Akeel et al., 2011]. For example, it was found that individual overexpression of 
OPCML and CEPU-1 (neurotrimin) has no effect, while OPCML-CEPU-1 DigLONs inhibit 
neurite outgrowth of chick brain cells in culture [Reed et al., 2004]. The opposite however 
was observed for LAMP and OBCAM, which lead to increased formation of synapses in rat 
brain cells when overexpressed separately, but not together [Hashimoto et al., 2009]. 
Furthermore, LSAMP and Ntm (neurotrimin) were found to act in a bifunctional manner 
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depending on the investigated cell type, promoting neurite outgrowth in some neuronal 
populations and inhibiting it in others; it has been suggested that inhibition of outgrowth is 
due to the formation of heterophilic dimers, while homophilic dimers lead to growth-
promoting effect [Gil et al., 1998; Gil et al., 2002; Schäfer et al., 2005]. For OPCML and 
neurotractin/kilon (NEGR1), most studies so far found neurite outgrowth-promoting effects 
[Marg et al., 1999; Hachisuka et al., 2000; Schäfer et al., 2005]. Overall, these studies show 
that IgLON function strongly depends on the molecular background of the cell they are 
expressed in, which can vary greatly between different cell types and developmental stages. 
Aside from binding to other IgLONs, no interactions between IgLONs family members and 
other proteins of the Ig superfamily have been observed [Marg et al., 1999; Schäfer et al., 
2005]. However, it has been suggested that they form complexes with transmembrane 
receptors since they possess the ability to transduce extracellular signals despite their lack 
of a membrane-spanning/cytoplasmic domain. One potential set of candidates for this 
interaction are G-protein-coupled receptors as inhibition of these proteins leads to reversal 
of IgLON-mediated effects on neurite outgrowth [Clarke and Moss, 1997; Akeel et al., 2011]. 
Another group of potential candidates are receptor tyrosine kinases (RTKs); several previous 
studies have shown that the IgCAMs L1 and NCAM can bind directly to the RTK FGFR1, 
induce its phosphorylation, and thus modulate downstream signalling [Williams et al., 1994; 
Saffell et al., 1997; Kulahin et al., 2008; Zecchini et al., 2011]. Furthermore, L1 can also bind 
and activate EGFR [Islam et al., 2004]. Elucidation of the full spectrum of IgLON interaction 
partners is likely to provide a more detailed insight into their cellular mechanisms and 
physiological functions. 
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1.4.4) Localisation in Lipid Rafts 
Within the cell membrane, IgLONs have been hypothesised to accumulate in specific 
dynamic, detergent-resistant membrane subdomains called lipid rafts. These regions are 
rich in cholesterol and glycosphingolipids, and characterised by being able to selectively 
include or exclude different proteins [Nichols and Lippincott-Schwartz, 2001; Reed et al., 
2004]. GPI-anchored molecules such as IgLONs have been shown to have a high affinity to 
lipid rafts, but it remains unclear whether they are permanently located in these areas or 
only under specific circumstances [Simons and Toomre, 2000; McNamee et al., 2002]. Other 
proteins found in lipid rafts include cytoskeletal proteins or signalling molecules such as 
transmembrane receptors, which can be recruited to lipid rafts by GPI-anchored molecules 
[Harris and Siu, 2002; Yamada et al., 2007]. It has been proposed that the size of lipid rafts 
varies, but is on average approx. 50 nm in diameter [Simons and Toomre, 2000]. 
Lipid rafts are areas of frequent endocytosis [Sharma et al., 2004]. However, since they 
specifically exclude markers of clathrin-mediated endocytosis, they have been proposed to 
initiate alternative, clathrin-independent pathways [Nichols and Lippincott-Schwartz, 2001]. 
Rafts can modify IgLON functioning in several ways. Firstly, recruitment of IgLONs to the raft 
domain promotes cis-oligomerisation, thus stabilising the molecules and hence enabling 
strong cell-cell interaction and adhesion via trans interactions [Nichols and Lippincott-
Schwartz, 2001; Harris and Siu, 2002]. Secondly, signalling is facilitated by protection of the 
IgLON-receptor complex from molecules such as phosphatases which could interfere with 
signalling, and by promotion of interaction with local kinases to activate the correct 
downstream signalling pathway [Simons and Toomre, 2000]. Furthermore, raft-associated 
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endocytosis or protein shedding could be mechanisms to modulate the duration of 
signalling events [Harris and Siu, 2002]. 
Most likely, several distinct types of lipid rafts exist which differ both with regards to 
molecule composition as well as endocytotic sorting mechanisms [Nichols and Lippincott-
Schwartz, 2001]. One of these subsets are the caveolae, which are characterised by the 
accumulation of cholesterol-binding membrane proteins called caveolins [Simons and 
Toomre, 2000; Nichols and Lippincott-Schwartz, 2001]. It has been suggested that 
endocytosed caveolae do not fuse with early endosomes (as seen for clathrin-dependent 
pathways, see Figure 11, page 71), but instead deliver their cargo to distinct intracellular 
organelles termed caveosomes [Nichols and Lippincott-Schwartz, 2001]. However, further 
research is needed to elucidate the precise differences in assembly, function and 
endocytosis of these and other types of lipid rafts. 
 
1.4.5) Pathological Implications 
Due to their high expression in the nervous system, IgLONs – particularly LSAMP – have 
frequently been associated with behavioural abnormalities. Several studies found that loss 
of LSAMP is associated with heightened exploratory activity and decreased anxiety in mice 
and rats, while the opposite was found for increased LSAMP protein levels [Nelovkov et al., 
2003; Nelovkov et al., 2006; Catania et al., 2008]. Furthermore, LSAMP knockout mice 
exhibited poorer spatial memory and weaker long-term potentiation, a process involved in 
synaptic plasticity [Qiu et al., 2010]. In humans, LSAMP might play a role in major depressive 
disorder, panic disorder, schizophrenia, bipolar disorder and suicidal behaviour [Must et al., 
2008; Behan et al., 2009; Koido et al., 2012]. Additionally, low expression of LSAMP has 
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been associated with an increased risk to develop atherosclerosis due to increased 
proliferation of aortic smooth muscle cells [Wang et al., 2008]. For NEGR1, a positive 
correlation with increased BMI (body mass index) and obesity has been observed in several 
studies [Willer et al., 2009; Lim et al., 2012]. 
 
1.4.5.1) IgCAMs and IgLONs in Cancer 
As tumourigenesis and cancer progression are frequently associated with changes in the 
way cells interact with each other and their environment, it is not surprising that a broad 
range of cell adhesion molecules such as IgCAMs have been implicated in cancerous 
processes, particularly invasion and metastasis. Furthermore, since IgCAMs not only 
regulate adhesion but also cell signalling, it has been suggested that members of this group 
of proteins are involved in almost all steps of cancerogenesis [Cavallaro and Christofori, 
2004]. 
One of the IgCAMs most frequently associated with cancer is L1, which has been implicated 
in ovarian, breast, prostate, lung and renal cancer as well as gliomas and melanomas due to 
its ability to increase cell motility and invasion [Cavallaro and Christofori, 2004; Gutwein et 
al., 2005; Novak-Hofer et al., 2008; Bombardelli and Cavallaro, 2010]. In ovarian cancer, it is 
overexpressed in a stage-dependent manner, has been associated with cisplatin resistance 
and metastasis, and is linked to poorer prognosis [Gutwein et al., 2005; Novak-Hofer et al., 
2008; Bombardelli and Cavallaro, 2010]. On a molecular level, L1 is able to promote 
migration and decrease apoptosis by interaction with receptor tyrosine kinases, particularly 
FGFR1 and EGFR [Bombardelli and Cavallaro, 2010]. Anti-L1 antibodies have been shown to 
reduce proliferation as well as activity of signalling molecules downstream of FGFR1, such as 
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Erk1/2, and synergise with tyrosine kinase inhibitors such as genistein [Novak-Hofer et al., 
2008]. Additional IgCAMs involved in cancer development and progression include NCAM 
(downregulated in highly malignant pancreatic cancers, upregulated in ovarian cancer and 
gliomas), MCAM and EpCAM (both upregulated in advanced ovarian cancer) or Mel-CAM 
(upregulated in melanoma, downregulated in breast cancer) [Cavallaro and Christofori, 
2004; Mezzanzanica et al., 2008; Bombardelli and Cavallaro, 2010; Zecchini et al., 2011]. 
 
Like other IgCAMs, IgLONs can be either up- or downregulated depending on the type of 
tumour. Interestingly, methylation and deletions rather than mutations seem to be the 
most frequent causes for alteration of IgLON expression in cancer. So far, most studies have 
focussed on gene expression profiling of tumours, while functional analyses remain rare. 
By far the largest number of studies has been carried out on OPCML, which has been shown 
to be a tumour suppressor in epithelial ovarian cancer (see 1.6.1) as well as in a wide variety 
of other cancer types. In cervical cancer, tumour cells were found to express significantly 
less OPCML than normal tissue; this reduction in expression was accompanied by OPCML 
promoter methylation in 63.9% of investigated cancer samples, while normal tissue was 
generally unmethylated [Ye et al., 2008]. However, in a small number of cases, OPCML 
promoter methylation did not result in reduced gene expression, or gene expression was 
reduced despite the OPCML promoter being unmethylated; other mechanisms therefore 
seem to play an additional role in OPCML regulation. In bladder cancer, OPCML promoter 
methylation was detected in 60% of cases and correlated with lower gene expression as well 
as poorer prognosis [Duarte-Pereira et al., 2011]. In a study on cholangiocarcinoma, OPCML 
– which was unmethylated in adjacent normal tissue – was found to be methylated in 72.5% 
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of cases, and >70% of these samples displayed reduced protein levels [Sriraksa et al., 2011]. 
Many other studies, despite not addressing the functional consequences, confirmed 
hypermethylation of OPCML, particularly in different types of lung cancer such as 
adenocarcinoma [Tsou et al., 2007], squamous cell lung cancer [Anglim et al., 2008], atypical 
adenomatous hyperplasia, adenocarcinoma in situ, and invasive lung adenocarcinoma 
[Selamat et al., 2011]. Other tumours showing methylation and concomitant 
downregulation of OPCML compared to their respective normal tissue counterparts include 
nasopharyngeal, esophageal, gastric, hepatocellular, colorectal, breast and prostate cancers 
[Cui et al., 2008]. In the latter study, no homozygous and only very infrequent hemizygous 
deletions were observed, indicating that methylation is the main mechanism for OPCML 
dysregulation in a broad range of cancer types. Treatment with demethylating agents 
restored expression of OPCML, and transfection of non-expressing cancer cells with OPCML 
resulted in reduced anchorage-dependent and -independent growth. Only a small number 
of cell lines showed reduction in OPCML expression without promoter methylation; in these 
cases, other mechanisms such as histone modification or mutations could be the underlying 
mechanism for OPCML downregulation. 
One of the few studies in which no correlation between OPCML promoter methylation and 
gene expression could be observed is the study by Reed et al. on brain tumours [Reed et al., 
2007]. Still, 83% of investigated tumours and 100% of investigated cancer cell lines showed 
a strong reduction or absence of OPCML protein compared to normal brain. In another 
report on gastric cancer, a stage-dependent reduction of OPCML gene expression was 
detected, but promoter methylation status was not investigated [Wang et al., 2006]. 
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Studies on other IgLONs in the context of cancer have been less abundant. Increased 
expression of NEGR1 has been associated with improved survival in infant acute 
lymphoblastic leukemia [Kang et al., 2012]; in neuroblastoma, its expression was decreased 
in advance-stage tumours compared with early-stage tumours [Takita et al., 2011]. In the 
latter study, no mutations or association with methylation were detected, but frequent 
heterozygous deletion, particularly in advanced tumours, could be observed. Furthermore, 
exogenous expression of NEGR1 led to reduced cell proliferation. 
 
LSAMP has most frequently been implicated in osteosarcoma. In 2010, Pasic et al. reported 
downregulation of LSAMP expression in 64.6% of investigated primary tumours and cell 
lines [Pasic et al., 2010]. Interestingly, while exogenous overexpression of LSAMP had no 
effect on proliferation, cell cycle progression or apoptosis, LSAMP depletion led to increased 
proliferation; these seemingly paradoxical findings could indicate that loss of LSAMP in 
osteosarcoma represents an early event and can hence not be compensated for by 
exogenous overexpression in tumours which have evolved further. Mutations or alternative 
splicing were not observed, but loss of heterozygosity (LOH) could be detected in 25% of 
samples. In a further study on osteosarcoma, expression of LSAMP was reduced in 27-56% 
of tumour samples and cancer cell lines, and associated with poorer survival [Kresse et al., 
2009]. Both methylation and genomic deletions were identified as mechanisms for LSAMP 
downregulation, with the latter being more common. These findings were supported by a 
further report on osteosarcoma, which observed deletion of LSAMP and subsequently 
reduced levels of mRNA transcripts [Yen et al., 2009]. 
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Apart from osteosarcoma, a recent study on acute myeloid leukaemia showed that the 
genetic region containing LSAMP is frequently deleted in this disease; however, the 
functional consequences of the deletion remain to be elucidated [Kühn et al., 2012]. In a 
study on familial clear cell renal cell carcinoma (CCRCC), Chen et al. reported frequent 
downregulation of LSAMP in CCRCC primary tumours and cell lines; exogenous expression of 
LSAMP in these cell lines led to reduced proliferation [Chen et al., 2003a]. While mutations 
of LSAMP could not be detected, promoter methylation was observed in up to 78% of cases, 
and treatment with the demethylating agent 5-aza-2′-deoxycytidine resulted in re-
expression of the gene. Furthermore, the investigated familial cases showed biallelic 
inactivation, with one allele being deleted and the other one hypermethylated. The group 
additionally addressed the role of LSAMP in colorectal cancers, and found its promoter to be 
methylated in 26% of tumours. 
 
Overall, the entire IgLON family – with the exception of neurotrimin, which might have 
opposite functions compared to OPCML, LSAMP and NEGR1 (see 1.6.1) – has frequently 
been suggested to have tumour suppressor function in a wide range of cancers. At least for 
OPCML, this effect might be based on interaction with receptor tyrosine kinases, a group of 
proteins involved in many cellular signalling pathways. Key characteristics of these 
molecules are described in the following sections.  
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1.5) Receptor tyrosine kinases (RTKs) 
Receptor tyrosine kinases (RTKs) are a group of diverse cell surface receptors involved in a 
large variety of signalling pathways, ultimately regulating a broad range of cellular functions 
such as cell survival, growth or proliferation. Within the human genome, 58 different RTKs 
have been identified so far, and many of them have been implicated in human cancers due 
to their importance in the aforementioned regulatory processes [Yarden and Pines, 2012]. 
Since a large variety of up- and downstream proteins play roles in RTK-induced signalling 
processes, the precise cellular response each RTK elicits strongly depends on the molecular 
background of the cell, i.e. on the cell type, developmental stage, and cellular 
microenvironment [Schlessinger, 2000].  
 
1.5.1) Structure and Function 
RTKs are transmembrane molecules composed of an extracellular ligand binding domain, a 
single transmembrane helix, and a cytoplasmic tyrosine kinase domain (Figure 10A) 
[Schlessinger, 2000]. Except for members of the insulin receptor family, they exist as 
monomers in the membrane which form stable dimers upon ligand binding [Schlessinger, 
2000]. Dimerisation results in phosphorylation of specific residues within the receptors’ 
intracellular tyrosine kinase domains, thus creating binding sites for various molecules, 
particularly enzymes or adaptor proteins containing Src-homology-2 (SH2) and 
phosphotyrosine-binding (PTB) domains [Aplin et al., 1998; Sorkin and Von Zastrow, 2002]. 
These molecules can subsequently recruit and/or activate further downstream molecules 
and thereby initiate a broad range of molecular signalling pathways, leading to changes in 
gene expression and consequently alteration of cellular properties and various processes 
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such as apoptosis, proliferation, migration, differentiation, angiogenesis, and metabolism 
[Arteaga, 2002]. Two of the pathways most frequently activated by RTKs are the PI3K/Akt 
and Ras/Erk pathways (Figure 10B). Activation of Akt frequently results in increased survival 
due to its interaction with mTOR, a pro-survival molecule, while activation of Erk1/2 
(downstream of Ras) promotes changes in gene expression through modulation of several 
types of transcription factors [Schlessinger, 2000]. 
 
 
Figure 10: Schematic structure (A) and function (B) of receptor tyrosine kinases (RTKs). 
RTK structures vary from family to family; simplified representatives of the EGFR, VEGFR and FGFR families are 
shown here (A). Generally, RTKs are monomeric molecules with a single transmembrane helix connecting the 
extra- and intracellular domains. Downstream signalling strongly depends on the type of RTK and ligand; two 
of the main pathways activated by different RTKs are the PI3K/Akt (left) and Ras/Erk (right) pathways (B). A: 
Figure created based on [Croce, 2008]. B: Figure created based on [Yarden and Pines, 2012]. 
 
1.5.2) Regulation 
Due to its immense biological importance, RTK activity needs to be tightly regulated, and 
signalling has to be terminated if no longer required. One mechanism of RTK inactivation is 
A) B) 
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dephosphorylation of the intracellular domain by protein tyrosine phosphatases (PTPs) 
[Schlessinger, 2000]. More frequently however, activation of RTKs is terminated by 
endocytosis to reduce the number of active receptors at the cell surface (Figure 11). 
Activated RTKs mainly assemble within clathrin-coated pits prior to cellular uptake; 
however, alternative mechanisms of endocytosis, e.g. via lipid rafts, have also been 
described. Within the cell, endocytosed RTK-containing vesicles mature from early to late 
endosomes with increasingly lower pH, thereby inducing the dissociation of the ligand from 
the receptor [Yarden and Sliwkowski, 2001]. Ligand-free receptors are generally recycled 
back to the cell surface, while undissociated ligand-receptor complexes are either tagged for 
proteasomal degradation by polyubiquitination or, more commonly, are degraded in 
lysosomes. 
 
 
Figure 11: RTK regulation and degradation by endocytosis. 
RTK endocytosis mainly occurs via clathrin-mediated pathways ①, but other mechanisms have been 
described as well ②. From early endosomes, ligand-free receptors can be rapidly recycled back to the cell 
surface (t½ = ~5-7 min) ③, while slow recycling (t½ = ~20 min) ④ occurs from both early and late endosomes. 
Degradation is mediated by proteasomes ⑤ or, more commonly, lysosomes (t½ = ~1-2 h) ⑥. Colour change 
to red indicates decline in pH. t½: half life time. Figure created based on [Sorkin and Von Zastrow, 2002] and 
[Yarden and Sliwkowski, 2001]. 
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1.5.3) Selected RTK Families in Ovarian Cancer 
Apart from downstream signalling molecules such as Ras or PTEN (see Figure 10B), which 
are frequently mutated in cancer, RTKs themselves can be the source of aberrant signalling 
due to mutation or overexpression. Based on their structure, RTKs can be grouped into 
different families (see Figure 10A). This project mainly focussed on the interaction of IgLONs 
with members from the EGFR, FGFR, and VEGFR families. 
The epidermal growth factor receptor (EGFR) family consists of four members, EGFR 
(ErbB1), HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4) and is mainly involved in pathways 
regulating cell growth. Ligands include molecules such as EGF and TNFα (EGFR) or NRG1 and 
NRG2 (HER3 and HER4); interestingly, HER2 does not seem to have ligand-binding activity, 
and its important role in many cancers has therefore been attributed to it being the 
preferred binding partner for the remaining family members [Yarden and Pines, 2012]. HER3 
is devoid of intracellular kinase activity but forms highly active heterodimers with HER2, 
thus strongly activating both the PI3K/Akt and Ras/Erk pathways, leading to increased 
proliferation and reduced apoptosis [Yarden and Pines, 2012]. Efficiency of regulation by 
endocytosis differs between the four family members, with EGFR frequently being degraded 
in the lysosome, HER3 constitutively being recycled to the cell surface, and 
heterodimerisation with HER2 leading to decreased endocytosis and increased recycling of 
the molecule’s binding partners [Yarden and Sliwkowski, 2001]. 
While the normal ovary expresses low levels of EGFR, between 50-98% of ovarian cancers 
have been reported to overexpress the molecule, often in a mutated, constitutively active 
form [Moscatello et al., 1995; Bartlett et al., 1996; Ilekis et al., 1997]. High expression of 
EGFR has frequently been associated with worse prognosis, presumably due to its 
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involvement in chemotherapy resistance [Bartlett et al., 1996]. Whether EGFR expression is 
associated with tumour stage or grade remains a matter of debate [Moscatello et al., 1995; 
Salomon et al., 1995; Bartlett et al., 1996]. Unlike many other cancers, HER2 seems to play a 
less important role than EGFR; still, it is overexpressed in about 25% of ovarian cancers and 
associated with reduced response to primary therapy as well as shorter survival [Salomon et 
al., 1995]. Overexpression in ovarian cancer has also been reported for HER3 and HER4 
[Yarden and Pines, 2012]. 
Receptors of the vascular endothelial growth factor receptor (VEGFR) and fibroblast 
growth factor receptor (FGFR) families mainly play roles in angiogenesis and proliferation 
[Folkman and Shing, 1992]. The VEGFR family comprises three members (VEGFR1-3), while 
the FGFR family has four members (FGFR1-4); as shown in Figure 10, their extracellular 
components are made up of several Ig domains. In ovarian cancer, overexpression of VEGFR 
family members leads to tumour progression, presumably due to their interaction with STAT 
(signal transducer and activator of transcription) proteins [Chen et al., 2004]. The FGFR 
family, particularly FGFR1 and FGFR4, has been associated with increased aggressiveness of 
ovarian tumours [Birrer et al., 2007]. 
 
1.5.3.1) RTK-targeting Drugs 
Drugs interfering with RTK functioning can be roughly divided into two different classes: 
molecules such as antibodies, which interact with the extracellular domain and thus inhibit 
ligand binding; and molecules such as small molecule tyrosine kinase inhibitors (TKIs), which 
bind to the intracellular kinase domain and compete with ATP, thus preventing 
phosphorylation [Arteaga, 2002]. While it has been suggested that treatment with TKIs is 
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advantageous over antibody therapy due to the molecules’ smaller size (leading to better 
bioavailability) and intracellular mechanism of action (meaning they are also effective in 
inhibiting constitutively active RTKs with deleted extracellular domains), both types of 
treatments could act synergistically [Roy and Perez, 2009]. However, clinical success so far 
has varied greatly between patients, and resistance remains a considerable problem [Yarden 
and Pines, 2012]. Examples of anti-RTK antibodies include cetuximab/Erbitux (EGFR) and 
trastuzumab/Herceptin (HER2), while erlotinib/Tarceva (EGFR), gefitinib/Iressa (EGFR) and 
lapatinib/Tykerb (HER2) represent RTK-specific TKIs [Roy and Perez, 2009; Yarden and Pines, 
2012]. 
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1.6) The PhD Project 
The main focus of the project was to investigate the role of the IgLON family in ovarian 
cancer and its interaction with members of the RTK families. Since OPCML had been 
extensively investigated in previous studies and found to be a bona fide tumour suppressor 
gene in ovarian cancer, the aim was to determine if the other IgLON family members, 
particularly LSAMP and NEGR1, could function in a similar manner. 
 
1.6.1) Previous findings: OPCML and other IgLONs in EOC 
Investigations so far have mainly focussed on the role of OPCML epithelial ovarian cancer, 
with only one study investigating the IgLON family as a whole. The first paper relating 
OPCML to EOC was published by Sellar et al. in 2003 and reported abrogation of OPCML 
expression in 83% of investigated primary ovarian tumours and 88% of ovarian cancer cell 
lines compared with normal human total ovary [Sellar et al., 2003]. While OPCML was found 
to be unmethylated and expressed in normal human ovarian surface epithelium, it was 
methylated in 83% of cancer samples and 82% of cancer cell lines. Methylation correlated 
with reduced gene expression, which was reversible by treatment with the demethylating 
agent 5'-aza-2'-deoxycytidine. A somatic missense mutation was detected in 1 of 212 
tumours, leading to a P→R amino acid substitution at position 95. In accordance with its 
central position in one of the β-sheets of domain 1, P95R resulted in a significant loss of cell 
aggregation. Exogenous expression of wildtype OPCML in the non-expressing ovarian cancer 
cell line SKOV3 led to reduced cell proliferation and increased aggregation in vitro; 
furthermore, OPCML-transfected SKOV3 cells showed diminished tumour growth and 
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attachment in nude mice in vivo. Based on these results it was suggested that loss of OPCML 
promotes early cancerogenesis by reducing aggregation and increasing proliferation. 
In a subsequent study by Teodoridis et al., OPCML methylation was found in 33% of stage III 
and IV epithelial ovarian tumours, prompting the authors to speculate that OPCML 
methylation could be associated with stage (as they found higher rates of methylation in 
borderline and early-stage tumours) or possibly histological subtype [Teodoridis et al., 
2005]. The lower frequency of methylation observed here compared with the study by Sellar 
et al. could also be an indication that silencing of OPCML can additionally be mediated by 
mechanisms other than methylation. 
 
Apart from OPCML, the remaining IgLON family members have been implicated in epithelial 
ovarian cancer as well. In a study by Ntougkos et al., it was found that mRNA levels of 
OPCML, LSAMP and particularly NEGR1 were reduced in tumour samples compared with 
healthy controls, while the opposite was observed for neurotrimin [Ntougkos et al., 2005]. 
These differences were found to be histology-specific, with OPCML being downregulated in 
clear cell carcinomas, LSAMP in endometrioid tumours, and NEGR1 in clear cell, 
endometrioid and serous cancers; upregulation of neurotrimin was particularly pronounced 
in serous EOC. Except for neurotrimin, expression of the individual IgLON family members 
was found to be positively correlated (LSAMP and NEGR1, OPCML and NEGR1, OPCML and 
LSAMP). No relationship between IgLON expression and stage or patient age was detected; 
however, levels of LSAMP were lower in undifferentiated tumours (grade 3) than in well and 
medium-differentiated samples (grades 1 and 2), suggesting a role for the protein in 
differentiation. Paradoxically, high expression of LSAMP was a negative predictor of survival; 
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the reason behind these findings remains to be determined, but could be due to the 
aforementioned association with tumour grade. 
Overall, two factors need to be kept in mind for this as well as most other studies on IgLON 
expression levels (see also 1.4.5.1): firstly, the majority of studies was carried out 
investigating mRNA levels, but did not address consequences at the protein level. It hence 
needs to be verified if protein expression is altered in the same fashion as gene expression 
in the investigated samples. Secondly, it has to be noted that ovarian tissue was generally 
used as the normal control; however, in light of the changing hypothesis on the origin of 
ovarian cancer (see 1.3.5.1) this may not be appropriate, and other tissues, e.g. fallopian 
tube tissue for serous EOC, may be more suitable to determine whether a gene or protein is 
over-/underexpressed in tumour samples. 
Therefore, as previous studies so far mainly focussed on IgLON gene expression, our group 
published a series of experiments earlier this year investigating the potential functional 
mechanisms of OPCML in epithelial ovarian cancer at the protein level [McKie et al., 2012]. 
One of the key findings was that OPCML seems to carry out its growth-suppressing functions 
by direct interaction with and downregulation of a broad set of RTKs. Stable and transient 
transfections of the non-expressing ovarian cancer cell lines SKOV3 and PEO1 with OPCML 
resulted in reduced protein levels of several RTKs such as HER2 or FGFR1; conversely, siRNA-
mediated silencing of OPCML in the normal epithelial surface cell line OSE-C2 led to 
upregulation of the same set of RTKs (Figure 12A). Furthermore, reduced phosphorylation of 
RTKs and the downstream signalling molecules Akt and Erk1/2, as well as inhibition of 
proliferation, were observed (Figure 12B). Since no changes in mRNA levels could be 
detected for the downregulated RTKs, protein reduction most likely occurs 
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posttranslationally. Expression of OPCML could be induced by treatment with EGF and 
FGF1/2, potentially suggesting a negative feedback mechanism. 
As OPCML was found to be able to bind to the RTKs it downregulates, but not the RTKs that 
remain unaffected (such as EGFR or FGFR2), its function seems to be based on direct 
interaction (Figure 12C). Pull-down experiments indicated that binding occurs via the 
extracellular RTK domains; this was supported by the finding that OPCML was able to 
downregulate full-length HER2 (p185) in transfected cells, but not its p95 version which 
lacks the extracellular domain. Concurrently, OPCML was only able to reduce cell 
proliferation induced by transfection of cells with p185, but not by p95. 
Interestingly, it was observed that HER2 in OPCML-transfected cells increasingly 
accumulated in detergent-resistant regions of the membrane, presumably lipid rafts (see 
1.4.4), and was found to colocalise with markers for caveolae rather than markers for early 
endosomes, i.e. clathrin-mediated endocytosis, in IFM. Furthermore, OPCML-overexpressing 
cells exhibited increased loss of surface HER2 compared to untransfected controls. Both 
observations indicate that OPCML induces sequestration of HER2 to lipid rafts, which could 
lead to increased clathrin-independent endocytosis of the receptor. The shift from clathrin-
mediated endocytosis, which often leads to receptor recycling, towards a raft-mediated 
uptake and consequently degradation of polyubiquitinated RTKs in the proteasome, could 
explain the high efficiency of RTK downregulation in OPCML-transfected cells. This 
hypothesis was undermined by the findings that presence of OPCML led to increased 
ubiquitination of HER2, and that inhibition of proteasomal activity – but not lysosomal 
activity – could prevent OPCML-induced HER2 downregulation (Figure 12D).  
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Figure 12: OPCML functioning in vitro. 
Overexpression of OPCML in vitro leads to downregulation of RTKs such as FGFR1 or HER2 in OPCML-
transfected SKOV3 cells (SKOBS3.5 and BKS2.1) compared to the empty vector control (V1.2), while the 
converse occurs upon OPCML silencing in normal surface epithelium cells (OSE-C2) (A). OPCML-expressing BKS-
2.1 and SKOBS-3.5 cells as well as OSE-C2 show decreased proliferation compared to V1.2 cells (B). 
Immunoprecipitation assays reveal interaction of OPCML with the RTK it downregulates (HER2, FGFR1) but not 
unaffected ones (EGFR) (C). Downregulation of HER2 by OPCML is inhibited using the proteasomal inhibitor 
MG-132, but not the lysosomal inhibitor chloroquine (CQ) (D). Figures from [McKie et al., 2012]. 
 
Interestingly, treatment of ovarian cancer cell lines with a recombinant OPCML protein 
(rOPCML) yielded a similar pattern of RKT downregulation as well as attenuated 
phosphorylation of downstream signalling molecules as observed for exogenous OPCML 
overexpression (Figure 13A), and showed profound reduction of proliferation in multiple cell 
lines (Figure 13B). In vivo, mice intraperitoneally injected with SKOV3 or A2780 ovarian 
cancer cells exhibited reduced ascites and tumour burden if treated with rOPCML compared 
to a BSA control (Figure 13C). 
A) B) 
C) 
D) 
PhD Thesis – Sarah Christen – Imperial College London Introduction 
80 
 
 
Figure 13: rOPCML functioning in vitro and in vivo. 
Treatment of SKOV3 and A2780 ovarian cancer cell lines with recombinant OPCML (rOPCML) results in 
downregulation of the same spectrum of RTKs as observed with exogenous overexpression of OPCML (A). 
Proliferation of various cancer cell lines is reduced upon treatment with rOPCML, while the OPCML-expressing 
normal ovarian surface cell line OSE-C2 remains unaffected (B). Tumour burden in mice intraperitoneally 
injected with A2780 and SKOV3 ovarian cancer cells is substantially reduced in animals treated with rOPCML 
compared to BSA-treated controls (C). Figures from [McKie et al., 2012]. 
 
Overall, these results show that OPCML – both exogenously and as a recombinant protein – 
is able to bind a specific repertoire of RTKs, induce their downregulation via clathrin-
independent, raft-based endocytosis leading to proteasomal degradation, and thus 
decrease RTK signalling and cell proliferation both in vitro and in vivo. 
A) B) 
C) 
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1.6.2) Hypothesis and Aims 
Since the therapeutic use of a recombinant protein mimicking the functions of an 
extracellular tumour suppressor molecule could have huge clinical implications, 
investigation of the remaining IgLON family members in addition to OPCML is warranted, 
particularly as not only OPCML but also LSAMP and NEGR1 are downregulated in epithelial 
ovarian cancer [Ntougkos et al., 2005]. We therefore hypothesise that LSAMP and NEGR1 
might also interact with receptor tyrosine kinases, but potentially a different spectrum; in 
that case, clinical treatment with different recombinant IgLONs could target a broad range 
of signalling pathways and thus overcome the frequently observed issue of pathway 
redundancy and development of drug resistance. 
The aims of this project were to investigate if LSAMP and NEGR1 exhibit comparable tumour 
suppressor properties as OPCML in vitro. Initially, similarities in structure, methylation 
status and clinical relevance were assessed to gain an insight into the IgLON family as a 
whole. Subsequently, functional implications of LSAMP and NEGR1 were investigated 
analogous to the work described for OPCML: their expression in various ovarian cancer cell 
lines, cellular localisation, response to growth factors, impact on RTK expression, and 
protein-protein interaction were addressed; furthermore, the consequences of IgLON 
overexpression and downregulation were investigated with regards to physiological 
properties such as proliferation, migration or colony-forming ability. 
As ovarian cancer remains the most lethal cancer in women, increased efforts to determine 
its causes and identify potential therapeutic applications are urgently required. To this end, 
the IgLON family represents an excellent subject of study due to its potential ease of clinical 
application and broad spectrum of action. 
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2.1) Bioinformatics 
2.1.1) Amino Acid Sequence Analyses 
Full IgLON amino acid sequences were retrieved from the Uniprot website 
(www.uniprot.org); the identifier for OPCML is Q14982, for LSAMP Q13449, for NEGR1 
Q7Z3B1, and for neurotrimin Q9P121. Comparison was carried out using the sequence 
alignment tools T-Coffee (http://tcoffee.crg.cat/apps/tcoffee/do:regular) and ClustalW2 
(www.ebi.ac.uk/Tools/msa/clustalw2). T-Coffee yields a broad overview of sequence 
comparison as it includes a colour index evaluating the alignment quality of blocks of several 
residues together, while analysis with ClustalW2 provides more specific information on each 
amino acid residue individually. 
 
2.1.2) Methylation Status Analysis 
OPCML and NEGR1 methylation status was compared between normal fallopian tube tissue 
samples (n=10) and high-grade serous tumours (n=242) from the TCGA dataset [TCGA, 
2011]. Statistical significance between methylation degrees in each cohort was assessed 
using the Mann-Whitney test calculated by R (www.r-project.org). No data was available for 
LSAMP or NTM (neurotrimin). 
 
2.1.3) Kaplan-Meier Survival Plots 
Survival analysis was carried out using a publicly available data collection of 295 fully 
annotated primary ovarian tumours [Tothill et al., 2008]. Gene expression levels in this 
dataset had been determined using the GeneChip® Human Genome U133 set (Affymetrix), 
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which contains probes for all four IgLONs (LSAMP: 214460_at; NEGR1: 229461_x_at, 
239548_at, 243357_at; NTM (neurotrimin): 222020_s_at, 227566_at, OPCML: 206215_at, 
214111_at). Probes were selected based on the UCSC Genome Browser 
(http://genome.ucsc.edu/cgi-bin/hgTracks), with sequences located towards the 3’ end of 
each gene preferentially chosen further analyses. 
After exclusion of unsuitable cases (e.g. incomplete survival information), 257 cases 
remained for generation of Kaplan-Meier plots. IgLON data was split into low and high 
expression (divided by the median) and analysed with regards to progression-free and 
overall survival. Statistical significance was investigated using the log rank test calculated by 
R (www.r-project.org). 
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2.2) Cell Culture Techniques 
2.2.1) Description of Cell Lines 
A summary of the main cell lines used in this project is given in Table 2 below; for details on 
these and additional cell lines, see Table 12, Appendix A. Most cell lines were obtained from 
the American Type Culture Collection (www.atcc.org). The immortalised normal surface 
epithelium cell line OSE-C2 was created by Davies et al. [Davies et al., 2003], while the 
SKOV3 derivatives V1.2, BKS2.1 and SKOBS3.5 were created by Sellar et al. [Sellar et al., 
2003]. PEO and PEA cell lines were established by Langdon et al. [Langdon et al., 1988]. 
For functional analyses, several cell lines were modified during this project to generate 
derivatives with stably increased (see 2.2.8) or decreased (see 2.2.6) IgLON expression levels 
(Table 2, highlighted in grey).  
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Table 2: Description of key cell lines 
Basic characteristics of the main cell lines used in this project. Grey shading indicates stably transfected cell 
lines generated both for IgLON silencing (LSAMP in 33-3, 35-3) and overexpression (LSAMP in LS14, NEGR1 in 
S6 and A29). For more details on these and other cell lines, see Table 12, Appendix A. 
Cell Line Description Selection 
OSE-C2 Immortalised “normal” ovarian surface epithelium (OSE) cell line. 
Expression of OPCML, LSAMP and NEGR1. 
- 
SKOV3 Ovarian cancer cell line (serous). Negligible expression of OPCML and 
NEGR1. LSAMP present. 
- 
BKS2.1 SKOV3 cells stably transfected with OPCML in pcDNA3.1. Approx. 30-fold 
increase of OPCML expression. 
125 µg/ml 
zeocin 
V1.2 Empty vector control to BKS2.1 (transfected with pcDNA3.1 empty vector). 
Negligible expression of OPCML. 
125 µg/ml 
zeocin 
33-3, 35-
3 
OSE-C2 cells stably transfected with LSAMP shRNA in pLKO.1 vector. 
Derived from independent transfections. 
3 µg/ml 
puromycin 
P3, P6 Empty vector control to 33-3 and 35-3 (transfected with pLKO.1 empty 
vector). 
3 µg/ml 
puromycin 
LS14 SKOV3 cells stably transfected with LSAMP in pcDNA™4/TO vector. 200 µg/ml 
zeocin 
EV4 Empty vector control to LS14 (transfected with pcDNA™4/TO empty 
vector). 
200 µg/ml 
zeocin 
S6, A29 SKOV3 cells stably transfected with NEGR1 in pReceiver-M10 vector. 
Derived from independent transfections. 
1 mg/ml 
geneticin 
EX1, EX5 Empty vector control to S6 and A29 (transfected with pReceiver-EX-NEG-
M10 empty vector). 
1 mg/ml 
geneticin 
 
 
2.2.2) Cell Maintenance and Quality Control 
Except for OSE-C2 cells, all cell lines were maintained in RPMI-1640 medium (HEPES 
modification; Sigma, St. Louis, USA) supplemented with 2 mM L-glutamine (Invitrogen, 
Carlsbad, USA), penicillin-streptomycin (50 units/ml penicillin, 50 µg/ml streptomycin; 
Gibco, Carlsbad, USA), and 10% foetal calf serum (FCS, First Link (UK) Ltd., Wolverhampton, 
UK) in a humidified incubator at 37 °C and 5% CO2. Additional antibiotics were added for 
selection purposes as required (Table 2). 
OSE-C2 cells were maintained in antibiotic-free RPMI-1640 medium in a humidified 
incubator at 33 °C and 5% CO2. 
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Mycoplasma tests were carried out once a month using the MycoAlert® Mycoplasma 
Detection Kit and the MycoAlert® Assay Control Set (both Lonza, Basel, Switzerland) 
according to the manufacturer’s instructions. 
 
2.2.3) Passaging and Seeding 
Depending on doubling time, cells were split every 4-7 days upon reaching 80-90% 
confluency. Incubation in trypsin (25 mg/ml trypsin in 0.02% EDTA; Sigma) for 2-5 minutes at 
37 °C was used to detach cells from the flask surface. After resuspension in full medium 
(containing 10% FCS) to stop trypsinisation, cells were pelleted by centrifugation at 1,500 
rpm for 5 min. Cells were then either counted for seeding using a haemocytometer (Bright-
Line®, Reichert, Depew, USA), or transferred into a new flask (1:2-1:15 dilution) with fresh 
full medium. 
 
2.2.4) Cryopreservation 
For long-term storage, cells were resuspended in antibiotic-free full medium supplemented 
with 10% DMSO (Sigma). Approx. 2.5-5x105 cells were used per cryovial and stored for 
several hours at -20 °C before being transferred into a -80 °C freezer. 
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2.2.5) Transient IgLON Silencing 
2.2.5.1) LSAMP 
OSE-C2 cells were seeded at a concentration of 1x105 cells per well in antibiotic-free full 
medium in a 6-well plate to achieve a confluency of 40-50% at the time of treatment. After 
24 h, cells were transfected with 10 nM LSAMP siRNA (six individual constructs, used either 
separately or pooled; Table 3) using Lipofectamine™ RNAiMAX (Invitrogen) according to the 
manufacturer’s instructions. In brief, siRNA was mixed with Lipofectamine™ reagent in FCS-
free medium to induce the formation of liposomes containing siRNA. As liposomes are made 
up of a lipid bilayer, they can easily fuse with cell membranes and thus introduce particles 
like siRNA into the cytoplasm of a cell. After 10 min, the siRNA/Lipofectamine™ mixture was 
added to the cells. Mock-transfected cells (treated with Lipofectamine alone) as well as cells 
transfected with non-targeting Stealth™ RNAi Negative Control (medium GC duplex, 
Invitrogen) were included as controls for cytotoxicity and sequence-independent effects. 
48 h post transfection, cells were harvested for analysis Western blotting analysis (see 
2.5.1). 
 
Table 3: LSAMP siRNA sequences. 
Apart from three commercially available siRNA constructs (MISSION® siRNA), three additional sequences were 
either taken from previous publications (P) or designed manually (I, E). Stealth™ RNAi Negative Control (Cat. 
No. 12935300, Invitrogen) was used to assess potential sequence-independent effects of transfection. All 
sequences were purchased from Sigma. For catalogue numbers, see Table 13, Appendix A. 
Name Sense Antisense Design 
1 5' CCUGUUCGCAGCGUGGAUU[dT][dT] 5' AAUCCACGCUGCGAACAGG[dT][dT] Pre-designed 
2 5' GAGUUCAGCCGGAUCGGAA[dT][dT] 5' UUCCGAUCCGGCUGAACUC[dT][dT] Pre-designed 
3 5' CACUGGUCCUACUGAGAUU[dT][dT] 5' AAUCUCAGUAGGACCAGUG[dT][dT] Pre-designed 
P 5' CCAAGUUUACUUGAUCGUA[dT][dT] 5' UACGAUCAAGUAAACUUGG[dG][dA] Published [Pasic et al., 2010] 
I 5' GGUUGAACCGUUCUGGCAU[dT][dT] 5' AUGCCAGAACGGUUCAACC[dT][dT] Custom design 
E 5' CCGGGAUGACACUAGGAUA[dT][dT] 5' UAUCCUAGUGUCAUCCCGG[dT][dT] Custom design 
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2.2.5.2) NEGR1 
Transfection of OSE-C2 cells with NEGR1 siRNA (Table 4) was carried out as described for 
LSAMP (see 2.2.5.1). However, siRNA was used at a concentration of 20 nM and already 
replaced with full antibiotic-free medium after 4 h to avoid cytotoxic effects. After 12-24 h, 
cells were harvested for Western blotting analysis (see 2.5.1). 
 
Table 4: NEGR1 siRNA sequences. 
Apart from three commercially available siRNA constructs, Stealth™ RNAi Negative Control (Cat. No. 12935300, 
Invitrogen) was used to assess potential sequence-independent effects of transfection. All sequences were 
purchased from Sigma. For catalogue numbers, see Table 14, Appendix A. 
Name Sense Antisense Design 
1 GAUAUAAUCAGCAGUGCUU[dT][dT] AAGCACUGCUGAUUAUAUC[dT][dT] Pre-designed 
2 CAAAUGAUAUGACCGUCAA[dT][dT] UUGACGGUCAUAUCAUUUG[dT][dT] Pre-designed 
3 CCUCUUUCACCAGCAUAUU[dT][dT] AAUAUGCUGGUGAAAGAGG[dT][dT] Pre-designed 
 
 
2.2.6) Stable LSAMP Silencing 
OSE-C2 cells were seeded at a concentration of 15x105 cells per 15 cm dish to achieve a 
confluency of 60-80% at the time of treatment. After o/n incubation, cells were transfected 
with either 10 µg LSAMP shRNA (Sigma; five different sequences pre-cloned into pLKO.1 
vector, Table 5; for pLKO.1 vector map, see Figure 70, Appendix A) or pLKO.1 empty vector. 
shRNA constructs were provided as frozen bacterial stocks and maxiprepped prior to use 
(see 2.3.7.2). Transfections were carried out using Effectene® Transfection Reagent (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions. In brief, DNA was 
condensed by incubation with enhancer in buffer EC for 2-5 min to achieve greater 
transfection efficiency. After addition of Effectene®, the mixture was incubated for another 
5-10 min to enable the formation of micelles around the condensed DNA. Following o/n 
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incubation with the DNA/Effectene® mixture in full medium, cells were incubated in fresh 
antibiotic-free full medium for 24 h. As pLKO.1 contains a puromycin resistance gene, 
successfully transfected clones were selected by addition of 3 µg/ml puromycin (Gibco) to 
the cell culture medium. Conditions leading to 100% puromycin-induced cell death in 
untransfected OSE-C2 cells had been previously established in the laboratory. Resistant 
colonies containing around 50-100 transfected cells were transferred individually into 6-well 
plates, and cell stocks were grown for further experiments. 
 
Table 5: LSAMP shRNA sequences. 
shRNA constructs in pLKO.1 vector were purchased as frozen bacterial stocks and maxiprepped (see 2.3.7.2) 
prior to transfection. For TRC numbers, see Table 15, Appendix A; for pLKO.1 vector map, see Figure 70, 
Appendix A. 
shRNA Sequence (5’ to 3’) 
33 CCGGCCGGGATGACACTAGGATAAACTCGAGTTTATCCTAGTGTCATCCCGGTTTTTG 
34 CCGGCGGTGAGAGGAATAAATGGATCTCGAGATCCATTTATTCCTCTCACCGTTTTTG 
35 CCGGCAAGTTTACTTGATCGTACAACTCGAGTTGTACGATCAAGTAAACTTGTTTTTG 
36 CCGGCTACTGAGATTGCTCTGCCTTCTCGAGAAGGCAGAGCAATCTCAGTAGTTTTTG 
37 CCGGCTGTGAACTATCCTCCCACTACTCGAGTAGTGGGAGGATAGTTCACAGTTTTTG 
 
 
2.2.7) Transient IgLON Overexpression 
2.2.7.1) LSAMP 
Transient LSAMP overexpression was carried out in two LSAMP-negative ovarian cancer cell 
lines, PEO1 and OVCAR4. Cells were seeded at a concentration of 15x105 cells per 15 cm 
dish to achieve a confluency of 60-80% at the time of treatment. After o/n incubation, cells 
were transfected with either 4 µg LSAMP cDNA (full-length LSAMP cloned into 
pcDNA™4/TO; for cloning protocol, see 2.3.2) or pcDNA™4/TO empty vector using 
Effectene® Transfection Reagent (for details on procedure see 2.2.6). Following o/n 
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incubation, the DNA/Effectene® mixture was replaced with fresh antibiotic-free medium 
and cells were harvested for Western blotting analysis (see 2.5.1) after an additional o/n 
incubation. 
 
2.2.7.2) NEGR1 
Transient overexpression of NEGR1 was carried out in the NEGR1-negative ovarian cancer 
cell line SKOV3. Cells were seeded at a density of 3x105 cells per 10 cm dish to achieve a 
confluency of 60-80% at time of treatment. After o/n incubation, cells were transfected with 
either 2 µg NEGR1 cDNA (full-length NEGR1 pre-cloned into pReceiver-M10 vector, Source 
BioScience, Nottingham, UK; map see Figure 71A, Appendix A) or empty vector (pSecTag2 
A,B,C, Invitrogen; map see Figure 72, Appendix A). Both constructs were cloned into DH5α 
bacteria (see 2.3.6.1) and maxiprepped prior to use (see 2.3.7.2). Transfections were carried 
out using Effectene® Transfection Reagent (for details on procedure see 2.2.6). After 5 h, 
the DNA/Effectene® mixture was replaced with fresh antibiotic-free medium and cells were 
harvested for Western blotting analysis (see 2.5.1) after o/n incubation. 
 
2.2.8) Stable IgLON Overexpression 
2.2.8.1) LSAMP 
Stable overexpression of LSAMP was carried out in PEO1, OVISE, SKOV3 and OSE-C2 cell 
lines. Cells were seeded at a concentration of 5x105 cells per 10 cm dish to achieve a 
confluency of 50-70% at the time of treatment. After 24 h, cells were transfected with 2 µg 
of either LSAMP cDNA (full-length LSAMP cloned into pcDNA™4/TO; for cloning protocol, 
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see 2.3.2) or pcDNA™4/TO empty vector using Effectene® Transfection Reagent (for details 
on procedure see 2.2.6). After 4 h incubation, the DNA/Effectene® mixture was replaced 
with fresh antibiotic-free medium. As pcDNA™4/TO contains a zeocin resistance gene, 
successfully transfected clones were selected by addition of zeocin to culture medium after 
36 h at a concentration 20 µg/ml (PEO1), 100 µg/ml (OVISE), 125 µg/ml (SKOV3) or 200 
µg/ml (OSE-C2). Conditions leading to 100% zeocin-induced cell death in untransfected cells 
had been previously established in the laboratory. Resistant colonies containing around 50-
100 transfected cells were transferred individually into 96-well plates, and cell stocks were 
grown for further experiments. 
 
2.2.8.2) NEGR1 
Stable overexpression of NEGR1 was carried out in the NEGR1-negative ovarian cancer cell 
line SKOV3. Cells were seeded at a density of 2.5x105 cells in a 10 cm dish to achieve a 
confluency of 60-80% at time of treatment. After 24 h, cells were transfected with either 2 
µg NEGR1 cDNA (full-length NEGR1 pre-cloned into pReceiver-M10) or empty vector 
(pReceiver-M10 EX-NEG-M10 negative control, both Source BioScience; maps see Figure 71, 
Appendix A). Both constructs were cloned into DH5α bacteria (see 2.3.6.1) and maxiprepped 
prior to use (see 2.3.7.2). Transfections were carried out using Effectene® Transfection 
Reagent (for details on procedure see 2.2.6). Following 5 h incubation with the 
DNA/Effectene® mixture in full medium, cells were incubated in fresh antibiotic-free full 
medium for 36 h. As pReceiver-M10 contains a geneticin resistance gene, successfully 
transfected clones were selected by addition of 1 mg/ml geneticin (Gibco) to the cell culture 
medium. Conditions leading to 100% geneticin-induced cell death in untransfected SKOV3 
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cells had been previously established in the laboratory. Resistant colonies containing around 
50-100 transfected cells were transferred individually into 96-well plates, and cell stocks 
were grown for further experiments. 
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2.3) Bacterial Techniques 
2.3.1) Bacteria Types and Cryopreservation 
For cloning and DNA preparations, DH5α bacteria (α-Select Chemically Competent Cells, 
Bacteriophage T1-Resistant, Bioline, London, UK) were used. Isopropyl β-D-1-
thiogalactopyranoside (IPTG)-induced protein overexpression was carried out using BL21 
bacteria (BL21(DE3)pLysS Competent Cells, Promega, Fitchburg, USA). 
For long-term storage, successfully transformed bacteria were mixed with glycerol to a final 
concentration of 50%, and stored at -80 °C. 
 
2.3.2) Procedure Overview 
Figure 14 gives an overview of the procedures used for the production of both full-length 
DNA (blue, to be used for ovarian cell line transfections) and recombinant protein (red, for 
interaction assays). In brief, IgLON DNA sequences were amplified by PCR, cloned into the 
pGEM®-T Easy expression system (Promega), selected in DH5α bacteria, and quality 
controlled by restriction digestion and sequencing. For the creation of LSAMP DNA 
expression vectors, full-length sequences were then subcloned into pcDNA™4/TO vector 
(Invitrogen) and maxiprepped from DH5α bacteria. For recombinant protein production, the 
shortened IgLON sequences were ligated into the vectors pGEX-6P-2 (GST tag; Amersham, 
Amersham, UK) and pHisTrx (6xHistidine/thioredoxin tag; kindly provided by Dr Edward 
McKenzie, University of Manchester). BL21 bacteria were then transfected with these 
constructs, and artificial protein overexpression was induced using IPTG. 
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Figure 14: Procedure overview for IgLON DNA and protein production. 
Production of full-length IgLON DNA for cell line transfection is outlined in blue, while production of DNA for 
recombinant protein expression is outlined in red. If applicable, differences in restriction enzymes, sequencing 
primers or vectors used are outlined above/below each step. 
 
 
2.3.3) Polymerase Chain Reaction (PCR) 
Primer pairs for normal PCR were designed manually based on the published DNA and 
protein sequences (retrieved from www.ensembl.org and www.uniprot.org, respectively; 
LSAMP: RefSeq NM_002338; NEGR1: RefSeq NM_173808). For full-length DNA 
amplification, primer pairs were designed to span the entire IgLON protein-coding region 
including the signalling sequence, while primers for recombinant protein production only 
contained the three Ig domains plus an additional 9 “spacer” nucleotides on either side. To 
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enable (sub)cloning of each fragment into several different vectors,  primers were modified 
to introduce suitable restriction sites; subsequently, the NEBcutter V2.0 
(http://tools.neb.com/NEBcutter2) was used to ensure that the introduced restriction sites 
were not present in the amplicon sequence as well. Primer-BLAST 
(www.ncbi.nlm.nih.gov/tools/primer-blast) was used to determine melting temperatures 
and rule out unspecific binding. 
Amplification of IgLON sequences was carried out using 200 ng OSE-C2 cDNA template in a 
total volume of 50 μl containing 1X NH4 buffer (incl. 1.5 mM Mg
2+, Bioline), 200 µM dNTPs, 
1 µM forward and reverse primers (Table 6) and 2 units Taq polymerase (Bioline). PCR 
conditions were as follows: 32 cycles of 94 °C for 30 sec (dissociation), 60 °C for 30 sec 
(annealing), and 72 °C for 45 sec (elongation). Amplification was assessed by electrophoresis 
of the products on a 1% agarose gel (Fisher Scientific) containing ethidium bromide (EtBr, 
Sigma) in 1x Tris-acetate-EDTA buffer (TAE, composition see Table 16, Appendix A) for 45 
min at 70 V using a Mini-sub Cell GT tank (Bio-Rad). Per well, 12 µl sample mixed with 3 µl 
5X loading buffer (Bioline) were loaded; fragment size was assessed by comparison to 
Hyperladder I (Bioline). 
 
Table 6: PCR primers. 
Primers were designed for the production of full-length IgLON DNA sequences (FL) and recombinant protein 
(r). For subcloning purposes, suitable restriction sites were introduced: AflII (forward primer) and EcoRI 
(reverse) for full-length DNA sequences, BamHI (forward) and XhoI (reverse) for recombinant protein DNA 
sequences. Tm: primer melting temperature; GC: GC content. 
Name Forward sequence (5' to 3') 
Tm 
[°C] 
GC 
[%] 
Reverse sequence (5' to 3') 
Tm 
[°C] 
GC 
[%] 
Amplicon 
[bp] 
LSAMP FL CTTAAGATGGTCAGGAGAGTTCAGCCG 65.7 52 GAATTCTTAACATTTGCTGAGAAGGCAGAG 64.3 40 1017 
rLSAMP GGATCCGGACTGCCTGTTCG 63.7 65 CTCGAGTCTGAAAAGGACTAGGCTGG  63.6 54 858 
NEGR1 FL CTTAAGATGGACATGATGCTGTTGGTG 63.6 44 GAATTCTTATTGTAGAATGGCATTCTTCAG 60.7 33 1062 
rNEGR1 GGATCCGGACAGAGTGTGGACTTCCC 61.9 62 CTCGAGACTTGGAGGGTTAAGAGGCAGG 61.6 57 858 
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2.3.4) Gel Extraction 
DNA fragments were visualised using a UV transilluminator and excised with a clean scalpel 
blade. DNA was extracted from each gel slice using a QIAquick® Gel Extraction Kit (Qiagen) 
according to the manufacturer’s instructions. In brief, gel slices were incubated at 50 °C in 
buffer QG until they had dissolved. After the addition of isopropanol to increase DNA yield, 
each sample was transferred onto a column containing a silica membrane. Buffer QG 
contains a pH indicator (to ensure a pH of ≤7.5) and a high concentration of chaotropic salts; 
both factors are necessary for optimal binding of the DNA to the membrane. Non-bound 
impurities such as salts, enzymes, unincorporated nucleotides, agarose, loading dyes or EtBr 
were removed by centrifugation (13,000 rpm, 1 min) and a subsequent wash with buffer PE 
(contains 80% ethanol) to remove excess salt. Buffer EB, which provides inverse conditions 
to buffer QG (10 mM Tris-Cl, pH 8.5, i.e. a basic pH and low salt concentration), was added 
to the membrane for DNA elution. 
 
2.3.5) Ligations 
Depending on the purpose, IgLON fragments were ligated into pGEM®-T Easy, pcDNA™4/TO, 
pGEX-6P-2 or pHisTrx vectors (Table 7). pGEM®-T Easy was used for initial IgLON cloning 
after PCR amplification. Subcloning into pcDNA™4/TO was used for DNA production, while 
subcloning into pGEX-6P-2 and pHisTrx was used for protein production. 
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Table 7: Vectors for DNA and protein production. 
IgLON sequences were initially cloned into the pGEM®-T Easy vector. Subcloning was carried out using pGEX-
6P-2 and pHisTrx vectors (for protein production) or pcDNA™4/TO (for DNA production). Amp: ampicillin; Zeo: 
zeocin. 
Name Vector size [bp] Tag size [kDa] Resistance gene 
pGEM®-T Easy 3015 - Amp 
pGEX-6P-2 4985 26 (GST tag) Amp 
pHisTrx 3187 12.5 (His tag: 0.8; thioredoxin tag: 11.7) Amp 
pcDNA
TM
4/TO 5078 - Amp, Zeo 
 
 
2.3.5.1) Ligation into pGEM®-T Easy Vector 
The pGEM®-T Easy system (for map see Figure 73A, Appendix A) was chosen due to its large 
number of different restriction sites, its single thymidine overhangs at each end of the 
vector which facilitates ligation, and its blue/white selection of successful clones (see 
2.3.6.1). 
Ligation of purified IgLON DNA fragments into the pGEM®-T Easy vector was performed in a 
total volume of 20 µl containing 1X T4 DNA ligase rapid ligation buffer (Promega; contains 
ATP), 50 ng vector, 100 ng purified PCR product (molar insert:vector ratio 6:1) and 6 units T4 
DNA ligase (Promega). Ligation was carried out for 1 hour at RT. 
 
2.3.5.2) Ligation into pcDNA™4/TO Vector 
Subcloning of IgLON DNA fragments into pcDNA™4/TO vector (for map see Figure 73B, 
Appendix A) was carried out o/n at RT using a molar insert:vector ratio of 20:1 in a total 
volume of 20 µl containing T4 ligation butter, 1 mM ATP, and 7.5 units ligase. Vector-only 
reactions were added as controls for transformation efficiency. 
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2.3.5.3) Ligation into pGEX-6P-2 and pHisTrx Vectors 
Subcloning into pGEX-6P-2 and pHisTrx vectors (for maps see Figure 74, Appendix A) was 
carried out o/n at RT using a molar insert:vector ratio of 4:1 in a total volume of 20 μl 
containing rapid ligation buffer (contains ATP) and 3 units T4 DNA ligase. Vector-only 
reactions were added as controls for transformation efficiency. 
 
2.3.6) Transformations 
2.3.6.1) Transformation and Selection of DH5α Competent Cells 
To transform DH5α bacteria with pGEM®-T Easy or pcDNA™4/TO vectors, 50 μl bacteria 
were thawed on ice and gently mixed with 25 ng ligated vector/insert DNA or self-ligated 
vector only. After a 20-minute incubation on ice, heat shock transformation was performed 
at 42 °C for 45 sec. 2xYT medium (composition see Table 17, Appendix A) was added after 2 
min on ice, and bacteria were then incubated at 37 °C for 1 h. Subsequently, bacteria were 
streaked onto a 100 µg/ml ampicillin (Sigma) selection agar plate, and incubated at 37 °C 
o/n. As the pGEM®-T Easy and pcDNA™4/TO vectors contain ampicillin resistance genes, 
only successfully transformed bacteria were able to form colonies. Colonies were picked 
using a sterile pipette tip and incubated individually in LB-Broth (composition see Table 18, 
Appendix A) containing 100 µg/ml ampicillin o/n on a shaker at 37 °C. 
For transformation with pGEM®-T Easy, ampicillin agar plates were covered with X-gal/IPTG 
(150 µl; stock: 40/32 mg/ml, Bioline). Presence of IPTG enables transcription of β-
galactosidase from the pGEM®-T Easy vector; the enzyme can then cleave X-gal, resulting in 
a blue product. However, since the multiple cloning site of the vector lies within the region 
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encoding β-galactosidase, successful cloning of an insert into the vector inhibits correct 
expression of the enzyme. Colonies containing the desired DNA fragment hence have a 
white colour, while absence of the insert from the vector results in blue colonies. Only 
completely white, separate colonies were selected for subsequent experiments. 
 
2.3.6.2) Transformation and Selection of BL21 Competent Cells 
To transform BL21 bacteria with pGEX-6P-2 or pHisTrx vectors, 50 μl bacteria were thawed 
on ice and gently mixed with 25 ng ligated vector/insert DNA or self-ligated vector only. 
After a 10-minute incubation on ice, heat shock transformation was performed at 42 °C for 
45 sec. 2xYT medium was added after 2 min on ice, and bacteria were then incubated at 37 
°C for 1 h. Subsequently, bacteria were streaked onto a 100 µg/ml ampicillin selection agar 
plate, and incubated at 37 °C o/n. As the pGEX-6P-2 and pHisTrx vectors contain ampicillin 
resistance genes, only successfully transformed bacteria were able to form colonies. 
Colonies were picked using a sterile pipette tip and incubated individually in LB-Broth 
containing 100 µg/ml ampicillin o/n on a shaker at 37 °C. 
 
2.3.7) DNA Preparation 
2.3.7.1) Miniprep 
To obtain small amounts of plasmid, DNA was miniprepped from transformed DH5α 
bacteria using the QIAprep® Miniprep Kit (Qiagen), which is based on the alkaline lysis 
described by Birnboim and Doly [Birnboim and Doly, 1979]. 
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In brief, bacteria from a 3 ml LB-Broth culture were pelleted by centrifugation (10,000 rpm, 
3 min) and resuspended in buffer P1 (contains EDTA to inhibit DNases by chelating divalent 
metal cations, and RNase A to degrade RNA). Cell lysis was initiated by adding buffer P2 
(contains SDS to break up the cells, and NaOH to denature the released DNA). After no more 
than 5 minutes, the lysis reaction was stopped by adding buffer N3 (contains potassium 
acetate (CH3CO2K), pH 4.8, which allows renaturing of plasmid but not chromosomal DNA, 
and leads to precipitation of SDS). Debris such as precipitated SDS and genomic DNA were 
pelleted by centrifugation (13,000 rpm, 10 min), and the resulting supernatant was 
transferred onto a column containing a silica membrane. During centrifugation, DNA was 
able to bind to the membrane (facilitated by Gu-HCl, a chaotropic salt present in buffer N3). 
After a wash step using buffer PE (pH 7.5; contains 80% ethanol to remove excess salt), DNA 
was eluted from the column under low salt and basic pH conditions using buffer EB (10 mM 
Tris-Cl, pH 8.5). 
Accuracy of both salt concentration and pH level throughout the procedure is crucial. While 
the salt concentration determines how strongly/loosely polynucleotides bind to the silica 
membrane, adjustment of the pH level ensures elution of the correct type of nucleic acid 
only. Generally, RNA can be eluted at a lower pH for a given salt concentration than DNA. 
For quality control purposes, LyseBlue reagent was added to buffer P1. This resulted in a 
blue colour upon addition of buffer P2 and provided a visual aid to ensure optimal buffer 
mixing. Addition of buffer N3 led to the mixture turning colourless again, indicating a 
homogenous solution and effective precipitation of SDS, genomic DNA and cell debris. 
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2.3.7.2) Maxiprep 
To obtain large quantities of transfection-grade plasmid, DNA was maxiprepped from DH5α 
bacteria using the QIAfilter Plasmid Purification Maxi kit (Qiagen), which is based on the 
alkaline lysis described by Birnboim and Doly [Birnboim and Doly, 1979]. Buffers P1 and P2 
are identical to the QIAprep® Miniprep Kit and are described above (section 2.3.7.1). 
In brief, bacteria from a 200 ml LB-Broth culture were pelleted by centrifugation (8,000 rpm, 
10 min, 4 °C) and resuspended in buffer P1. Cell lysis was initiated by adding buffer P2. After 
no more than 5 minutes, the lysis reaction was stopped by adding cold buffer P3 (contains 
potassium acetate (CH3CO2K), pH 5.5, which allows renaturing of plasmid but not 
chromosomal DNA, and leads to precipitation of SDS). After mixing thoroughly, the solution 
was transferred into a QIAfilter Maxi Cartridge and left to settle for approx. 10 min, or until 
the white precipitate containing proteins, genomic DNA and SDS had accumulated at the 
top of the solution. It was then filtered and applied to a QIAGEN-tip 500 containing a silica 
bead-based anion-exchange resin covered in positively charged DEAE (diethylaminoethanol) 
groups, which are able to interact with the DNA’s negatively charged backbone. The column 
had previously been equilibrated with the low-salt buffer QBT (contains 750 mM NaCl, pH 
7.0) to create conditions optimal for binding of plasmid DNA but not RNA, proteins or other 
metabolites. After binding, the column was washed twice using the medium-salt buffer QC 
(contains 1 M NaCl, pH 7.0) to disrupt non-specific hydrophobic interactions and remove all 
contaminants, including nucleic acid-binding proteins. DNA was eluted using the high-salt, 
high-pH buffer QF (contains 1.25 M NaCl, pH 8.5). 
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2.3.8) Restriction Digest 
2.3.8.1) Full-length IgLON DNA 
As both LSAMP and NEGR1 full-length DNA had been amplified using primers which 
introduced restriction sites for the enzymes AflII and EcoRI, the same protocol was used for 
both IgLONs. 
In a total volume of 20 μl, 4 µg of purified DNA were digested with 20 units each of AflII and 
EcoRI in buffer 4 and 100 µg/ml BSA (all New England Biolabs, Ipswich, USA) for 2 h at 37 °C. 
The products were electrophoresed on a 1% agarose gel in TAE containing EtBr (see 2.3.3), 
and DNA from successfully transformed colonies was prepared for sequencing (see 2.3.9) to 
ensure inserts were mutation-free. 
 
2.3.8.2) Recombinant IgLON DNA 
As both LSAMP and NEGR1 recombinant protein DNA had been amplified using primers 
which introduced restriction sites for the enzymes BamHI and XhoI, the same protocol was 
used for both IgLONs. 
In a total volume of 20 μl, 4 µg of purified DNA were digested with 20 units each of BamHI 
and XhoI in buffer 3 and 100 µg/ml BSA (all New England Biolabs) for 4 h at 37 °C. The 
products were electrophoresed on a 1% agarose gel in TAE containing EtBr (see 2.3.3), and 
DNA from successfully transformed colonies was prepared for sequencing (see 2.3.9) to 
ensure inserts were mutation-free. 
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2.3.9) Sequencing 
Reactions were prepared in a total volume of 10 μl containing 3.2 pM sequencing primers 
(Table 8) and 300-600 ng plasmid DNA. Sequencing was carried out by the MRC CSC 
Genomics Core Laboratory at Imperial College London. Results were analysed using the 
Chromas Lite software (version 2.01, Technelysium Pty Ltd). 
 
Table 8: Sequencing primers. 
Using the sequencing primers outlined below, all plasmid/insert constructs were sequenced to ensure they 
contained mutation-free inserts. Primer binding sites were located on the vectors, flanking both ends of the 
insert. F: forward primer; R: reverse primer. 
Name Sequencing primers 
pGEM®-T T7 (F), SP6 (R) 
pGEX-6P-2 pGEX5 (F), pGEX3 (R) 
pHisTrx T7 (F), T7 (R) 
pcDNATM4/TO CMV (F), BGH (R) 
 
 
2.3.10) Protein Overexpression 
To produce recombinant IgLON proteins, 200 ml 2xYT medium was inoculated with 200 µl 
rIgLON+pGEX-6P-2- or rIgLON+pHisTrx-transformed BL21 bacteria from a 5 ml starter 
culture. After 3 h on a shaker at 37 °C, 1 mM IPTG (Bioline) was added to induce IgLON 
transcription, and incubation was carried on for a further 3 h. Bacteria were then pelleted 
by centrifugation (8,000 rpm, 10 min, 4 °C) and resuspended in PBS containing 1% Triton, 1 
mg/ml lysozyme, and 1 unit/ml DNase I. After incubation on a shaker for 30 min at RT, 1 ml 
of the suspension was separated into soluble and insoluble fractions, while the rest was 
kept for purification (see 2.3.11). 
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Separation of cytoplasmic and membrane-bound proteins was achieved by centrifugation at 
13,000 rpm for 10 min. The supernatant, containing soluble proteins, was transferred into a 
fresh tube, while the pellet containing insoluble, membrane-associated proteins was 
resuspended in 1% SDS. Both fractions were electrophoresed on a 10% SDS gel (see 2.5.1.3), 
and protein expression was assessed using Coomassie Brilliant Blue staining (see 2.5.1.4). 
 
2.3.11) Protein Purification 
Purification of recombinant IgLONs was carried out using the protein solution described 
above (see 2.3.10). The insoluble cell membrane fraction was isolated by centrifugation 
(12,000 rpm, 30 min, 4 °C) and the supernatant discarded. The pellet was washed several 
times by resuspension in 2% Triton/PBS followed by centrifugation (12,000 rpm, 20 min, 4 
°C) until it exhibited a clean white colour. Resuspension in 8M urea o/n at RT on a shaker 
was used to achieve full denaturation. After passing the sample through a 0.45 µm filter, it 
was transferred into a dialysis tube (molecular weight cut-off: 12,400; Sigma) to remove 
urea and achieve refolding. Dialysis was carried out against PBS (48 h, 4 °C, buffer replaced 
twice daily), and the resulting protein sample was passed through a 0.2 µm filter prior to 
storage at 4 °C. 
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2.4) Functional Assays 
2.4.1) Confocal Immunofluorescence Microscopy (IFM) 
Cells were seeded at a density of 5x104 cells per well in a 6-well plate with each well 
containing an autoclaved cover slip. After 24 h, cells attached to the cover slips were 
washed twice with PBS and fixed in 4% paraformaldehyde (PFA) in PBS at 37 °C for 10-30 
min. After two washes with PBS, excess PFA was quenched and removed by incubation in 
100 mM glycine/PBS for 30 min at RT followed by two further washes in PBS. Cell 
membranes were permeabilised by incubation in IFM buffer (IFMB, containing 0.2% 
saponin, 2% FCS, and 2% BSA in PBS) for 30 min at RT. Blocking was carried out by 
incubation in 10% goat serum in IFMB for 30 min at RT. After one wash in IFMB, cells were 
incubated in primary antibody (Table 9) o/n at 4 °C. Secondary antibody was added after 
three washes in IFMB and incubated for 1 h at RT; from this point on, all steps were carried 
out in the dark. Following three washes in IFMB to remove excess antibody, a second 
fixation was carried out in 4% PFA for 15 min at RT. Quenching was performed using 
100 mM glycine/PBS for 30 min at RT after washing twice with PBS. Cover slips were then 
washed twice more in PBS, briefly cleaned by immersion in Milli-Q water for 1 sec, and 
placed upside-down on a drop of Vectashield® Mounting Medium with DAPI (Vector 
Laboratories, Peterborough, UK) on a microscopy slide (Gerhard Menzel GmbH, 
Braunschweig, Germany). After o/n incubation at 4 °C, excess liquid was carefully removed, 
and cover slips were sealed to the slide using nail varnish. Slides were analysed using Leica 
Application Suite (Advanced Fluorescence, 2.3.5 build 5378, Leica Microsystems, Wetzlar, 
Germany) on a TCS SP5 microscope (Leica). 
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Table 9: Primary and secondary antibodies for immunofluorescence Microscopy. 
Phalloidin, which stains the cytoskeleton by selectively binding to F-actin, is conjugated directly to the dye; 
hence, no primary antibody is needed. All secondary antibodies were purchased from Invitrogen. G: goat; M: 
mouse; R: rabbit, D: donkey. 
Protein 
Primary Antibody Secondary Antibody 
Species Dilution Clonality Supplier Name Species Dilution 
OPCML Mouse 1:50 Monoclonal R&D Systems Alexa Fluor® 546 G-anti-M 1:500 
LSAMP Rabbit 1:50 Polyclonal Sigma Alexa Fluor® 488 G-anti-R 1:500 
NEGR1 Rabbit 1:50 Polyclonal Abcam Alexa Fluor® 488 G-anti-R 1:500 
EGFR Goat 1:50 Polyclonal R&D Systems Alexa Fluor® 546 D-anti-G 1:500 
HER2 Mouse 1:50 Monoclonal Calbiochem Alexa Fluor® 546 G-anti-M 1:500 
FGFR1 Mouse 1:50 Monoclonal Abcam Alexa Fluor® 546 G-anti-M 1:500 
Cav-1 Mouse 1:50 Monoclonal R&D Systems Alexa Fluor® 546 G-anti-M 1:500 
Phalloidin - - - - Alexa Fluor® 546 phalloidin - 1:50 
 
 
2.4.2) Stimulation Assays: EGF and FGF 
Cells were seeded into 6-well plates at a density of 1x105 cells per well to achieve a 
confluency of 70-80% at the time of treatment. After 24 h, full medium was replaced with 
serum-free medium to reduce RTK signalling. Following a further 24-hour incubation, 
treatment was carried out with either 50 ng/ml EGF (Promega) or 10 ng/ml FGF1 (R&D 
Systems, Minneapolis, USA) in serum-free medium. After 0, 30, 60, 90, 120 and 150 min, 
cells were washed twice with PBS and harvested for Western blotting analysis (see 2.5.1). 
 
2.4.3) Protein Degradation Assays: MG-132 and Chloroquine 
To determine if protein degradation occurred via the proteasomal or lysosomal pathway, 
cells were treated with either MG-132 (Calbiochem, Merck KGaA, Darmstadt, Germany) or 
chloroquine (Sigma). MG-132 is a reversible, cell-permeable 26S proteasome inhibitor which 
reduces the degradation of ubiquitin-tagged proteins. Chloroquine is a lysosomotropic agent 
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which, as a weak base, increases the intralysosomal pH and thus inhibits digestive enzymes 
present within the lysosome. 
Cells were seeded at 1x105 cells per well in full medium in a 6-well plate to achieve 60-80% 
confluency at the time of treatment. After 24 h, medium was changed to serum-free 
medium. Following another 24 h, cells were treated either with 0.05, 0.1, 0.5, 1, 1.5 and 
2 μM MG-132, or with 1, 20, 50, 100, 150 and 200 μM chloroquine for 4.5 h. Subsequently, 
cells were harvested for Western blotting analysis (see 2.5.1). 
To avoid loss of efficiency, MG-132 was not used for more than 1 month after reconstitution 
and not freeze-thawed more than once, while chloroquine was made up fresh before each 
use. 
 
2.4.4) Proliferation Assay: WST-1 
WST-1 is a reagent based on the MTT proliferation assay developed by Mosmann 
[Mosmann, 1983], in which the addition of MTT, a yellow tetrazole, to cell culture medium 
leads to the formation of formazan, a purple product that can be quantified by 
measurement of absorption. This reaction is catalysed by enzymes (mitochondrial succinate-
tetrazolium reductases) that are active in living cells only, and is hence an indicator of cell 
viability as the amount of produced formazan is directly proportional to cell number. 
However, formazan is only partially soluble; the use of WST-1 (Water-soluble tetrazolium 
salt) instead of MTT has therefore several advantages, particularly the omission of the 
solubilisation step and hence decreased toxicity. 
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Cells were seeded at a density of 700 cells per well in a 96-well plate, with 4 replicates per 
cell line. After 24, 48, 72 and 96 h (up to 120 h for OSE-C2 and its derivatives), WST-1 
reagent (Roche) was added at a 1:10 dilution. Following a 1 h incubation, plates were 
shaken thoroughly for 1 min on a shaker, and absorbance was measured at 440 nm 
(OPTImax Tunable Microplate Reader using SoftMax® Pro software, Molecular Devices, 
Wokingham, UK). Each time point was normalised to a medium-only control as well as the 
24 h reading during analysis (Excel, Microsoft Corporation, Redmond, USA). 
 
2.4.5) Migration Assays 
2.4.5.1) xCELLigence Migration Assay 
Cell migration was initially monitored in real-time using the xCELLigence system (Roche) 
with a CIM-Plate 16. The plate is made up of 16 wells divided into two chambers each; the 
bottom chambers were filled with full medium, while the top chambers were filled with 
4x104 cells in serum-free medium. Top and bottom chambers of each well are separated by 
a porous membrane which cells can pass through; the bottom of this membrane is covered 
by gold electrodes. As cells migrate towards the bottom, full-medium-filled chamber, they 
cover the electrodes, a process which increases the electrodes’ impedance. Increase in 
impedance can be monitored over time as a quantitative measure of cell number (cell 
index). Each cell line was seeded in 2-3 replicates, and wells containing serum-free medium 
in both chambers were used as no-migration controls. Readings were taken every 15 
minutes for 24-72 h. 
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2.4.5.2) Scratch Assay 
Besides migration assays using the xCELLigence system, wound-healing assays were carried 
out as well. Cells were seeded at 5x105 cells per well in full medium in a 6-well plate to 
achieve 100% confluency at the time of treatment. After 24 h, two scratches were made 
using a cell scraper; subsequently, medium was replaced to remove detached cells. Cells 
were photographed after 0, 4, 8, 12 and 24 h using a Nikon Eclipse TE2000-U microscope 
(Nikon, Tokyo, Japan) and Image-Pro Plus (Media Cybernetics, Inc., Bethesda, USA) imaging 
software. 
 
2.4.6) Spheroid-Formation Assay 
Cells were seeded in 96-well low-attachment plates (Corning) at a density of 200 cells per 
well, with 12 replicates per cell line. After 18 days, cells were pooled from either 4 or 8 wells 
and transferred into a 10 cm dish; medium was renewed after 24 h to remove unattached 
cells. Following a further 7 days, dishes were washed twice with cold PBS, and colonies were 
fixed for 7 min in cold methanol. Staining was carried out by incubation in 1% crystal violet 
solution for 10 min. After several washes with water, plates were dried and photographed 
using a Lumix DMC-LX1 camera. Only colonies larger than 1 mm in diameter and with clear 
spheroid origin (i.e. with increased cell density towards the centre of the colony) were 
counted. 
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2.4.7) Protein-Protein Interaction Assays 
2.4.7.1) Pull-Down 
Interaction of recombinant OPCML (rOCMPL, 6xHis/thioredoxin tag; kindly provided by Elisa 
Zanini, Imperial College London) with rLSAMP (GST tag) was assessed using the MagneGST™ 
Pull-Down System (Promega) according to the manufacturer’s instructions.  In brief, purified 
GST-rLSAMP or a GST-only control were conjugated to MagneGST™ magnetic beads (pre-
equilibrated with wash/binding buffer) by incubation for 30 min at RT on a rotating 
platform. Using a magnetic stand, the supernatant was separated from the beads and 
replaced with wash/binding buffer. After three washes, the beads were incubated with 
6xHis-rOPCML for 1 hour at 4 °C to allow binding. Unbound protein was removed by 
washing the beads five times with wash/binding buffer, and extent of binding was assessed 
by Western blotting (see 2.5.1). 
 
2.4.7.2) Co-Immunoprecipitation (Co-IP) 
As PEO1 cells express both NEGR1 as well as a broad range of RTKs, they were chosen for 
co-IP experiments. 4x106 cells were seeded in a 10 cm dish and incubated for 24 h. To 
preserve membrane-bound proteins, cells were detached by incubation in EDTA only. After 
centrifugation at 1,500 rpm for 5 min, the resulting cell pellet was kept at -80 °C o/n to 
facilitate lysis. Subsequently, it was resuspended in co-IP lysis buffer (see Table 19, Appendix 
A) and incubated on ice for 30 min. The following samples were prepared: 
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 Lysate: PEO1 cell lysate only 
 IP: PEO1 cell lysate + NEGR1 primary antibodies (see Table 10, page 116) + Protein G 
Sepharose® beads (Sigma) 
 AB control: Co-IP lysis buffer + NEGR1 primary antibodies + Protein G Sepharose® 
beads 
 Lysate control: PEO1 cell lysate + Protein G Sepharose® beads 
 
Samples incubated with antibody (IP, AB control) were left on a shaker o/n at 4 °C prior to 
addition of Sepharose® beads. Beads were prepared by centrifugation (10,000 rpm, 1 min), 
removal of the EtOH supernatant, and two washes in co-IP lysis buffer. After addition of the 
beads, the samples were incubated at 4 °C for 1 h to allow binding. Subsequently, all 
samples were centrifuged (10,000 rpm, 2 min), and the supernatant containing unbound 
protein or other impurities was removed. Following 2 washes in co-IP lysis buffer and 2 
washes in PBS, the beads were resuspended in 1X SDS-PAGE loading buffer and analysed via 
Western blotting (see 2.5.1). 
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2.5) Analytical Methods 
2.5.1) Protein Analysis 
2.5.1.1) Cell Lysis 
Prior to harvesting, cells were washed twice with cold PBS to remove residual medium. After 
addition of SDS lysis buffer (composition see Table 20, Appendix A; 80 µl per 6-well plate, 
350 µl per 100 mm dish), cells were detached using a cell scraper (Corning). Viscosity was 
reduced by passing the lysates several times through a 27G needle (BD Microlance™ 3). For 
long-term storage, lysates were kept at -20 °C. 
 
2.5.1.2) MicroBCA Assay 
MicroBCA assays are derived from the procedure developed by Smith et al. [Smith et al., 
1985], which is based on the principle that bicinchoninic acid (BCA) forms purple complexes 
with Cu+ ions in an alkaline environment. The solutions used in the MicroBCA Protein Assay 
kit (Thermo Scientific, Waltham, USA) contain both BCA and Cu2+ ions (in the form of 
copper(II) sulphate, CuSO4) in a highly alkaline buffer (pH 11.25). After addition of these 
solutions to the protein samples, Cu2+ is reduced to Cu+ by the proteins’ peptide bonds; the 
amount of product is proportional to the amount of protein present. Each Cu+ ion then 
forms a water-soluble, purple-coloured chelate complex with two BCA molecules, which 
exhibits a high absorbance at a wavelength of 562 nm. 
The MicroBCA Protein Assay kit was used according to the manufacturer’s instructions. In 
brief, all samples as well as a medium-only control were pipetted into a 96-well plate in 
1:50, 1:250 and 1:500 dilutions. BSA at 1.25, 2.5, 5, 10, 15, 20 and 25 µg/ml was used as a 
PhD Thesis – Sarah Christen – Imperial College London Materials and Methods 
114 
standard. MicroBCA solutions MA, MB and MC were mixed (ratio 25:24:1) and added to 
each well (ratio 1:1). After 2 h at 37 °C, absorption was measured at 562 nm. Based on the 
BSA samples, a standard curve was drawn from which the protein content of each unknown 
sample could be extrapolated using Excel. 
 
2.5.1.3) SDS-PAGE 
Protein samples were separated according to size via SDS polyacrylamide gel 
electrophoresis (SDS-PAGE). Resolving gels were prepared with a final concentration of 10% 
acrylamide (Ultra Pure Proto Gel®, Acrylamide:Bis-Acrylamide 37.5:1, National Diagnostics), 
thus covering a broad range of sizes at an acceptable resolution. For details on gel 
preparation see Table 21, Appendix A. 
Protein samples were prepared by dilution in 5X loading buffer (composition see Table 22, 
Appendix A). To denature proteins and enable binding of SDS to the peptide chains, samples 
were boiled at 95 °C for 5 minutes, followed by a 2-min centrifugation step at 13,000 rpm. 
After loading equal protein amounts for each sample on the gel as well as 5 µl PageRuler™ 
Prestained Protein Ladder (Thermo Fisher Scientific, Waltham, USA), electrophoresis was 
carried out at 200 V for 60-80 min using the Mini-PROTEAN Tetra System (Bio-Rad, Hercules, 
USA) filled with running buffer (composition see Table 23, Appendix A). Gels were then 
either stained with Coomassie Brilliant Blue (see 2.5.1.4) or analysed via Western blotting 
(see 2.5.1.5). 
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2.5.1.4) Coomassie Brilliant Blue Staining 
SDS gels were immersed in Coomassie Brilliant Blue R-250 (0.1% Coomassie, 20% methanol, 
10% acetic acid) and incubated for 45 min at RT on a shaker. Coomassie solution was then 
replaced with destain solution (10% methanol, 7.5% acetic acid) to remove background 
staining. Destain solution was changed frequently until clear protein bands became visible. 
For long-term storage, gels were dried using gel drying buffer (10% methanol, 10% glycerol, 
7.5% acetic acid) and gel drying frames (Diversified Biotech, Dedham, USA). 
 
2.5.1.5) Western Blotting 
Proteins were transferred from SDS-PAGE gels (see 2.5.1.3) onto nitrocellulose membranes 
(Trans-Blot® Transfer Medium, Bio-Rad) for 1 h at 100 V using a Mini Trans-Blot Cell (Bio-
Rad) filled with transfer buffer (composition see Table 24, Appendix A). Transfer quality was 
assessed by reversible Ponceau S staining (Sigma). 
After blocking of free binding sites with 5% milk for 1 h at RT on a shaker, membranes were 
incubated in primary antibody (Table 10) o/n at 4 °C on a shaker. Following three washes 
with the appropriate buffer for 4 min to remove excess primary antibody, corresponding 
secondary antibody conjugated to horseradish peroxidase (HRP) was added for 1 h at RT. 
Three washes for 8 min were carried out to remove background staining, and membranes 
were incubated with Immobilon™ Western Chemiluminescent HRP Substrate (2 
ml/membrane, Millipore, Billerica, USA) for 4 min at RT to visualise protein bands. 
Immobilon™ contains both luminol and hydrogen peroxide, and the protein-bound HRP 
then catalyses the oxidation of luminol by hydrogen peroxide. Oxidated luminol emits light 
as it decays to a lower energy state; this was detected by exposure of the membrane to 
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X-ray film (Scientific Laboratory Supplies, Hessle, UK) for 2 sec to 7 min. An SRX-101A 
developer (Konica Minolta Medical & Graphic Inc., Grand Rapids, USA) was used to develop 
the films. All membranes were reprobed for β-tubulin or β-actin to ensure equal loading. 
 
Table 10: Primary antibodies for Western blotting. 
Depending on the antibody, PBST or TBST were used for blocking (with 5% milk), washing, and all incubation 
steps (with 5% milk). The size given is the apparent size on the gel in kDa. All secondary antibodies (Dako, 
Glostrup, Denmark) were diluted 1:2,000 unless stated otherwise. For rabbit primary antibodies, goat-anti-
rabbit secondary antibodies were used; for mouse, goat-anti-mouse; and for goat, rabbit-anti-goat. G: goat; M: 
mouse; R: rabbit. *: Incubation in 5% BSA instead of 5% milk. 
#
: Secondary antibody dilution 1:5,000. 
Protein Buffer Species Dilution Clonality Supplier Size [kDa] 
β-actin PBST Mouse 1:5,000 monoclonal Abcam 42 
Akt TBST Rabbit 1:2,000 polyclonal Cell Signaling 56 
pAkt (S473) TBST Rabbit 1:2,500 polyclonal Abcam 56 
Axl PBST Mouse 1:500 polyclonal Abcam 165 
EGFR PBST Goat 1:1,000 polyclonal R&D 170 
pEGFR (Y1173) TBST* Rabbit 1:1,000 polyclonal R&D 170 
EphA2 PBST Mouse 1:500 monoclonal R&D 120 
Erk1/2 PBST Rabbit 1:2,000 polyclonal Abcam 42, 44 
pErk1/2 (T185, Y187, T202, Y204) TBST Mouse 1:1,000 monoclonal Abcam 42, 44 
FAK PBST Rabbit 1:1,000 monoclonal Abcam 125 
pFAK (Y397) TBST* Rabbit 1:1,000 polyclonal Abcam 125 
FGFR1 PBST Rabbit 1:1,000 polyclonal Abcam 92 
pFGFR1 (Y766) TBST Rabbit 1:1,000 polyclonal Abcam 92 
FGFR2 PBST Rabbit 1:250 polyclonal Abcam 92 
HER2 TBST Mouse 1:1,000 monoclonal Calbiochem 180 
pHER2 (Y1248) TBST Rabbit 1:1,000 polyclonal Abcam 180 
HER3 PBST* Mouse 1:100 monoclonal R&D 185 
LSAMP PBST Rabbit 1:500 polyclonal Sigma 55 
NEGR1 PBST Rabbit 1:500 polyclonal Abcam 55 
OPCML
#
 PBST Goat 1:5,000 polyclonal R&D 55 
α/β-tubulin TBST Rabbit 1:1,000 polyclonal Cell Signaling 55 
VEGFR1 PBST Rabbit 1:1,000 monoclonal Abcam 151 
pVEGFR1 (Y1213) TBST* Rabbit 1:400 polyclonal R&D 151 
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2.5.1.6) Densitometry 
To quantify protein bands on Western blot membranes, band intensities were determined 
for each protein sample as well as its corresponding loading control (β-tubulin or β-actin) 
using ImageJ (Wayne Rasband, National Institutes of Health, Bethesda, USA). Using Excel, 
the density of each protein band was subsequently expressed as the percentage compared 
to all bands on the same blot, and divided by the value for the corresponding loading 
control band to account for loading differences. Finally, relative densities were normalised 
to the control cell line (e.g. untreated cells). 
 
2.5.2) RNA and DNA Analysis 
2.5.2.1) RNA Extraction 
RNA was extracted using the RNeasy® Mini kit (Qiagen) according to the manufacturer’s 
instructions. In brief, seeded cells were washed twice in PBS and lysed using buffer RLT 
(containing guanidine thiocyanate, which both aids cell lysis and inactivates RNases). To 
complete cell disruption, lysates were kept at -20 °C o/n and subsequently passed several 
times through a 21G needle (BD Microlance™ 3). After the addition of 70% ethanol to create 
optimal RNA binding conditions, the sample was applied to a column containing a silica 
membrane. After centrifugation (10,000 rpm, 15 sec), bound RNA was washed once each in 
buffer RW1 (containing guanidine thiocyanate and ethanol to support binding and washing) 
and buffer RPE (contains ethanol to remove excess salt). RNA was eluted in water, and 
nucleic acid concentration was determined using a Nanodrop 1000-Vis Spectrophotometer 
(NanoDrop Technologies, Wilmington, Delaware, USA). 
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2.5.2.2) DNase Treatment 
DNase treatment was carried out using Precision™ DNase (PrimerDesign, Southampton, UK) 
according to the manufacturer’s instructions. Per 100 µl RNA sample, which was premixed 
with DNase reaction buffer, 1 µl DNase was added. After DNA digest at 30 °C for 10 min, the 
enzyme was heat-inactivated by incubation at 55 °C for 5 min. 
 
2.5.2.3) cDNA Synthesis 
Transcription of mRNA into cDNA was carried out using M-MLV Reverse Transcriptase. To 
allow annealing of 0.5 µg oligo-dT primers to 1 µg RNA, samples were incubated at 70 °C for 
5 min. Each tube was then immediately transferred onto ice, and a master mix containing 
M-MLV RT buffer, 2 mM dNTPs and 200 units M-MLV Reverse Transcriptase (all Promega) 
was added. Reverse transcription was carried out by incubation at 37 °C for 1 h, followed by 
an enzyme-inactivation step at 95 °C for 5 min. 
 
2.5.2.4) Quantitative Real-Time PCR (qRT-PCR) 
Prior to IgLON qRT-PCR, suitable reference/housekeeping genes were selected using the 
geNorm™ Housekeeping Gene Selection Kit (PrimerDesign). In brief, qRT-PCR reactions were 
carried out across a broad range of cell lines using primers for 12 potential reference genes. 
Data was analysed using the geNorm™ software (qbasePLUS, Biogazelle, Zwijnaarde, Belgium) 
which calculates the expression stability of each reference gene across all samples according 
to the method described by Hellemans et al. [Hellemans et al., 2007]. For the cell lines 
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investigated in this study, ATP5B and CYC1 yielded the best results (primer information in 
Table 11); hence, the average of both genes was used as a normalisation control in qRT-PCR. 
qRT-PCR primers for LSAMP had been described previously [Pasic et al., 2010], while primers 
for NEGR1 were custom-designed by PrimerDesign. Additional primer pairs were created 
manually based on the published DNA sequences (retrieved from www.ensembl.org; 
LSAMP: RefSeq NM_002338; NEGR1: RefSeq NM_173808). To avoid gDNA amplification, 
primers spanning exon-exon junctions were selected using Vector NTI® (Invitrogen). 
Subsequently, primer-BLAST (www.ncbi.nlm.nih.gov/tools/primer-blast) was used to 
determine melting temperatures and rule out unspecific binding. The primer pairs by Pasic 
et al. (for LSAMP) and PrimerDesign (for NEGR1) yielded the most accurate results (primer 
sequences in Table 11). 
qRT-PCR reactions were prepared in 96-well plates in a total volume of 20 µl per well 
containing 25 ng DNA and 300 nM primers in Precision™ Mastermix (PrimerDesign; contains 
0.025 U/μl Taq Polymerase, 5 mM MgCl2, dNTP Mix (200 μM each), ROX reference dye for 
normalisation of fluorescence across all wells, and SYBRgreen dye to visualise amplified 
double-stranded target DNA). Each sample was set up in triplicate, and samples containing 
no cDNA but water (no template control, NTC) or mRNA only (no reverse transcription, 
NoRT) were used as controls for gDNA presence or other contaminants. 
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Table 11: qRT-PCR primers 
Primer pairs for LSAMP were obtained from a publication by Pasic et al. [Pasic et al., 2010], while all other 
primers were custom-designed by PrimerDesign. If possible, primers for qRT-PCR spanned two exons in order 
to minimise gDNA amplification. 
Name Forward sequence (5' to 3') 
Tm 
[°C] 
GC 
[%] 
Reverse sequence (5' to 3') 
Tm 
[°C] 
GC 
[%] 
Amplicon 
[bp] 
ATP5B Not disclosed; anchor nucleotide position is 1193, RefSeq NM_001686.3. 139 
CYC1 Not disclosed; anchor nucleotide position is 915, RefSeq NM_001916.3. 174 
LSAMP ATCCTCAGGTGCGTTGTAGAAG 60.0 50 CTTGTCATGTCCAGCAAAAATG 56.8 41 84 
NEGR1 AGCACTTCGGCAATTATACCT 55.7 43 CAGCAGGAGAAAAGAACATCAG 55.9 45 130 
 
 
Amplification was carried out using the 7900HT Fast Real-Time PCR cycler (Applied 
Biosystems, Foster City, USA) according to the following protocol: initial strand dissociation 
at 95 °C for 10 min, 40 cycles of annealing/elongation/dissociation at 60 °C for 60 sec and 
95 °C for 15 sec, and final dissociation at 60-95 °C for 20 min. Data was analysed using the 
SDS v2.3 software (Applied Biosystems) and Excel. mRNA expression levels were compared 
using the ΔΔCt method: for each sample, the Ct (cross threshold) value of the reference 
gene was subtracted from the respective IgLON Ct (ΔCt); normalisation over all samples was 
achieved by subtracting the ΔCt of the control sample from all other ΔCts (ΔΔCt). mRNA 
levels were then plotted as percentage or fold-change. 
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2.6) Statistical Analyses 
Unless stated otherwise, data are expressed as the arithmetic mean across all replicates ± 
standard error of mean (SEM). Significance was analysed using Student’s t-Test (Excel). The 
following levels of significance were used: *: p<0.05; **: p<0.01; ***: p<0.001. Significance 
levels are given in the text, while exact p-values are stated below the corresponding graphs. 
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3.1) Introduction 
Due to the immensely promising results for OPCML, the whole IgLON family was initially 
investigated in silico to provide a suitable foundation for subsequent functional in vitro 
studies. After identification of splice variants for each IgLON, the proteins’ structural 
similarities and hence the likelihood of them being involved in comparable cellular 
processes were investigated by aligning their amino acid sequences and analysing them with 
regards to certain key residues. To gain an insight into the importance of IgLONs in a clinical 
context, their expression levels were analysed with regards to patient survival. Furthermore, 
it was investigated if methylation, which had been found to play an important role in 
OPCML silencing in ovarian cancer [Sellar et al., 2003], was involved in the regulation of 
expression for other IgLONs as well. 
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3.2) IgLON Isoforms 
As previous studies on the IgLON family had mainly focussed on splice variants in rat and 
chicken, an online search for human protein isoforms was carried out using the Ensembl 
database (www.ensembl.org); protein-coding transcript variants were compared using 
ClustalW2 (www.ebi.ac.uk/Tools/msa/clustalw2). Full sequence alignments can be found in 
appendix B (Figure 76), while a schematic representation of these findings is given here 
(Figure 15). 
 
 
Figure 15: Schematic representation of IgLON isoforms. 
For OPCML and LSAMP, four protein isoforms each could be determined. NEGR1 was found in three isoforms, 
while seven major isoforms as well as three strongly shortened variants (not displayed here) exist for 
neurotrimin. Left side: N-terminal signal peptide (yellow; different pattern indicate different amino acid 
sequences); middle: domains (1: green; 2: grey; 3: pink); right: C-terminal propeptide (blue). 
 
For OPCML, only four isoforms were found online despite previous descriptions of six 
variants in humans [Cui et al., 2008]; this is most likely due to several of the splice variants 
described by Cui et al. coding for the same protein. Transcripts 001 and 003 only differ in 
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their signal peptides; transcript 201 contains the same signal peptide as 001 but includes an 
additional nine amino acid (aa) residues between domain 3 and the propeptide. Transcript 
002 lacks the signal peptide as well as the first three aa of domain 1 but is otherwise 
identical with transcript 001. 
For LSAMP, four protein-coding transcripts were found. Compared to transcript 001, 
transcripts 002 and 201 contained an additional 23 aa between domain 3 and the 
propeptide, while transcript 006 lacked the complete C-terminus from the middle of domain 
2 onwards. All four isoforms had different signal peptides. 
NEGR1 was found in three different isoforms. Compared to transcript 001, transcript 002 
lacked the signal peptide and most of domain 1 (bar six aa residues), while transcript 201 
showed deletions of the C-terminal half of domain 2 as well as the first two amino acids of 
the signal peptide. 
For neurotrimin, 10 transcript variants were identified. Transcripts 001, 003 and 008 contain 
identical signal sequences; however, while transcript 003 lacks the propeptide, transcript 
008 contains an 11 aa insertion between domain 3 and the propeptide. Transcript 002 has a 
different signal peptide but is otherwise identical to transcript 001, while transcript 202 
both contains the same signal peptide as transcript 002 as well as the aforementioned 11 aa 
C-terminal insert. Transcripts 009, 013, 014 and 020 only have sequence lengths of 18-191 
aa and therefore represent strongly truncated proteins compared to the other isoforms, 
which contain 316-355 aa. It is therefore questionable if they are truly fully functioning 
proteins or rather represent experimental artefacts, particularly as they show only very 
limited sequence similarity compared to the other variants (Figure 76, Appendix B). 
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3.3) IgLON Sequence Alignments 
3.3.1) Whole Protein Sequence Alignment 
As a protein’s functions are inherently defined by its sequence, the amino acid chains of the 
respective transcripts 001 of the four members of the IgLON family were compared to gain a 
preliminary insight into potential structural resemblances. Alignment using ClustalW2 
revealed a high degree of sequence similarity between the family members and 
conservation of several key residues (Figure 16). OPCML and neurotrimin, which are the 
only two IgLONs encoded on the same chromosome, had the highest sequence identity with 
76% (for full scores, see Table 25, Appendix B). For the remaining IgLONs, sequence 
similarity varied between 45% and 55%. 
IgLONs are made up of three Ig domains, with the tertiary structure of each domain defined 
by two cysteine residues forming a disulfide bond. Across all four molecules, each of these 
cysteine pairs is conserved (Figure 16: highlighted in blue for domain 1, green for domain 2, 
red for domain 3). Interestingly, the P95R loss-of-function mutation in OPCML [Sellar et al., 
2003] (highlighted in yellow) lies in an area of 6 amino acids with strongly reduced sequence 
similarity between the IgLONs. Neither the OPCML wildtype (P) nor the mutant (R) residue is 
present in the sequence of any other IgLON family member. 
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 OPCML ---MGVCGYLFLPWKCLVVVSLRLLFLVPTGVPVRSGDATFPKAMDNVTVRQGESATLRC 57 
Neurotrimin ---MGVCGYLFLPWKCLVVVSLRLLFLVPTGVPVRSGDATFPKAMDNVTVRQGESATLRC 57 
LSAMP -----MVRRVQPDRKQLPLVLLRLLCLLPTGLPVRS--VDFNRGTDNITVRQGDTAILRC 53 
NEGR1 MDMMLLVQGACCSNQWLAAVLLSLCCLLPSCLPAGQSVDFPWAAVDNMMVRKGDTAVLRC 60 
Consensus      :        : *  * * *  *:*: :*. .       . **: **:*::* *** 
 
OPCML TIDDRVTRVAWLNRSTILYAGNDKWSIDPRVIILVNTPTQYSIMIQNVDVYDEGPYTCSV 117 
Neurotrimin TIDNRVTRVAWLNRSTILYAGNDKWCLDPRVVLLSNTQTQYSIEIQNVDVYDEGPYTCSV 117 
LSAMP VVEDKNSKVAWLNRSGIIFAGHDKWSLDPRVELEKRHSLEYSLRIQKVDVYDEGSYTCSV 113 
NEGR1 YLEDGASKGAWLNRSSIIFAGGDKWSVDPRVSISTLNKRDYSLQIQNVDVTDDGPYTCSV 120 
Consensus  :::  :: ****** *::** ***.:**** :      :**: **:*** *:*.***** 
 
OPCML QTDNHPKTSRVHLIVQVPPQIMNISSDITVNEGSSVTLLCLAIGRPEPTVTWRHLSVKEG 177 
Neurotrimin QTDNHPKTSRVHLIVQVSPKIVEISSDISINEGNNISLTCIATGRPEPTVTWRHISPK-A 176 
LSAMP QTQHEPKTSQVYLIVQVPPKISNISSDVTVNEGSNVTLVCMANGRPEPVITWRHLTPT-G 172 
NEGR1 QTQHTPRTMQVHLTVQVPPKIYDISNDMTVNEGTNVTLTCLATGKPEPSISWRHISPS-A 179 
Consensus **:: *:* :*:* ***.*:* :**.*:::***..::* *:* *:*** ::***:: . . 
 
OPCML QGFVSEDEYLEISDIKRDQSGEYECSALNDVAAPDVRKVKITVNYPPYISKAKNTGVSVG 237 
Neurotrimin VGFVSEDEYLEIQGITREQSGDYECSASNDVAAPVVRRVKVTVNYPPYISEAKGTGVPVG 236 
LSAMP REFEGEEEYLEILGITREQSGKYECKAANEVSSADVKQVKVTVNYPPTITESKSNEATTG 232 
NEGR1 KPFEN-GQYLDIYGITRDQAGEYECSAENDVSFPDVRKVKVVVNFAPTIQEIKSGTVTPG 238 
Consensus   * .  :**:* .*.*:*:*.***.* *:*: . *::**:.**:.* * : *.  .. * 
 
OPCML QKGILSCEASAVPMAEFQWFKEETRLATGLDGMRIENKGRMSTLTFFNVSEKDYGNYTCV 297 
Neurotrimin QKGTLQCEASAVPSAEFQWYKDDKRLIEGKKGVKVENRPFLSKLIFFNVSEHDYGNYTCV 296 
LSAMP RQASLKCEASAVPAPDFEWYRDDTRIN-SANGLEIKSTEGQSSLTVTNVTEEHYGNYTCV 291 
NEGR1 RSGLIRCEGAGVPPPAFEWYKGEKKLFNGQQGIIIQNFSTRSILTVTNVTQEHFGNYTCV 298 
Consensus :.. : **.:.** . *:*:: :.::  . .*: ::.    * * . **::..:****** 
 
OPCML ATNKLGNTNASITLYGPGAVIDGVNSASRALACLWLSGTLLAHFFIKF-------- 345 
Neurotrimin ASNKLGHTNASIMLFGPGAVSEVSNGTSRRAGCVWLLPLLVLHLLLKF-------- 344 
LSAMP AANKLGVTNASLVLFRPGSVRG-INGSISLAVPLWLLAASLLCLLSKC-------- 338 
NEGR1 AANKLGTTNASLPLNPPSTAQYGITGSADVLFSCWYLVLTLSSFTSIFYLKNAILQ 354 
Consensus *:**** ****: *  *.:.    ..:       *     :  :             
Figure 16: Amino acid sequence alignment of the IgLON family members. 
Alignment created using ClustalW2. Amino acid sequence alignment revealed a high degree of sequence 
similarity across the IgLON family. Conserved cysteine pairs, which form the Ig domains in all four molecules, 
are highlighted in blue (domain 1), green (domain 2), and red (domain 3). The P95R loss-of-function mutation 
in OPCML is highlighted in yellow. Key to amino acids: red: small, hydrophobic, aromatic (AVFPMILW); blue: 
acidic (DE); magenta: basic (RK); green: hydroxyl, amine, amide, basic (STYHCNGQ); grey: others. Consensus 
symbols: “*”: identical; “:”: conserved substitutions (same colour group); “.”: semi-conserved substitution 
(similar shapes). For alignment scores see Table 25, Appendix B.  
 
 
3.3.2) Domain Sequence Alignment 
Comparison of the individual Ig domains of all four IgLONs was carried out using T-Coffee. 
For all IgLONs, it was found that the three Ig domains within the same molecule only share 
6-22% amino acid identity. Between molecules however, domains at the same position were 
found to have a sequence identity of 44-90% and reveal distinct domain-specific patterns 
(Figure 17; for full scores, see Table 26, Appendix B).  
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Figure 17: Amino acid sequence alignment of the three Ig domains. 
Alignment created using T-Coffee. While sequence identity between different domains across all four 
molecules is low, a clear domain-specific pattern can be observed for domains at the same position. Numbers 
in brackets indicate domain position. Box: P95R mutation. Arrows: cysteines forming disulfide bonds. CORE 
index: Determines correctly aligned blocks of residues. Consensus symbols: “*”: identical. “:”: conserved 
substitution. “.”: semi-conserved substitution.  
 
 
The high sequence similarity within each Ig domain across the IgLON family members 
indicates that the domain order is structurally conserved across all family members. This 
suggests that the development of the IgLON family was a result of gene duplication rather 
than domain shuffling (Figure 18). 
 
OPCML(1) PKAM------DNVTVRQGESATLRCTIDDRV-TRVAWLNRSTILYAGNDKW 
Neurotrimin(1) PKAM------DNVTVRQGESATLRCTIDNRV-TRVAWLNRSTILYAGNDKW 
LSAMP(1) VRSVDFNRGTDNITVRQGDTAILRCVVEDKN-SKVAWLNRSGIIFAGHDKW 
NEGR1(1) VDFPWA--AVDNMMVRKGDTAVLRCYLEDGA-SKGAWLNRSSIIFAGGDKW 
OPCML(2) PQIMN---ISSDITVNEGSSVTLLCLAIGRPEPTVTWRHLSVKE------- 
Neurotrimin(2) PKIVE---ISSDISINEGNNISLTCIATGRPEPTVTWRHISPK-------- 
LSAMP(2) PKISN---ISSDVTVNEGSNVTLVCMANGRPEPVITWRHLTPT-------- 
NEGR1(2) PKIYD---ISNDMTVNEGTNVTLTCLATGKPEPSISWRHISPS-------- 
OPCML(3) PPYIS---KAKNTGVSVGQKGILSCEASAVPMAEFQWFKEETRLATGLD-- 
Neurotrimin(3) PPYIS---EAKGTGVPVGQKGTLQCEASAVPSAEFQWYKDDKRLIEGKK-- 
LSAMP(3) PTITE----SKSNEATTGRQASLKCEASAVPAPDFEWYRDDTRINSA-N-- 
NEGR1(3) PTIQE----IKSGTVTPGRSGLIRCEGAGVPPPAFEWYKGEKKLFNGQQ-- 
Consensus           ..     *    : *       .   * .            4 
 
 
OPCML(1) SIDPRVIILVNTPTQYSIMIQNVDVYDEGPYTCSVQTDNH------PK-TS 
Neurotrimin(1) CLDPRVVLLSNTQTQYSIEIQNVDVYDEGPYTCSVQTDNH------PK-TS 
LSAMP(1) SLDPRVELEKRHSLEYSLRIQKVDVYDEGSYTCSVQTQHE------PK-TS 
NEGR1(1) SVDPRVSISTLNKRDYSLQIQNVDVTDDGPYTCSVQTQHTPR-TMQVH-LT 
OPCML(2) -----GQ--GFVSEDEYLEISDIKRDQSGEYECSALNDVAAPDVRKVK-IT 
Neurotrimin(2) -----AV--GFVSEDEYLEIQGITREQSGDYECSASNDVAAPVVRRVK-VT 
LSAMP(2) -----GR--EFEGEEEYLEILGITREQSGKYECKAANEVSSADVKQVK-VT 
NEGR1(2) -----AK--PFE-NGQYLDIYGITRDQAGEYECSAENDVSFPDVRKVKVVV 
OPCML(3) -----GMRIENKGRMSTLTFFNVSEKDYGNYTCVATNKLGNT---NAS-IT 
Neurotrimin(3) -----GVKVENRPFLSKLIFFNVSEHDYGNYTCVASNKLGHT---NAS-IM 
LSAMP(3) -----GLEIKSTEGQSSLTVTNVTEEHYGNYTCVAANKLGVT---NAS-LV 
NEGR1(3) -----GIIIQNFSTRSILTVTNVTQEHFGNYTCVAANKLGTTN-ASLP-LN 
Consensus                  : .  :   . * * * . ..             0 
CORE index: BAD AVG GOOD 
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Figure 18: Hypothesis on the evolution of the IgLON protein family. 
As the order of the three Ig domains is maintained within each IgLON family member, domain shuffling (A) is 
an unlikely explanation for the formation of the individual proteins. Based on the sequence alignment data 
presented in Figure 17, it is therefore hypothesised that the driver of the IgLON family development was gene 
duplication (B). 
 
Out of the three Ig domains, domain 3 is the least conserved with only 51.0% sequence 
similarity across the IgLON family (p<0.01, Figure 19; for full scores, see Table 27, Appendix 
B).  
 
 
Figure 19: Ig domain sequence conservation across the IgLON family. 
Comparing the three Ig domains separately revealed that domains 3 (51.0%) are significantly less conserved 
across the four molecules than domains 1 (62.2%, p=0.00466) and 2 (61.2%, p=0.00726). For full alignment 
scores, see Table 27, Appendix B. 
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3.4) IgLON Expression 
3.4.1) Kaplan-Meier Survival Plots 
Kaplan-Meier survival plots can be used to visualise patient survival with regards to a 
specific attribute, e.g. expression levels of a certain gene. It can thus be determined if this 
particular attribute has a beneficial or detrimental impact on survival. 
Graphs for progression-free (PFS) as well as overall survival (OS) were generated for each 
IgLON based on a publicly available, fully annotated expression dataset for ovarian cancer 
comprising 295 primary epithelial ovarian tumours [Tothill et al., 2008]. As expected, plots 
for OPCML indicated that high (i.e. above median) expression of OPCML is beneficial both 
with regards to progression-free as well as overall survival; however, these associations just 
missed significance (Figure 20A, B). For LSAMP, no significant correlation could be found 
with OS (D); however, it was negatively correlated with PFS (p < 0.05; C). NEGR1 was not 
found to be associated with either PFS or OS (E, F), while HNT (neurotrimin) was negatively 
correlated with both progression-free (p < 0.05, G) and overall survival (p < 0.001, H). 
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C) D) 
B) A) 
E) F) 
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Figure 20: Kaplan-Meier survival plots. 
While the positive association of high OPCML expression with survival just missed significance (A, B), both 
LSAMP (PFS; C) and neurotrimin (HNT; PFS and OS; G, H) were negatively correlated. No significant effect of 
NEGR1 could be detected (E, F). Log rank p values and probe identifiers are given above each diagram. X axis: 
Time (months); Y axis: Survival. OS: overall survival; PFS: progression-free survival. Graphs kindly prepared by 
Dr Ed Curry, Imperial College London. 
 
 
3.4.2) Methylation Status 
As methylation is one of several potential mechanisms which can lead to reduction of 
protein expression and hence play an important role in cancer, it was investigated if IgLON 
methylation differed between healthy tissue and tumour samples in the TCGA dataset 
[TCGA, 2011]. 
Methylation of OPCML and NEGR1 was analysed in normal fallopian tube tissue samples 
(n=10) and high-grade serous tumours (n=242). No data was available for LSAMP and HNT 
(neurotrimin). Statistical analyses revealed that methylation of NEGR1 was significantly 
reduced in tumour samples compared to normal tissue (p<0.05, Figure 21), while no 
difference could be detected for OPCML (p>0.05). However, it was observed that 
H) G) 
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methylation of OPCML was significantly higher than for NEGR1 both in FT and HGS samples 
(p < 0.001). 
 
         
Figure 21: Methylation status of NEGR1 (A) and OPCML (B). 
Methylation status of NEGR1 (A) and OPCML (B) was compared in fallopian tube tissue samples (FT, n=10) and 
high-grade serous tumours (HGS, n=242). Differences in degrees of methylation were analysed using the 
Mann-Whitney test. While tumour samples exhibited significantly reduced methylation for NEGR1 in HGS 
(p=0.023), no difference could be detected for OPCML (p=0.574). Methylation of OPCML in FT and HGS was 
significantly higher than for NEGR1 (FT: median of 0.344 and 0.103, respectively; p = 1.795x10
-6
. HGS: median 
of 0.398 and 0.071, respectively; p = 3.405x10
-69
). Graphs kindly prepared by Dr Wei Dai, Imperial College 
London. 
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3.5) Summary 
For each IgLON family member, several protein isoforms were identified. The most 
frequently observed variations were differences in the signal peptide as well as C-terminal 
insertions between domain 3 and the GPI anchor. 
 
Bioinformatic analyses showed that the IgLON family members overall possess a high 
degree of amino acid sequence conservation. Furthermore, key residues such as the 
cysteine pairs within each of the three Ig domains are conserved. However, the loss-of-
function P95R mutation detected in OPCML lies in a region with low sequence identity and 
is unique to OPCML. 
 
Taking a closer look at the individual Ig domains, it was found that domains at same position 
(1, 2 or 3) in different IgLON molecules are more similar than domains at different positions 
within same molecule. This indicates that the domain order is maintained across all four 
proteins, and suggests that the IgLON family was formed by gene duplication. Out of the 
three domains, domain 3 has the lowest degree of conservation when compared across all 
four family members. 
 
Kaplan-Meier survival plots revealed the expected positive correlation of OPCML with 
progression-free and overall survival, but this trend was outside statistical significance. 
Progression-free survival was significantly reduced upon overexpression of LSAMP and HNT 
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(neurotrimin), while overall survival was negatively correlated with HNT expression. No 
statistically significant association could be found for NEGR1. 
 
Methylation status of NEGR1 and OPCML was analysed in fallopian tube tissue samples and 
high-grade serous tumours. For OPCML, no difference could be detected between healthy 
control samples and tumours, while the degree of NEGR1 methylation was significantly 
reduced in tumour samples. Both in control and in tumour samples, methylation of OPCML 
was significantly higher than for NEGR1. 
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4.1) Introduction 
To gain an insight into potential functions of LSAMP in vitro, a broad range of experiments 
was carried out using the transformed normal ovarian epithelium cell line OSE-C2 as well as 
a panel of ovarian cancer cell lines. Firstly, basic characteristics such as LSAMP expression 
levels, localisation, or response to growth factors were analysed. Subsequently, transfection 
experiments were carried out in several different cell lines to assess the effects of LSAMP 
overexpression or silencing on cellular properties such as RTK expression, proliferation or 
migration. Finally, protein-protein interaction was addressed, investigating binding of 
LSAMP to its sister molecule OPCML. 
Over the course of the project, several difficulties regarding the resources used for LSAMP 
experiments were encountered. Especially antibodies, siRNAs and expression vectors 
require further optimisation: while it was discovered that the antibody used both for 
Western blotting as well as IFM was unable to detect recombinant LSAMP and hence may 
rather recognise a precursor protein than the mature form of LSAMP, transfections often 
led to significant side effects in transfected versus untransfected cells. The interpretation of 
the experiments described here is therefore dependent upon further verification; 
suggestions for such approaches as well as already undertaken optimisation efforts are 
presented at the end of this chapter (see 4.6). 
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4.2) Characterisation of LSAMP 
Initial characterisation of LSAMP was mainly carried out using the ovarian epithelium cell 
line OSE-C2 as well as the cancer cell line SKOV3 and its derivatives BKS2.1 (OPCML-
transfected) and V1.2 (empty vector control). Cell lines were analysed with regards to 
intrinsic LSAMP expression levels, response to growth factor stimulation, and subcellular 
localisation of LSAMP in relation to various other proteins. 
 
4.2.1) LSAMP Expression Levels 
To determine basal LSAMP expression levels across a range of cell types, 25 ovarian cancer 
cell lines as well as the normal ovarian epithelium cell line OSE-C2 were grown on either full 
or serum-free medium and collected after 24 h to be analysed by Western blotting (Figure 
22A). 
Densitometry analysis confirmed that LSAMP expression levels were downregulated in the 
majority of cell lines, with only four samples (SKOV3-S/-F, SKOBS3.5-S/-F) showing doubled 
LSAMP expression compared with OSE-C2 cells, but 30 lower than half (Figure 22B). Absence 
of serum resulted in upregulation of LSAMP expression in most cell lines except SKOV3, V1.2 
and IGROV; however, this effect was mainly detectable via densitometry analysis. 
No correlation could be observed between LSAMP expression and OPCML status in SKOV3 
(0x OPCML), V1.2 (SKOV3 empty vector control, 0x OPCML), BKS2.1 (SKOV3 OPCML-
transfected, 30x increased expression) and SKOBS3.5 cells (SKOV3 OPCML-transfected, 2x 
increased expression). While SKOV3 and SKOBS3.5 cells exhibited similar LSAMP protein 
levels, expression in BKS2.1 and particularly V1.2 cells was reduced. 
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LSAMP levels did not appear to be related to ovarian cancer subtype: amongst the clear cell 
carcinomas were 4 non-expressing and 3 expressing cell lines; serous 5 non-expressing and 
4 expressing; endometrioid 0 non-expressing and 2 expressing. 
Of the isogenic paired ovarian cancer cell lines (PEO1/4/6, PEO14/23, PEA1/2), established 
from primary tumours displaying cisplatin sensitivity/resistance, respectively, none were 
found to express LSAMP. 
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Figure 22: LSAMP expression levels in OSE-C2 and 25 ovarian cancer cell lines. 
LSAMP expression was assessed across a broad range of ovarian cell lines via Western blotting (A) and 
normalised using densitometry (B). Compared to OSE-C2 (normal ovarian surface epithelium cells), SKOV3, 
BKS2.1, SKOBS3.5, A2780 and ES2 showed increased LSAMP expression, while a large number of cancer cells 
did not express LSAMP at all. OSE-C2 cells are marked in blue, serous cancers are red, endometrioid green and 
clear cell yellow. If no outline is shown, data on the origin of the cell line was conflicting. No information could 
be obtained for OVCAR4. For more information on these cell lines, see Table 12, Appendix A. F: Full medium; S: 
Serum-free medium; s: cisplatin-sensitive; r: cisplatin-resistant. OVTOKO, KK, TOV21G, ES2 and KOC7C lysates 
were kindly provided by Dr Michelle Chen, Imperial College London. 
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To assess if the different levels of LSAMP expression observed in the investigated ovarian 
cell lines were related to RTK levels, expression of EGFR and FGFR1 was analysed in the 
same set of cell lines. No obvious trend could be detected in Western blots (Figure 23). 
 
 
 
Figure 23: EGFR and FGFR1 expression levels in OSE-C2 and 25 ovarian cancer cell lines. 
Investigation of EGFR and FGFR1 expression levels across a broad spectrum of ovarian cell lines did not reveal 
a correlation between LSAMP and RTK levels. F: full serum; S: serum-free. s: cisplatin-sensitive; r: cisplatin-
resistant. Blot was created prior to β-actin normalisation.  
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4.2.2) Growth Factor Stimulation 
Previous experiments in the laboratory suggested that OPCML is upregulated in response to 
certain growth factors and thus may be involved in a negative feedback loop [McKie et al., 
2012]. Results for LSAMP however indicated little effect of serum presence on its expression 
(see Figure 22, page 140); furthermore, if an effect was seen, presence of serum rather led 
to diminished protein levels. To investigate this further, several cell lines were assessed with 
regards to changes in LSAMP expression upon stimulation with EGF or FGF. 
 
4.2.2.1) EGF Stimulation 
OSE-C2 cells as well as the ovarian cancer cell lines PEO1, SKOV3 and OVISE were stimulated 
with 50 ng/ml EGF for 0-150 minutes. On Western blots, no change in LSAMP expression 
could be observed: OSE-C2 and SKOV3 maintained their LSAMP expression levels, while 
PEO1 and OVISE remained non-expressers (Figure 24). Densitometry analysis however 
showed that LSAMP was downregulated in SKOV3 cells to less than 40% of protein levels 
present in unstimulated cells after 70 minutes post stimulation with EGF. This coincided 
with a peak in phosphorylation of EGFR at 30-70 minutes, which was followed by a gradual 
decrease. In OSE-C2 cells, only a minor downregulation between 30-90 minutes and quick 
re-establishment of normal LSAMP expression levels by 120 minutes was observed. 
However, due to the aforementioned difficulties regarding the LSAMP antibodies, these 
results require further validation. 
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Figure 24: EGF stimulation of OSE-C2, PEO1, SKOV3 and OVISE cells. 
Cells were stimulated with 50 ng/ml EGF for 0-150 minutes. No effect of EGF presence on LSAMP could be 
detected in Western blots (A). Densitometry analyses however revealed downregulation in OSE-C2 (B) and 
particularly SKOV3 cells (C) upon EGF stimulation. 
 
 
4.2.2.2) FGF stimulation 
In addition to EGF, OSE-C2 cells were also stimulated with 10 ng/ml FGF for 0-150 minutes. 
As observed for EGF stimulation, this resulted in downregulation of LSAMP expression; 
however, this effect was again mainly detectable via densitometry analysis and therefore 
needs to be validated further (Figure 25). Of note, stimulation did not initiate RTK 
phosphorylation. 
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Figure 25: FGF stimulation of OSE-C2 cells. 
Cells were stimulated with 10 ng/ml FGF for 0-150 minutes. No effect of FGF presence on LSAMP could be 
detected in Western blots (A), while densitometry revealed downregulation (B). RTK phosphorylation was not 
induced. 
 
 
4.2.3) Confocal Immunofluorescence Microscopy 
Confocal immunofluorescence microscopy (IFM) was used to establish the localisation of 
LSAMP within cells and to investigate potential colocalisation with various other molecules. 
 
4.2.3.1) LSAMP Localisation in OSE-C2 Cells 
As LSAMP expression had been found to differ slightly between cells grown on full (F) and 
serum-free (S) medium (see Figure 22, page 140), the influence of serum presence on the 
cellular localisation of LSAMP was assessed as well. However, no difference could be 
observed between OSE-C2 cells maintained on full or serum-free medium (Figure 26): under 
both conditions, LSAMP was mainly found within the nucleus (stained with DAPI) or in its 
periphery, as well as on the cells’ leading edges. Nonetheless, as observed on Western blots, 
LSAMP expression was slightly increased on serum-free medium (B) compared to full 
medium (A), particularly within the nucleus.  
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Figure 26: Cellular localisation of LSAMP in OSE-C2 cells. 
Cells were grown on full (A) or serum-free medium (B). No major difference in LSAMP localisation could be 
observed; LSAMP was present mainly in the nucleus and on the cells’ leading edges (arrows). LSAMP signal 
intensity was increased in cells maintained on serum-free medium. 
 
 
4.2.3.2) LSAMP Colocalisation with OPCML  
To assess if LSAMP is present in the same cellular regions as OPCML, colocalisation of the 
two IgLONs was investigated in OSE-C2 as well as SKOV3 and its two derivatives, V1.2 
(empty vector) and BKS2.1 (OPCML-overexpressing). 
OSE-C2 cells, which express both LSAMP and OPCML endogenously, revealed a certain 
degree of colocalisation, especially around the cells’ leading edges (Figure 27A). In 
comparison, LSAMP expression in both SKOV3 (B) and V1.2 cells (C), which do not express 
OPCML, was mainly found in the periphery of the nucleus, but not on the membrane like in 
OSE-C2. 
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As expected, the signal for OPCML was strongly increased in the OPCML-transfected cell line 
BKS2.1 (D). However, localisation or expression levels of LSAMP seemed unaffected by this 
change and the protein was mainly present in the perinuclear region. Since OPCML was 
primarily detected in the cytoplasm’s periphery and on the membrane, the two IgLONs did 
not colocalise. 
Overall, there seems to be a difference between IgLON distribution in the non-cancerous 
OSE-C2 line and in SKOV3/V1.2/BKS2.1 cancer cells. While both LSAMP and OPCML show a 
rather even distribution in OSE-C2, their expression is much more region-specific in SKOV3 
cells and its derivatives, regardless of OPCML expression levels. However, this trend was less 
obvious in further experiments (see below). 
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Figure 27: Colocalisation of LSAMP with OPCML. 
Localisation of LSAMP and OPCML was investigated in OSE-C2 (A), SKOV3 (B), V1.2 (C) and BKS2.1 (D) cells. 
LSAMP is present on both the cell membrane (arrows) as well as around the nucleus in OSE-C2; however, it is 
absent from the cell membrane in the cancer cell lines. OPCML shows some colocalisation with LSAMP in OSE-
C2 cells, but not in BKS2.1 where it is mainly present at the cells’ outer membranes.  
 
 
4.2.3.3) LSAMP Colocalisation with Cav-1 
Previous results in the laboratory found OPCML to colocalise with caveolin-1 (cav-1) [McKie 
et al., 2012]. Here, this was similarly investigated for LSAMP in OSE-C2, SKOV3, V1.2 and 
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BKS2.1 cells. Caveolin-1 is a marker for caveolae, a distinct type of lipid raft; hence, presence 
of LSAMP in these regions could indicate a role in clathrin-independent endocytosis. 
However, while cav-1 could clearly be located on the cells’ membranes, LSAMP remained 
mainly cytoplasmic; colocalisation between the two molecules was found to be minimal 
(Figure 28). 
 
 
 
Figure 28: Colocalisation of LSAMP with caveolin-1. 
Localisation of LSAMP and cav-1 was investigated in OSE-C2 (A), SKOV3 (B), V1.2 (C) and BKS2.1 (D) cells. Cav-1, 
a marker for caveolae, was clearly visible on the cells’ membranes, but did not colocalise with LSAMP. 
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4.2.3.4) LSAMP Colocalisation with Phalloidin and FGFR1  
Due to its presence at leading edges in OSE-C2 cells, LSAMP colocalisation with the 
cytoskeleton was investigated using phalloidin, a toxin which specifically binds to F-actin. 
Additionally, in order to gain a preliminary insight into LSAMP’s relationship with receptor 
tyrosine kinases, FGFR1 was selected as a representative of the RTKs which interact with 
and are downregulated by OPCML. 
Staining of the cytoskeleton with phalloidin was clearly observable, but no colocalisation 
with LSAMP could be detected (Figure 29A). LSAMP and FGFR1 however showed a small 
degree of colocalisation, particularly around the nucleus and on the cells’ leading edges 
(Figure 29B).  
 
 
Figure 29: Colocalisation of LSAMP with phalloidin (A) and FGFR1 (B) in OSE-C2 cells. 
No colocalisation of LSAMP with the cytoskeletal marker phalloidin could be observed in OSE-C2 cells (A). 
However, FGFR1 and LSAMP showed a small degree of overlap, particularly around leading edges (B). 
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4.3) Overexpression of LSAMP 
In order to facilitate assessment of the protein’s functional impact in vitro, LSAMP 
overexpression experiments were carried out using several different ovarian cancer cell 
lines. After initial transient transfections, cells were also transfected stably to carry out long-
term assays such as proliferation. PEO1, OVCAR4 and OVISE were chosen based on the 
observation that they do not express LSAMP intrinsically (see Figure 22, page 140). SKOV3 
and OSE-C2 cells were added in later experiments due to their reliability with regards to 
transfections, despite expressing LSAMP endogenously. 
 
4.3.1) Transient LSAMP Overexpression in PEO1 and OVCAR4 
Initially, the LSAMP-negative ovarian cancer cell lines PEO1 and OVCAR4 were transiently 
transfected with full-length LSAMP cloned into the expression vector pcDNA™4/TO. 
However, even after several optimisation steps, transient transfection was not successful 
(Figure 30). Particularly PEO1 cells exhibited strong visual signs of stress after transfection, 
which is reflected in their low levels of β-actin. Stable transfections were therefore carried 
out to allow for more recovery time after treatment as well as a more thorough selection 
process. 
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Figure 30: Transient LSAMP overexpression in PEO1 and OVCAR4. 
Western blotting revealed that both PEO1 and OVCAR4, which do not express LSAMP intrinsically, could not be 
transfected successfully. EV: Transfection with empty pcDNA™4/TO vector; LS: transfection with LSAMP in 
pcDNA™4/TO. 
 
 
4.3.2) Stable LSAMP Overexpression in PEO1 
Despite careful evaluation of optimal transfection conditions, initial Western blots did not 
indicate upregulation of LSAMP in PEO1 cells under stable transfection conditions either 
(Figure 31A). However, there was a visible difference between LSAMP-transfected (A) and 
empty vector-transfected cells (B) with regards to other proteins: compared to 
untransfected PEO1 cells, expression of FGFR1 and phosphorylation of EGFR and Erk1/2 was 
substantially upregulated after transfection with LSAMP. For a potential tumour suppressor 
gene, these findings were unexpected. However, it has to be noted that the opposite was 
seen in empty vector controls, indicating potential off-target effects or transfection-induced 
stress. 
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Figure 31: Stable LSAMP overexpression in PEO1 cells. 
Stable transfection of PEO1 cells could not be confirmed by Western blotting as no signal was detectable for 
LSAMP. Nonetheless, the LSAMP-transfected clone P+L-11 (A) showed an increase in pEGFR, FGFR1 and 
pErk1/2; however, their levels were reduced in the empty-vector transfected clone P-10 (B). These 
observations could be confirmed by densitometry analysis (C). PEO1: untransfected cells; P+L-11: PEO1 
transfected with LSAMP in pcDNA™4/TO; P-10: PEO1 transfected with pcDNA™4/TO empty vector. 
 
 
To determine if antibody-related issues were the cause for apparent LSAMP absence on 
Western blots, qRT-PCR was carried out to establish levels of LSAMP mRNA expression in all 
three cell lines. This revealed that LSAMP expression in the empty vector clone P-10 was 
indeed slightly reduced compared to untransfected PEO1 cells, although this difference was 
not significant (p>0.05, Figure 32). However, no upregulation could not be detected in the 
putative overexpression clone P+L-11 (p>0.05), nor did it differ significantly from its empty 
vector counterpart (p>0.05). Consequently, this system did not represent a suitable 
resource for further experiments, and the observed differences in RTK expression are 
unlikely to be LSAMP-related. 
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Figure 32: Stable LSAMP overexpression in PEO1, qRT-PCR. 
Overexpression of LSAMP in PEO1 could not be confirmed via qRT-PCR as expression in the LSAMP-transfected 
clone P+L-11 did not differ significantly from PEO1 (p=0.53085) or the empty vector clone P-10 (p=0.77104). 
LSAMP expression in P-10 actually seemed to be considerably reduced compared to PEO1; however, this trend 
was not significant either (p=0.38977). PEO1: untransfected cells; P-10: PEO1 transfected with pcDNA™4/TO 
empty vector; P+L-11: PEO1 transfected with LSAMP in pcDNA™4/TO. 
 
 
4.3.3) Stable LSAMP Overexpression in OVISE 
Parallel to PEO1, LSAMP overexpression was also carried out using a second non-expressing 
cell line, OVISE. Selected clones were analysed with regards to LSAMP expression via qRT-
PCR; however, the putative LSAMP overexpression clone P+L-21 actually showed a 
significantly reduced expression of LSAMP compared to untransfected OVISE cells (p<0.05, 
Figure 33). LSAMP expression in the empty vector clone P-7 seemed to be reduced as well; 
however, this trend was not significant (p>0.05). Therefore, as no significant upregulation of 
LSAMP could be observed in P+L-21 compared to untransfected OVISE cells or the empty 
vector control P-7, these clones did not represent suitable resources for further 
experiments. 
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Figure 33: Stable LSAMP overexpression in OVISE, qRT-PCR. 
Overexpression of LSAMP in OVISE could not be confirmed via qRT-PCR. While the empty vector clone P-7 did 
not differ significantly from the untransfected OVISE control (p=0.11895), the putative overexpression clone 
P+L-21 actually expressed significantly less LSAMP than untransfected OVISE cells (p=0.02483). P+L-21 LSAMP 
levels were also reduced compared to the P-7; however, this trend was not significant (p=0.11924). OVISE: 
untransfected cells; P-7: OVISE transfected with pcDNA™4/TO empty vector; P+L-21: OVISE transfected with 
LSAMP in pcDNA™4/TO. 
 
 
4.3.4) Stable LSAMP Overexpression in SKOV3 
As neither PEO1 nor OVISE cell lines could be successfully transfected with LSAMP, it was 
decided to use SKOV3 cells due to their previously observed reliability with regards to 
transfection. It has to be noted however that SKOV3 are not the optimal choice for assessing 
functional effects of increased LSAMP expression as they express a basal level of intrinsic 
LSAMP. 
 
4.3.4.1) Protein Expression Levels 
Transfection of SKOV3 cells with LSAMP was achieved to a limited degree. While levels of 
LSAMP in the transfected clone LS14 did not differ greatly from untransfected SKOV3 cells, 
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they were strongly increased compared to the empty-vector control EV4 (Figure 34). Similar 
to previous findings for OPCML, levels of HER2, pHER and pErk1/2 were downregulated in 
LSAMP-transfected LS14 cells compared to EV4 and SKOV3. FGFR1 and pAkt remained 
unchanged in LS14 compared to SKOV3, but were increased compared to EV4. EGFR could 
only be detected in SKOV3 but not in either of the transfected cells. Paradoxically, HER3 
expression could only be detected in EV4 but not LS14 or SKOV3. Expression of NEGR1 was 
not observed in any cell line. 
 
 
      
Figure 34: Stable LSAMP overexpression in SKOV3 cells. 
While levels of LSAMP expression did not differ greatly between untransfected SKOV3 cells and LSAMP-
transfected LS14 cells, LSAMP expression in LS14 was strongly increased compared to the empty vector control 
EV4, which overall exhibited lower levels of protein expression than SKOV3. Both Western blotting (A) and 
densitometry (B) confirmed that LSAMP presence in LS14 cells leads to a reduction in HER2, pHER2 and 
pErk1/2 below levels of untransfected cells, while FGFR1 and pAkt were increased compared to the empty 
vector control. SKOV3: untransfected cells; EV4: SKOV3 transfected with pcDNA™4/TO empty vector; LS14: 
SKOV3 transfected with LSAMP in pcDNA™4/TO. 
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Even though LSAMP expression levels in LS14 did not differ greatly from untransfected 
SKOV3 cells, they were strongly increased compared to the empty vector control EV4; hence 
this represented the first successful creation of an overexpression/empty vector control 
pair, although the limitations of the antibody used need to be kept in mind. 
To analyse the observed differences between these cell lines further, several functional 
assays were carried out. However, it has to be kept in mind that EV4 is not an exact 
representation of its parental cell line as it overall exhibited lower expression levels for all 
investigated proteins than SKOV3. These differences could be due to the fact that SKOV3 
cells were grown on zeocin-free medium, while transfected cells were maintained in 
medium containing zeocin as a selection antibiotic. Furthermore, transfection itself can have 
substantial off-target effects. Therefore, while EV4 might not be identical to untransfected 
SKOV3 cells, it still represents a useful control for transfection and selection-related side 
effects. 
 
4.3.4.2) Proliferation Assay 
To assess if the observed downregulation of several RTKs as well as pErk1/2 in LSAMP-
transfected LS14 clones had a functional impact, a series of proliferation assays was carried 
out. Indeed, LS14 cells showed a significantly slower proliferation rate than SKOV3 (p<0.05 
at 96 h, Figure 35); however, the same could be observed for the empty vector control 
(p>0.05). Furthermore, no significant difference was found between the LSAMP-
overexpressing and empty vector clones (p>0.05). 
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Figure 35: Proliferation assay of stably LSAMP-transfected SKOV3 cells. 
Proliferation of LSAMP-overexpressing LS14 clones differed significantly from untransfected SKOV3 cells 
(p=0.04931 at 96 h); however, the same was observed for the empty vector control EV4 (p=0.03612). 
Furthermore, LS14 and EV4 were not significantly different from each other (p=0.37411). SKOV3: 
untransfected cells; EV4: SKOV3 transfected with pcDNA™4/TO empty vector; LS14: SKOV3 transfected with 
LSAMP in pcDNA™4/TO. 
 
 
To assess if the presence of serum had an influence on growth rates, cells were also 
analysed on medium with an FCS content of 0.5% instead of 10%. This led to an even more 
significant difference between LSAMP-transfected cells and untransfected SKOV3 cells 
(p<0.001 at 96 h, Figure 36); however, the same could again be observed for the empty 
vector control (p<0.001). Growth rates for both transfected cell lines were almost identical 
(p>0.05). 
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Figure 36: Proliferation assay of stably LSAMP-transfected SKOV3 cells on 0.5% FCS. 
On reduced-serum medium, proliferation of LS14 cells stably overexpressing LSAMP differed even stronger 
from the SKOV3 untransfected cells than in full-serum medium (p=0.000003 at 96 h); however, so did the 
empty vector control EV4 (p=0.00056). Furthermore, no difference could be observed between both 
transfected cell lines (p=0.96491). SKOV3: untransfected cells; EV4: SKOV3 transfected with pcDNA™4/TO 
empty vector; LS14: SKOV3 transfected with LSAMP in pcDNA™4/TO. 
 
 
4.3.4.3) Migration Assays 
Migration was initially assessed using the xCELLigence system (Roche). This suggested that 
LSAMP-transfected cells migrate significantly faster than SKOV3 cells (p<0.001 overall trend, 
Figure 37), while empty vector-transfected cells migrate slower (p<0.001). As expected, 
SKOV3 cells in control wells containing serum-free medium in both chambers only migrated 
minimally. 
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Figure 37: xCELLigence migration assay of stably LSAMP-transfected SKOV3 cells. 
LSAMP-transfected LS14 cells showed significantly increased migration compared to SKOV3 (overall 
p=6.905x10
-12
), while EV4 empty vector controls migrated considerably slower (overall p=0.000496). SKOV3: 
untransfected cells; SKOV3 SFM: SKOV3 non-migration control in serum-free medium; EV4: SKOV3 transfected 
with pcDNA™4/TO empty vector; LS14: SKOV3 transfected with LSAMP in pcDNA™4/TO. 
 
 
Due to these rather unexpected findings, migration was additionally assessed using a 
scratch assay. As opposed to the results obtained from the xCELLigence system, no increase 
in migration of LSAMP-transfected cells could be observed here; all three cell lines exhibited 
a similar degree of confluency after 24 h. SKOV3 cells had a marginally narrower gap at this 
time point; however, the initial scratch had also been slightly less wide than for EV4 and 
LS14. 
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Figure 38: Scratch migration assay of stably LSAMP-transfected SKOV3 cells. 
Throughout the 24-hour time course, differences between SKOV3, LSAMP-transfected and empty vector 
controls were minimal. SKOV3 exhibited marginally increased confluency after 24 h; however, the initial 
scratch had been slightly narrower than the others. SKOV3: untransfected cells; EV4: SKOV3 transfected with 
pcDNA™4/TO empty vector; LS14: SKOV3 transfected with LSAMP in pcDNA™4/TO. Image optimisation 
courtesy of Robin Baumgarten, Imperial College London. 
 
 
4.3.4.4) Spheroid-Formation Assay 
Spheroid-formation assays were carried out to investigate the ability of transfected and 
non-transfected cell lines to proliferate anchorage-independently. It could be observed that 
SKOV3 cells transfected with LSAMP were able to form a substantially lower number of 
colonies than untransfected SKOV3 cells or empty vector controls (Figure 39). Furthermore, 
colonies were also smaller in size: SKOV3 produced the largest cell patches, empty vector-
transfected EV4 colonies were slightly smaller, and LSAMP-transfected LS14 colonies 
exhibited the strongest reduction in size. 
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Figure 39: Spheroid-formation assay of stably LSAMP-transfected SKOV3 cells. 
In replica combined from 4 or 8 wells (96-well plate), LSAMP-transfected LS14 cells showed substantially 
inhibited anchorage-independent growth compared to untransfected SKOV3 and empty vector controls EV4, 
both with regards to colony size and number (A). Colonies larger than approx. 1 mm in diameter were counted, 
and numbers from both dishes were combined (B). While the relative colony number in EV4 was marginally 
upregulated compared to untransfected SKOV3 cells, LS14 showed a strong decrease. SKOV3: untransfected 
cells; EV4: SKOV3 transfected with pcDNA™4/TO empty vector; LS14: SKOV3 transfected with LSAMP in 
pcDNA™4/TO. 
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4.3.5) Stable LSAMP Overexpression in OSE-C2 
While overexpression in SKOV3 cells indicated that LSAMP might have tumour suppressing 
function, these results required further verification. Therefore, the protein was also 
overexpressed in normal OSE-C2 ovarian epithelium cells to assess its effects in a non-
cancerous context. As for SKOV3, it should be noted that OSE-C2 express a basal level of 
intrinsic LSAMP (Figure 22, page 140) and are hence not the optimal choice. 
 
4.3.5.1) Protein Expression Levels 
As for most other cell lines, transfection of OSE-C2 cells with LSAMP could only be achieved 
to a limited degree: LSAMP expression in the transfected clone LS2 was upregulated 
compared to the empty vector control EV18, but both clones actually showed decreased 
levels of LSAMP compared to untransfected OSE-C2 cells (Figure 40). These findings strongly 
resembled previous observations in stably transfected SKOV3 cells (see 4.3.4.1), supporting 
the assumption that transfection as well as selection and subsequent maintenance of clones 
on zeocin leads to an overall reduction of protein levels. Empty vector clones therefore are 
not an exact representation of untransfected cells but a useful control for transfection- and 
antibiotic-induced side effects. Again, antibody- and expression vector-related issues need 
to be kept in mind; hence, these results only represent preliminary observations which 
require further validation. 
Contrary to observations in LSAMP-transfected SKOV3 cells, Western blotting of OSE-C2 and 
its derivatives showed that presence of LSAMP in the LS2 overexpression clone leads to an 
upregulation of EGFR, pEGFR, HER2, pHER2 and Akt levels compared to EV18 cells, while 
expression and phosphorylation of FGFR1 were not affected. Overall, these findings were 
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unexpected for a tumour suppressor gene; however, despite RTK upregulation, no 
phosphorylation of the downstream signalling molecules Erk1/2 and Akt could be observed 
in LS2. 
 
        
Figure 40: Stable LSAMP overexpression in OSE-C2 cells. 
Western blotting (A) showed that increase of LSAMP levels in LSAMP-transfected LS2 cells concurrently leads 
to increased levels of EGFR, pEGFR, HER2, pHER2 and pAkt compared to untransfected OSE-C2 and empty 
vector controls EV18. However, densitometry (B) revealed that the observed increase in LS2 is rather due to 
unequal loading and that protein levels in LS2 generally do not differ greatly from OSE-C2 levels; still, the 
observed increase compared to EV18 was confirmed. OSE-C2: untransfected cells; EV18: OSE-C2 cells 
transfected with pcDNA™4/TO empty vector; LS2: OSE-C2 cells transfected with LSAMP in pcDNA™4/TO. 
 
 
4.3.5.2) Proliferation 
Proliferation of OSE-C2 cells as well as its LSAMP-transfected and empty vector derivatives 
was investigated to assess if the unexpected upregulation of RTK expression and 
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had any functional consequences. Surprisingly, this revealed that LS2 clones grew 
significantly slower than EV18 (p<0.001 at 120 h, Figure 41). However, proliferation of 
LSAMP-transfected cells was also significantly slower compared to untransfected OSE-C2 
cells (p<0.001) despite an – at least according to densitometry analysis – similar RTK 
expression pattern. The observed differences in proliferation between LSAMP-transfected 
LS2 clones and empty vector/untransfected controls therefore do not seem to be related to 
LSAMP expression levels. 
 
 
 
Figure 41: Proliferation assay of stably LSAMP-transfected OSE-C2 cells. 
While EV-18 empty vector cells showed a slightly reduced proliferation rate compared to untransfected OSE-
C2 cells (p=0.012095 at 120 h), LS2 cells transfected with LSAMP grew considerably slower than both 
(p=0.000003 compared to OSE-C2, p=0.000308 compared to empty vector). OSE-C2: untransfected cells; LS-2: 
OSE-C2 cells transfected with LSAMP in pcDNA™4/TO; EV-18: OSE-C2 cells transfected with pcDNA™4/TO 
empty vector. 
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4.4) Silencing of LSAMP 
As the results obtained in LSAMP overexpression experiments had been rather ambiguous, 
LSAMP knockdown experiments were carried out to achieve additional validation. Since 
both OSE-C2 normal epithelial lines as well as SKOV3 cancer cells express LSAMP, the 
molecule was silenced in both. 
 
4.4.1) Transient LSAMP Silencing in SKOV3 
Transient LSAMP silencing was initially attempted in SKOV3 cells to assess if the cells’ 
cancerous properties would change after manipulation. However, even after extensive 
optimisation with regards to siRNA concentration, incubation times, seeding density or 
presence/absence of FCS, no downregulation could be achieved (Figure 42). 
 
                  
Figure 42: Transient LSAMP silencing in SKOV3 cells. 
Silencing of LSAMP in SKOV3 cells was not successful, as revealed via Western blotting (A) and subsequent 
densitometry analysis (B). 2: LSAMP siRNA, sequence 2; NC: non-targeting control; MC: mock-transfected 
control; U: untreated SKOV3 cells. 
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4.4.2) Transient LSAMP Silencing in OSE-C2 
As for experiments with SKOV3 (see above), siRNA treatment of OSE-C2 cells required 
optimisation of various factors (for more details, see 4.6). Ultimately, siRNA sequences 2 
and 3 were found to lead to the most prominent downregulation (Figure 43). However, 
since this effect was not reliably reproducible, subsequent experiments were carried out 
using stable clones. 
 
 
 
Figure 43: Transient LSAMP silencing in OSE-C2 cells. 
siRNA treatment of OSE-C2 cells was investigated by Western blotting (A) and subsequent densitometry 
analysis (B). After several optimisation steps, LSAMP could be successfully silenced using siRNA sequences 1, 2, 
3 and P, as well as a pool of all six sequences (P6). Slight off-target effects were observed in non-targeting 
controls NC1 and NC2 as well as the mock-transfected control (MC). 1, 2, 3, P, I, E: LSAMP siRNA sequences; P6: 
combination of all six LSAMP siRNA sequences; NC1 and NC2: non-targeting controls; MC: mock-transfected 
control; U: untreated. 
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4.4.3) Stable LSAMP Silencing in OSE-C2 
As LSAMP downregulation could not be achieved using siRNA even after extensive 
optimisation efforts, experiments using shRNA were carried out to allow for a more 
thorough selection of suitable clones. 
 
4.4.3.1) mRNA and Protein Expression Levels 
After transfection of OSE-C2 cells with LSAMP shRNA, clones 33-3 and 35-3 exhibited 
strongly reduced levels of LSAMP protein compared to the empty vector controls P3 and P6 
(Figure 44A). However, it has to be noted that, similarly to previous overexpression 
experiments, LSAMP expression in both P3 and P6 also differed considerably from 
untransfected OSE-C2 cells; this observation could be confirmed in densitometry analysis 
(Figure 44B). Further validation of these results is hence required. 
 
    
Figure 44: Stable LSAMP silencing in OSE-C2 cells. 
shRNA clones 33-3 and 35-3 showed highly decreased levels of LSAMP compared to empty vector controls P3 
and P6 on Western blots (A). Concurrently, levels of pEGFR, FGFR1 and pErk1/2 were decreased as well. 
However, it has to be noted that expression of LSAMP in P3 and P6 was strongly increased compared to 
untransfected OSE-C2 (B). OSE-C2: untransfected cells; 33-3, 35-3: OSE-C2 cells transfected with LSAMP shRNA 
in pLKO.1; P3, P6: OSE-C2 cells transfected with pLKO.1 empty vector. 
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Interestingly, presence of LSAMP coincided with upregulation of FGFR1 expression as well as 
increased phosphorylation of EGFR and Erk1/2. A similar effect, albeit with a different 
spectrum of affected proteins, had already been observed previously in LSAMP-
overexpressing OSE-C2 cells (see 4.3.5.1). To validate these – for a putative tumour 
suppressor gene rather surprising – results further, the clones obtained here were therefore 
also analysed via qRT-PCR. This showed that both clones transfected with LSAMP shRNA did 
indeed contain less LSAMP mRNA than EV clones (p<0.05 for all except 33-3 versus P3, 
Figure 45) and even untransfected OSE-C2 cells (p<0.05 for 35-3). As already suggested by 
densitometry analysis, empty vector clones P3 and P6 exhibited slightly increased levels of 
LSAMP compared to OSE-C2, although this increase was only significant for P3 at mRNA 
level (p<0.05). 
 
 
Figure 45: Stable LSAMP silencing in OSE-C2 cells, qRT-PCR. 
Expression of LSAMP was significantly reduced in the stably silenced clone 35-3 (versus OSE-C2: p=0.00040; P3: 
p=0.00061; P6: p=0.00133), while 33-3 only differed significantly from P3 (p=0.02215) but not P6 or OSE-C2 
(p=0.08328 and p=0.17850, respectively). No statistical difference was observed between OSE-C2 and P6 
(p=0.25225), while LSAMP expression in P3 was significantly higher than in the untransfected cell line 
(p=0.02965). OSE-C2: untransfected cells; 33-3, 35-3: OSE-C2 cells transfected with LSAMP shRNA in pLKO.1; P3, 
P6: OSE-C2 cells transfected with pLKO.1 empty vector. 
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4.4.3.2) Proliferation 
During normal passaging of cells, it was observed that the LSAMP-silenced clones seemed to 
grow slower than their empty vector counterparts. A series of proliferation assays 
confirmed this: both 33-3 and 35-3 LSAMP shRNA clones multiplied significantly slower than 
the empty vector clones P3 and P6 as well as untransfected OSE-C2 cells (p<0.001 at 120 h 
for OSE-C2 and P6, p<0.01 for P3, Figure 46). These findings were in agreement with the 
observed reduction in RTK and pErk1/2 levels in the clones; however, neither proliferation 
assays nor Western blots could be reproduced reliably, and work with these clones was 
hence not pursued further. 
 
 
Figure 46: Proliferation assay of stably LSAMP-silenced OSE-C2 cells. 
Proliferation of LSAMP shRNA clones 33-3 and 35-3 was significantly reduced compared to untransfected OSE-
C2 cells and empty vector clones (33-3: p=0.000258 for OSE-C2, p=0.008066 for P3, p=0.000098 for P6; 35-3: 
p=0.000170 for OSE-C2, p=0.009843 for P3, p=0.000053 for P6). OSE-C2: untransfected cells; 33-3, 35-3: OSE-
C2 cells transfected with LSAMP shRNA in pLKO.1; P3, P6: OSE-C2 cells transfected with pLKO.1 empty vector. 
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4.5) rLSAMP Expression and Pull-Down of OPCML 
To obtain recombinant LSAMP, BL21 bacteria were transformed with the rLSAMP sequence 
cloned into the expression vectors pHisTrx (adding a 6xHis/thioredoxin tag) and pGEX-6P-2 
(adding a GST tag). As expected for a membrane-bound protein, the putative LSAMP band 
observed on Coomassie gels was located in the detergent-insoluble sample upon fraction 
separation (Figure 47A). To confirm that this band indeed represented LSAMP, samples 
were also analysed via Western blotting. However, while a 6x-His tag antibody confirmed 
the presence of LSAMP in the insoluble fraction (B), LSAMP itself could not be detected in 
any of the samples. This was later found to be due to the antibody itself: since recombinant 
LSAMP lacks parts of the full length molecule, it only contains half of the LSAMP antibody 
recognition sequence, making successful binding highly unlikely (C). 
 
            
Figure 47: Recombinant LSAMP production. 
Coomassie staining (A) revealed a protein band at the expected weight in the insoluble fraction, both for pGEX-
6P-2 and pHisTrx (see arrows; weight of rLSAMP + GST-tag: approx. 57 kDa; rLSAMP + 6xHisTrx-tag: approx 44 
kDa). This could be confirmed by Western blotting with a 6xHis antibody (B). LSAMP was not visible due to 
reduced binding of the antibody to the shortened peptide sequence of recombinant LSAMP; only the area 
highlighted in grey can be found in both sequences (C). 
A) B) 
C) 
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To assess if OPCML and LSAMP interact, a pull-down assay was carried out with GST-tagged 
rLSAMP and His-tagged rOPCML (kindly provided by Elisa Zanini, Imperial College London). 
Coomassie staining revealed a clean band at the expected size for rOPCML in the rOPCML-
only control (Figure 48A, lane 1), and the same band could be observed in the rLSAMP pull-
down sample (lane 3). However, it was unclear if rOPCML was present in the negative GST-
only control as well (lane 2). Western blotting confirmed rOPCML presence in lanes 1 and 3, 
but also revealed pull-down of rOPCML in the GST-only control, albeit to a lower extent than 
with GST-rLSAMP. OPCML and LSAMP may therefore interact; however, unspecific 
interaction of rOPCML with GST can not be excluded. 
 
               
Figure 48: Pull-down of rOPCML with rLSAMP. 
Coomassie staining (A) revealed rOPCML presence in lane 1 and 3 (white arrow), while GST was clearly 
detected in lane 2 (black arrow; 26 kDa). Western blotting (B) however also confirmed presence of rOPCML in 
the negative GST-only control (lane 2). 
 
  
A) B) 
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4.6) Optimisation of Resources 
Upon realisation that the antibody which had been used throughout the project might 
detect an immature LSAMP precursor protein in EOC cell lines that still contains the N-
terminal signal sequence (see Figure 47, page 170), several other antibodies were ordered 
and investigated in Western blotting experiments. Figure 49 shows how the originally used 
antibody (A) compares to the three additionally investigated ones (B-D); panel E indicates 
the respective antigen binding sites within the full-length (immature) LSAMP protein. 
 
 
 
 
Figure 49: LSAMP antibody tests. 
Four different antibodies, from Sigma (A: cat. no. AV45277; B: cat. no. SAB1100052), Abcam (C: cat. no. 
ab64427) and Genetex (D: cat. no. GTX115550) were investigated; their respective antigen binding sites are 
represented in panel E (left side: N-terminal signal peptide (yellow); middle: domains (1: green; 2: grey; 3: 
pink); right: C-terminal propeptide (blue)). The same ladder and blotting conditions were used for all four 
membranes. Blue arrows indicate the expected band for full-length, glycosylated LSAMP (55 kDa). 
A) B) 
D) C) 
E) 
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Using the Abcam or Genetex antibodies, the expected 55 kDa band for the mature, fully 
glycosylated LSAMP protein could not be detected, while a strong signal was visible here for 
the Sigma 166-179 antibody. Due to the unusually high intensity of the 55 kDa band, it was 
determined if this observation could be due to cross-reactivity of the antibody with OPCML 
(Figure 50). This revealed that at least a partial detection of OPCML with the Sigma 166-179 
antibody can not be excluded as the bands observed for both LSAMP and, after stripping of 
the membrane, for OPCML were almost identical. Cross-reactivity of the OPCML antibody 
with potentially non-removed primary LSAMP antibody after stripping is unlikely as the 
LSAMP antibody had been raised in rabbit, while the OPCML antibody was produced in goat. 
Due to these limitations, work was continued with the initial Sigma antibody. 
 
 
Figure 50: Investigation of cross-reactivity of antibody Sigma 166-179 with OPCML. 
Membranes were probed with LSAMP antibody Sigma 166-179 (left), stripped (middle), and subsequently 
probed with OPCML antibody. Due to the highly similar band pattern, cross-reactivity of the antibodies seems 
likely. 
 
Even though the selected Sigma antibody seemed the most suitable option compared with 
the three additionally investigated alternatives, further optimisation should be carried out 
both for Western blotting and IFM experiments. One possibility to verify that the antibody 
works reliably would be the use of cell lines from previous publications which successfully 
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established the presence or absence of LSAMP protein. Since studies on LSAMP expression 
in cancer so far mainly focussed on determination of mRNA expression (see 1.4.5.1), it may 
be necessary to obtain neural cells, which were found to express high levels of LSAMP (but 
also other IgLONs). Alternatively, incubation of cells with phosphatidylinositol-
phospholipase C (PI-PLC), which specifically removes GPI-anchored proteins, could be 
employed to determine if the putative LSAMP band is still visible after treatment. Again, it 
has to be kept in mind that the other IgLONs are also GPI-anchored; hence, cross-reactivity 
within the IgLON family could thus not be excluded and would have to be investigated 
separately. 
The successful establishment of convincing (i.e. initially qRT-PCR-verified overexpression or 
knockdown clones) would have represented a strong advantage in LSAMP antibody 
optimisation experiments. Since qRT-PCR did not indicate LSAMP overexpression in PEO1 
(see 4.3.2) or OVISE cells (see 4.3.3), primers targeting the expression vector itself should 
have been used to determine if the construct had been taken up successfully at all. 
Additionally, usage of the previously employed vector pcDNATM3.1 (for OPCML 
overexpression in BKS2.1 cells) instead of pcDNATM4/TO should have been tried to 
potentially facilitate construct uptake. 
Besides the suggestions mentioned above, several other optimisation approaches were 
already tried during the project, particularly in siRNA experiments with OSE-C2 cells. Factors 
such as length of siRNA exposure (Figure 51A), siRNA concentration (B) or presence/absence 
of serum (C) were investigated. The conditions described in the Materials and Methods 
section (see 2.2.5.1) and presented in the results chapter (Figure 51B, 10 nM; see also 4.4.2) 
yielded the largest degree of LSAMP downregulation, but was not reliably reproducible. 
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Figure 51: siRNA optimisation. 
Factors such as siRNA incubation time (A: 4 hours; B, C: 48 hours), siRNA concentration (B, 10 nM and 50 nM) 
or presence/absence of serum (C; F: full serum; S: serum-free) were investigated. Full-serum conditions and 
48 h incubation with 10 nM siRNA (B, left image) yielded the best results. 
 
For IFM experiments, similar antibody optimisation experiments as described above for 
Western blotting should have been carried out. Known LSAMP-overexpressing cells could 
have been used to verify that the antibody is able to detect LSAMP in IFM experiments, 
while cell lines with no detectable LSAMP expression on Western blots could have been 
used as negative controls. Initial IFM experiments using SKOV3 (high LSAMP expression 
levels in Western blots, see Figure 22, page 140), BKS2.1, OSE-C2 (medium expression) and 
V1.2 (low expression) however did not replicate Western blotting findings (Figure 27 and 
Figure 28, pages 147 and 148). 
A) 
B) 
C) 
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Nonetheless, IFM analysis of siRNA-transfected cells revealed some differences between 
treatments, but mainly with regards to nuclear LSAMP (Figure 52): while untreated /mock-
transfected/non-targeting OSE-C2 cells showed a relatively high degree of nuclear staining 
for LSAMP, signal was reduced in cells treated with LSAMP siRNA sequence 2. This indicates 
that the antibody used may work in IFM experiments; however, as mentioned above, it 
mainly seems to detect an immature, nuclear version of LSAMP. 
 
 
Figure 52: LSAMP expression in LSAMP siRNA-treated OSE-C2 cells. 
While LSAMP was detectable in untreated OSE-C2 cells (A), cells treated with lipofectamine only (mock-
transfected, B) and cells treated with non-targeting siRNA (C), signal was strongly reduced in cells treated with 
LSAMP siRNA (D), particularly in the nucleus. 
B) 
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4.7) Summary 
Initial experiments revealed that LSAMP expression levels were decreased in most 
investigated ovarian cancer cell lines compared to the normal ovarian surface epithelium 
cell line OSE-C2. No relationship between LSAMP expression and OPCML levels, cancer 
subtype, cisplatin resistance or levels of EGFR and FGFR1 expression could be detected. In 
accordance with the observation that cells maintained on full medium showed slightly 
reduced levels of LSAMP expression compared to cells grown on serum-free medium across 
several cell lines, stimulation of SKOV3 with EGF and OSE-C2 cells with FGF resulted in 
downregulation of LSAMP protein levels. 
 
In immunofluorescence microscopy experiments with OSE-C2 cells, LSAMP was found to be 
predominantly present around the nucleus and on the cells’ leading edges. A low degree of 
colocalisation with OPCML and FGFR1 could be observed, but not with caveolin-1 or 
phalloidin. In SKOV3 cancer cells as well as its OPCML-transfected derivative BKS2.1, 
colocalisation of LSAMP and OPCML was minimal as expression of both molecules was 
highly region-specific: while LSAMP accumulated around the nucleus, OPCML could mainly 
be found at the membrane. 
 
LSAMP overexpression and silencing proved much more complex than anticipated; hence, 
only a limited number of cell lines could be analysed in functional assays regarding cellular 
characteristics such as proliferation or migration. The creation of empty vector control cell 
lines which mirrored protein expression levels of untransfected cells was particularly 
problematic. In several experiments, LSAMP overexpression/downregulation could be 
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detected compared to the respective empty vector clones; however, these observations 
were mainly due to protein levels in empty vector clones differing strongly from 
untransfected cells, while overexpression/knockdown clones only exhibited minimal 
changes compared to parental cell lines. 
Besides the issues of cell line creation and selection, the results obtained from these clones 
were also conflicting. While stable overexpression of LSAMP in SKOV3 cells led to lower RTK 
expression and phosphorylation, the opposite was observed in OSE-C2 cells: both in 
knockdown and overexpression experiments, presence of LSAMP coincided with higher 
levels of RTKs and pErk1/2. Transfection of PEO1, OVCAR4 and OVISE cells with LSAMP could 
not be achieved successfully. 
With regards to proliferation, no difference between LSAMP-transfected cells and empty 
vector controls could be observed in SKOV3 cells, although both transfected clones grew 
slower than untransfected cells. Despite increased RTK levels, LSAMP-overexpression in 
OSE-C2 cells led to decreased proliferation rates; however, the same was found for 
transfection with LSAMP shRNA. Paradoxically, untransfected OSE-C2 cells exhibited similar 
proliferation rates as empty vector clones in both assays, despite being more similar to 
overexpression/knockdown clones regarding protein expression levels. 
Migration and spheroid-formation assays were carried out with LSAMP-transfected SKOV3 
cells. While migration experiments using the xCELLigence system showed that LSAMP-
transfected cells migrate faster and empty vector controls migrate slower than 
untransfected SKOV3 cells, differences between these clones in scratch assays were only 
marginal. In spheroid-formation assays, LSAMP-transfected cells exhibited a strongly 
reduced ability to develop colonies. 
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In protein-protein binding assays, interaction of recombinant LSAMP and OPCML could be 
detected; however, it is unclear if these observations represent the formation of a DigLON 
complex or are merely due to unspecific binding of rOPCML to GST. Additionally, the 
experiment revealed that only half of the LSAMP antibody binding sequence is located 
within the mature LSAMP protein, a finding which might have considerable implications for 
the other assays described here, particularly IFM experiments and Western blots. Future 
experiments therefore urgently require additional optimisation of the antibody; moreover, 
transfection experiments, both knockdown as well as overexpression approaches, need to 
be validated in more detail. 
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5.1) Introduction 
Similar as described for LSAMP in chapter 4, basic characteristics of NEGR1 such as 
expression levels or response to growth factor stimulation were initially assessed in several 
ovarian cell lines. Subsequently, overexpression experiments were carried out both 
transiently and stably using SKOV3 cells. Successfully transfected clones were analysed with 
regards to RTK expression and phosphorylation levels, colocalisation with other molecules, 
proliferation, migration and spheroid-formation. In addition to overexpressing experiments, 
transient silencing of NEGR1 was carried out in OSE-C2 cells. Finally, protein-protein 
interaction as well as protein degradation were addressed. 
 
 
 
5.2) Characterisation of NEGR1 
Initial in vitro experiments focussed on analysing basic characteristics of NEGR1 in OSE-C2 
and SKOV3 cell lines, as well as the SKOV3 derivatives BKS2.1 (OPCML-transfected) and V1.2 
(empty vector control). Both basal NEGR1 expression levels as well as its response to growth 
factor stimulation were assessed. Furthermore, NEGR1 expression was determined in 
isogenic cell lines established before and after the onset of platinum resistance. 
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5.2.1) NEGR1 Expression Levels 
NEGR1 protein expression in OSE-C2, SKOV3, V1.2 and BKS2.1 cells was initially analysed 
using Western blotting (Figure 53A); however, as no expression of NEGR1 could be detected 
in any of the samples, all four cell lines were also analysed by qRT-PCR (B). This revealed 
that NEGR1 mRNA is present at low levels in normal ovarian OSE-C2 cells, but significantly 
downregulated in cancer cells (p<0.05). In later experiments, this could also be confirmed by 
Western blotting using extended exposure times (40 min; see Figure 55, page 184). 
 
            
Figure 53: NEGR1 expression levels in OSE-C2, SKOV3, V1.2 and BKS2.1 cells. 
While expression of NEGR1 protein in OSE-C2 could not be visualised using Western blotting (A), mRNA 
expression was clearly detectable in qRT-PCR experiments (B). In SKOV3 and its derivatives V1.2 and BKS2.1, 
NEGR1 expression is significantly reduced compared to OSE-C2 (SKOV3: p= 0.00206; V1.2: p= 0.00210; BKS2.1: 
p= 0.00223). +ve: positive control, SKOV3 transiently transfected with NEGR1 (see 5.3.1). 
 
 
5.2.1.1) NEGR1 Expression in Isogenic Cell Lines 
In addition to OSE-C2 and SKOV3 and its derivatives, two isogenic ovarian cancer cell line 
pairs were analysed via Western blotting with regards to NEGR1 expression. While PEO14 
and PEA1 cell lines were established from primary tumours which still displayed cisplatin 
sensitivity, their respective matching cell lines PEO23 and PEA2 were established after the 
onset of platinum resistance. Interestingly, a reduction in NEGR1 expression was observed 
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in the cisplatin-resistant cell lines (PEO23 and PEA2) compared to their sensitive 
counterparts (PEO14 and PEA1, respectively), both on full and serum-free medium (Figure 
54). 
 
  
Figure 54: NEGR1 expression levels in the isogenic cell line pairs PEO14/23 and PEA1/2. 
Western blotting (A) and corresponding densitometry analysis (B) showed that NEGR1 expression is reduced in 
cisplatin-resistant cells (PEO23 and PEA2, grey bars) compared to their cisplatin-sensitive counterparts (PEO14 
and PEA1, black bars). F: full medium; S: serum-free medium. 
 
 
5.2.2) EGF stimulation 
Stimulation with EGF was carried out in OSE-C2 and SKOV3 cells. However, unlike previous 
results for LSAMP (see 4.2.2), Western blotting did not reveal any impact on NEGR1 
expression in either cell line: OSE-C2 remained NEGR1-expressing, while SKOV3 remained 
non-expressing (Figure 55). Furthermore, densitometry analysis of OSE-C2 cells showed no 
downregulation of NEGR1 after stimulation with EGF. This is in line with the observations for 
PEO14, PEO23, PEA1 and PEA2 described above, where no differences between cells grown 
on full and serum-free medium could be observed (Figure 54). 
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As expected upon ligand stimulation, EGFR showed increased phosphorylation after 30-60 
minutes. In normal OSE-C2 cells, activation gradually decreased again, while the cancer cell 
line SKOV3 maintained its increased levels of phosphorylated EGFR. It has to be noted that 
that the exposure time for this membrane was 40 minutes, as NEGR1 could not be visualised 
otherwise due to its low expression levels. 
 
 
                     
 
                    
Figure 55: EGF stimulation of OSE-C2 and SKOV3 cells. 
Cells were stimulated with 50 ng/ml EGF for 0-150 minutes. No effect of EGF presence on NEGR1 protein levels 
could be detected in Western blots (A) or densitometry of NEGR1 bands in OSE-C2 cells (B). As expected, 
phosphorylation of EGFR peaked at 30-60 minutes and gradually decreased again. Expression of NEGR1 could 
only be visualised after a 40-minute exposure. 
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5.3) Overexpression of NEGR1 
As SKOV3 cells were found to not express NEGR1 endogenously, they were optimal 
candidates for overexpression experiments. Both transient and stable transfected cell lines 
were generated; while transiently transfected cells were used to gain a quick preliminary 
insight into potential functions of NEGR1 in vitro, stable clones were required for long-term 
assays such as proliferation. 
 
5.3.1) Transient NEGR1 Overexpression in SKOV3 
Transient overexpression of NEGR1 using a commercially available NEGR1 cDNA construct 
was achieved successfully, showing strongly increased expression in NEGR1-transfected 
SKOV3 cells compared to empty vector controls (Figure 56). Assessment of a broad set of 
RTKs as well as downstream signalling molecules revealed that overexpression of NEGR1 led 
to downregulation of pHER2, EGFR, pEGFR, pFGFR1, pAkt, Erk1/2, FGFR2, FAK, pFAK, 
pVEGFR1, Axl and OPCML levels. HER2, Akt, pErk1/2, HER4, FGFR1, VEGFR1 and LSAMP 
expression remained unchanged, while EphA2 appeared to be slightly upregulated. 
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Figure 56: Transient NEGR1 overexpression in SKOV3 cells. 
Overexpression of NEGR1 in SKOV3 resulted in downregulation of most investigated RTKs; only EphA2 
appeared to be slightly upregulated in Western blots (left) and densitometry analysis (right). EV: SKOV3 
transfected with pSecTag2 A,B,C empty vector; NEGR1: SKOV3 transfected with NEGR1 in pReceiver-M10. 
Transfection kindly set up by Dr Arthur McKie. 
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5.3.2) Stable NEGR1 Overexpression in SKOV3 
In order to enable an in-depth investigation of the effects of NEGR1-induced RTK 
downregulation on cell characteristics such as expression or migration, stable transfectants 
were generated. 
 
5.3.2.1) Protein Expression Levels 
Stable transfection of SKOV3 with NEGR1 was achieved successfully, and two independently 
generated clones were established, S6 and A29 (Figure 57). Clone A29 showed strongly 
increased NEGR1 expression compared to untransfected SKOV3 cells and the empty vector 
controls EX1 and EX5. In comparison, levels of NEGR1 in S6 cells were only slightly increased 
and could therefore only be visualised by Western blotting using exposure times which were 
too long for simultaneous exposure with A29 at equal loading. Using two clones with 
differing degrees of NEGR1 overexpression throughout all subsequent experiments enabled 
determination as to whether the observed effects were NEGR1 expression level-dependent. 
 
 
Figure 57: Selected SKOV3 NEGR1-overexpression clones. 
Compared to untransfected SKOV3 and empty vector-transfected EX1 and EX5 cells, NEGR1 expression was 
slightly upregulated in the stably NEGR1-transfected clone S6, and strongly in clone A29. 
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Presence of NEGR1 in A29 cells led to complete abrogation of EGFR, pEGFR, HER2, pHER2, 
LSAMP, HER3, FGFR1, pFGFR1 and OPCML levels, while expression and phosphorylation of 
Akt were strongly reduced (Figure 58). For most RTKs, expression was downregulated to 
below protein levels detected in the normal ovarian cell line OSE-C2. S6 cells showed a 
similar trend as A29, but overall degrees of downregulation were less pronounced. pErk1/2, 
which was strongly upregulated in A29 cells, represented the only exception from the 
general trend. Protein expression and phosphorylation levels in the empty vector controls 
EX1 and EX5 were generally comparable to untransfected SKOV3 cells.  
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Figure 58: Stable NEGR1 overexpression in SKOV3 cells. 
Expression and phosphorylation levels of most of the proteins analysed were reduced in the weak NEGR1 
overexpression clone S6, and completely depleted in the strong overexpresser A29 compared to SKOV3 
untransfected cells as well as the empty vector controls EX1 and EX5 in Western blots (left) and densitometry 
analysis (right). OSE-C2: untransfected ovarian surface epithelium cell line; SKOV3: untransfected cancer cell 
line; EX1, EX5: SKOV3 transfected with pReceiver-M10 empty vector; S6, A29: SKOV3 transfected with NEGR1 in 
pReceiver-M10. 
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5.3.2.2) Confocal Immunofluorescence Microscopy 
While qRT-PCR suggested no correlation between OPCML and NEGR1 expression levels (see 
Figure 53B, page 182), Western blotting implied that presence of NEGR1 leads to slight 
downregulation of OPCML (Figure 58). To investigate if the two proteins influence each 
other’s cellular localisation, BKS2.1 (OPCML-overexpressing SKOV3 cells), A29 (NEGR1-
overexpressing SKOV3 cells) and SKOV3 cells (untransfected, low intrinsic expression of 
OPCML and NEGR1) were analysed via IFM. As expected, only minimal staining of NEGR1 
and OPCML could be detected in untransfected SKOV3 cells (Figure 59A). In OPCML-
transfected BKS2.1 cells, NEGR1 expression was slightly increased (B); similar to findings for 
LSAMP (see 4.2.3.2), OPCML was localised towards the membrane of the cells, while NEGR1 
was mainly detected in the nucleus. In NEGR1-overexpressing A29 cells (C), NEGR1 was 
additionally present in the cytoplasm as well as the nucleus; levels of OPCML were 
marginally increased compared to SKOV3. 
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Figure 59: Colocalisation of NEGR1 with  OPCML in SKOV3 (A), BKS2.1 (B) and A29 (C) cells. 
Minimal IgLON expression was detectable in SKOV3 cells (A). Increased NEGR1 expression was visible in 
OPCML-overexpressing BKS2.1 cells (B), but no colocalisation with OPCML could be observed. NEGR1-
overexpressing cells A29 (C) did not reveal colocalisation either but indicated a limited positive relationship 
between expression levels of the two IgLONs. 
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To investigate if downregulation of EGFR and HER2 expression upon NEGR1 overexpression 
coincided with shifts in the proteins’ localisation, co-staining of NEGR1 with both RTKs was 
carried out in SKOV3, EX1, EX5, S6 and A29 cells. While staining with EGFR (Figure 60) was 
weak, HER2 expression (Figure 61) was clearly visible in SKOV3, EX1 and EX5 (A-C) and 
reduced in the majority of S6 and A29 cells (D, E). As seen before, NEGR1 was mainly 
confined to the nucleus in untransfected cells, but showed a broader distribution in NEGR1-
overexpressing S6 and A29 cells. However, the difference in staining between 
untransfected/wildtype and transfected cells was not as pronounced as had been observed 
previously in OPCML-transfected clones; hence, it therefore remains to be investigated if 
the employed antibody is suitable for IFM experiments. 
Colocalisation of NEGR1 was more pronounced with EGFR than with HER2; particularly in 
the overexpression clones, small, defined areas of particularly strong NEGR1 signal 
coincided with EGFR accumulation, especially on the cell membrane. 
 
  A) 
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Figure 60: Colocalisation of NEGR1 with EGFR in 
SKOV3 (A), EX1 (B), EX5 (C), S6 (D) and A29 (E) 
cells. 
Overall, EGFR staining was weak, and only little 
difference could be observed between empty 
vector-transfected/untransfected cells and 
NEGR1 clones. Overlap with EGFR staining was 
mainly detected in small patches of increased 
NEGR1 accumulation in S6 (D) and A29 (E). 
SKOV3: untransfected cancer cell line; EX1, EX5: 
SKOV3 transfected with pReceiver-M10 empty 
vector; S6, A29: SKOV3 transfected with NEGR1 
in pReceiver-M10. 
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Figure 61: Colocalisation of NEGR1 with HER2 in 
SKOV3 (A), EX1 (B), EX5 (C), S6 (D) and A29 (E) 
cells. 
Downregulation of HER2 in S6 (D) and A29 (E) 
was clearly visible compared to SKOV3, EX1 and 
EX5 (A, B, C). A clear difference in HER2 intensity 
could be observed between empty vector-
transfected/untransfected cells and NEGR1 
overexpression clones. SKOV3: untransfected 
cancer cell line; EX1, EX5: SKOV3 transfected 
with pReceiver-M10 empty vector; S6, A29: 
SKOV3 transfected with NEGR1 in pReceiver-
M10. 
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5.3.2.3) Proliferation Assay 
A series of proliferation assays were carried out to assess if the observed negative impact of 
NEGR1 on RTK expression and phosphorylation had any functional consequences. Both S6 
and A29 clones showed significantly decreased proliferation rates compared to SKOV3, EX1 
and EX5 (p<0.05 and p<0.0.1 at 96 h, except for S6 versus SKOV3, which was just outside the 
designated significance levels; Figure 62). 
 
 
Figure 62: Proliferation assay of stably NEGR1-transfected SKOV3 cells. 
Proliferation rates were determined using a WST-1 assay. Significantly reduced proliferation compared to 
SKOV3, EX1 and EX5 was observed for both S6 (versus EX1: p=0.03283; EX5: p=0.01174; but not for S6 v 
SKOV3: p=0.08779) and A29 clones (SKOV3: p=0.04670; EX1: p=0.01315; EX5: p=0.00154). No difference was 
found between SKOV3, EX1 and EX5 (p>0.45) and S6 and A29 (p=0.35095). SKOV3: untransfected cells; EX1, 
EX5: SKOV3 transfected with pReceiver-M10 empty vector; S6, A29: SKOV3 transfected with NEGR1 in 
pReceiver-M10. 
 
To determine if the observed reduction in proliferation in NEGR1-overexpressing cells was 
serum-dependent, cells were also grown in medium containing 0.5% instead of 10% FCS. 
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transfected and untransfected/empty vector controls, indicating a high degree of serum 
dependence of NEGR1-transfected S6 (p<0.05 at 96 h, Figure 63) and particularly A29 cells 
(p<0.01 and p<0.001). 
 
 
 
Figure 63: Proliferation assay of stably NEGR1-transfected SKOV3 cells on FCS-reduced medium. 
Proliferation rates were determined using a WST-1 assay. Significantly reduced proliferation compared to 
SKOV3, EX1 and EX5 was observed for both S6 (versus SKOV3: p=0.01472; EX1: p=0.03810; EX5: p=0.03733) 
and A29 clones (SKOV3: p=0.00001; EX1: p=0.00388; EX5: p=0.00052). No difference was found between 
SKOV3, EX1 and EX5 (p>0.40) and S6 and A29 (p=0.44305). SKOV3: untransfected cells; EX1, EX5: SKOV3 
transfected with pReceiver-M10 empty vector; S6, A29: SKOV3 transfected with NEGR1 in pReceiver-M10. 
 
 
5.3.2.4) Migration Assays 
Initial migration assays were carried out using the xCELLigence system. This indicated 
increased migration of A29 cells, while SKOV3 showed the lowest migration (Figure 64). EX1 
and EX5, which did not differ significantly from each other (p>0.05), migrated slower than 
A29, but faster than S6.  
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Figure 64: xCELLigence migration assay of stably NEGR1-transfected SKOV3 cells. 
A29 cells migrated significantly faster than all other cell lines (compared to SKOV3: p=6.748x10
-29
; EX1: 
p=0.00021; EX5: p=2.875x10
-28
; S6: 1.527x10
-10
). S6 migrated faster than SKOV3, but slower than EX1 and EX5 
(compared to SKOV3: p=3.418x10
-25
; EX1: p=2.345x10
-26
; EX5: p=0.00028). EX1 and EX5 did not differ 
significantly from each other (p=0.87667), but from SKOV3 (p=7.492x10
-29
 for EX1, p=1.298x10
-31
 for EX5). 
SKOV3: untransfected cells; EX1, EX5: SKOV3 transfected with pReceiver-M10 empty vector; S6, A29: SKOV3 
transfected with NEGR1 in pReceiver-M10. 
 
 
To confirm the rather unexpected results obtained from the xCELLigence system, a simple 
scratch migration assay was carried out additionally. Using this approach, A29 and S6 were 
found to migrate slower than SKOV3 and the empty vector controls over a 24 h time period; 
however, it has to be taken into account that the initial scratches in the NEGR1-transfected 
cell lines were slightly wider than in controls (Figure 65). Nonetheless, the observed results 
speak against an NEGR1-induced increase of migration which had been suggested by the 
xCELLigence system. 
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Figure 65: Scratch migration assay of stably NEGR1-transfected SKOV3 cells. 
Throughout the 24-hour time course, no striking differences could be observed between the five cell lines. S6 
and A29 seemed to be less confluent at 24 h compared to SKOV3, EX1 and EX5; however, it has to be noted 
that the initial scratches were slightly wider. SKOV3: untransfected cells; EX1, EX5: SKOV3 transfected with 
pReceiver-M10 empty vector; S6, A29: SKOV3 transfected with NEGR1 in pReceiver-M10. Image optimisation 
courtesy of Robin Baumgarten, Imperial College London. 
 
 
5.3.2.5) Spheroid-formation Assay 
Spheroid-formation assays were used to assess anchorage-independent growth. While 
untransfected SKOV3 cells formed the largest colonies, all other cell lines produced colonies 
that were slightly reduced in size, with A29 cells exhibiting the smallest cell patches (Figure 
66A). Counting revealed that while S6 cells had formed only marginally fewer colonies than 
SKOV3, EX1 and EX5, colony number was strongly reduced in A29 (Figure 66B). 
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Figure 66: Spheroid-formation assay of stably NEGR1-transfected SKOV3 cells. 
In replica combined from 4 or 8 wells (96-well plate), NEGR1-transfected A29 cells showed striking inhibition of 
anchorage-independent growth compared to untransfected SKOV3 and empty vector controls EX1 and EX5, 
both with regards to colony size and number (A). Colonies larger than approx. 1 mm in diameter were counted, 
and numbers from both dishes were combined (B). While EX1 and EX5 showed a small increase and decrease, 
respectively, compared to untransfected SKOV3 cells, S6 and particularly A29 showed a clearly reduced 
number of colonies. SKOV3: untransfected cells; EX1, EX5: SKOV3 transfected with pReceiver-M10 empty 
vector; S6, A29: SKOV3 transfected with NEGR1 in pReceiver-M10. 
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5.4) Silencing of NEGR1 
To assess if NEGR1 downregulation would lead to the opposite result as observed for 
overexpression, i.e. increased expression of RTKs, the molecule was silenced in OSE-C2 using 
a transient siRNA approach. Due to the low intrinsic levels of NEGR1 in OSE-C2 (see Figure 
55, page 184), the protein could not be visualised via Western blotting (Figure 67). However, 
a notable upregulation of HER2 was observed in cells treated with NEGR1 siRNA 2 and, to a 
lesser extent, with siRNA 3. 
 
      
Figure 67: Transient NEGR1 silencing in SKOV3 cells. 
NEGR1 expression could not be visualised via Western blotting. However, upregulation of HER2 levels in cells 
treated with NEGR1 siRNA 2 could be observed both on Western blots (A) and in densitometry analysis (B). 1, 
2, 3: NEGR1 siRNAs; Pool: combination of siRNAs 1, 2 and 3; NC: non-targeting control. MC: mock-transfected 
control. 
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5.5) NEGR1 Co-Immunoprecipitation 
As NEGR1 presence was observed to have a strong negative impact on the expression levels 
of several RTKs, it was investigated if downregulation is based on direct binding of the 
molecules to each other, as was shown previously for OPCML [McKie et al., 2012]. Since 
PEO1 cells had been found to express a broad range of RTKs as well as NEGR1, co-
immunoprecipitation (co-IP) experiments were carried out using lysates of this cell line, and 
interaction of NEGR1 with EGFR, HER2, HER3 and FGFR1 was assessed. 
Potential binding was detected for HER3 and FGFR1 as both RTKs were present in the IP 
sample; however, they also exhibited signals in the “Lysate control” negative control, 
although the band for FGFR1 was only minimal. Curiously, no band was visible for HER3 in 
the complete lysate positive control.  
Interaction of NEGR1 with EGFR and HER2 seems unlikely, as neither RTK was present in the 
IP sample; however, further replicates and optimisation of the procedure are needed to 
obtain more conclusive results. Paradoxically, NEGR1 could not be detected in the whole 
lysate, but in the IP sample as well as the AB negative control. 
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Figure 68: Co-Immunoprecipitation assay of NEGR1 with EGFR, HER2, HER3 and FGFR1. 
No interaction of NEGR1 with EGFR or HER2 could be detected as neither RTK was present in the IP sample. 
Interaction with HER3 and FGFR1 is possible; however, both also exhibit protein bands in the “Lysate control” 
negative control sample. Lysate: PEO1 cell lysates; IP: immunoprecipitation sample, PEO1 cell lysate + NEGR1 
primary antibody + beads; AB control: Lysis buffer + NEGR1 primary antibody + Sepharose beads; Lysate 
control: PEO1 cell lysate + Sepharose beads. 
 
 
5.5.1) Protein Degradation Assays with MG-132 and Chloroquine 
A29 NEGR1 overexpression clones were treated with both MG-132 and chloroquine to 
assess if the observed downregulation of RTKs occurred through the proteasomal or the 
lysosomal degradation pathway, respectively. Restoration of EGFR protein levels could 
already be detected at concentrations of 0.05 µM MG-132, while HER2 became detectable 
at 0.1, 0.5 and 1 µM (Figure 69A). In chloroquine-treated cells, EGFR presence could be 
detected between 1 and 150 µM, with the most striking effect observed at 20 µM (Figure 
69B). Surprisingly, HER2 levels in untreated cells did not seem downregulated in A29 to the 
low levels previously observed, and thus no difference could be detected upon treatment 
with chloroquine. However, it is highly likely that this difference is primarily due to a higher 
passage number of the cells used in chloroquine experiments compared to those 
investigated in the MG-132 assays (see 6.6.3). 
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Figure 69: MG-132 (A) and chloroquine (B) treatment of NEGR1-transfected A29 cells. 
While EGFR presence could be detected using 0.05 µM MG-132 (top), HER2 became visible when using 
between 0.1 and 1 µM. In chloroquine-treated cells, EGFR1 signal was strongly upregulated at 20 µM (bottom); 
however, no conclusions could be drawn for HER2 which did not appear to be downregulated in untreated A29 
cells in the first place. 
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5.6) Summary 
Initial experiments showed that NEGR1 is present in the normal ovarian surface epithelium 
cells OSE-C2, but downregulated in the cancer cell line SKOV3 as well as its OPCML-
transfected derivatives. No alterations in protein expression could be observed in response 
to EGF stimulation in OSE-C2 and SKOV3 cells. Interestingly, levels of NEGR1 were 
considerably reduced in platinum-resistance cell lines when compared to their isogenic 
platinum-sensitive counterparts. 
 
Transient overexpression of NEGR1 in SKOV3 led to downregulation of expression and 
phosphorylation of a broad repertoire of RTKs and downstream signalling molecules with 
only a few exceptions, most notably HER2 and FGFR1. However, in stable NEGR1-
overexpressing cells both molecules were downregulated as well, and only pErk1/2 showed 
upregulation upon transfection with NEGR1. 
Whether expression of NEGR1 and OPCML are correlated remains to be determined; while 
qRT-PCR suggested no relationship, Western blotting indicated downregulation upon NEGR1 
overexpression, and confocal immunofluorescence microscopy revealed a slight positive 
relationship between the two molecules. However, no colocalisation could be observed, 
with OPCML being mainly present around the membrane and NEGR1 around the nucleus. 
Proliferation assays were in line with the results observed on Western blots and showed a 
strong downregulation of proliferation in NEGR1-transfected cells. Using growth medium 
with reduced FCS content, this effect became even more pronounced. 
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As seen for LSAMP, the xCELLigence migration assay yielded rather paradox results, with 
A29 (high NEGR1 overexpression) clones migrating faster than the empty vector controls, 
but S6 (low NEGR1 overexpression) migrating slower. Scratch assays however showed that 
migration of both NEGR1-transfected clones was similar or possibly reduced compared to 
untransfected SKOV3 cells and empty vector controls. 
Spheroid-formation assays revealed that NEGR1-transfected clones are unable to form 
colonies as numerous and large as untransfected SKOV3 cells and empty vector controls. 
 
siRNA experiments were carried out to assess if the negative impact of NEGR1 presence on 
RTK expression can be reversed by silencing of the molecule in OSE-C2 cells. Unfortunately 
NEGR1 could not be visualised via Western blotting due to its low expression levels; 
however, upregulation of HER2 was observed in two out of three siRNA-treated samples. 
 
Co-immunoprecipitation experiments were used to investigate if downregulation of RTKs is 
mediated by direct binding. Both FGFR1 and HER3 potentially interact with NEGR1, while no 
binding of NEGR1 with EGFR or HER2 could be observed. 
To determine if RTK downregulation occurs via the proteasome or lysosome, cells were 
treated with MG-132 and chloroquine. As opposed to OPCML, where only MG-132 showed 
an effect, both inhibitors were able to suppress EGFR degradation in NEGR1-transfected 
cells. MG-132 treatment also inhibited HER2 downregulation; however, experiments with 
chloroquine need to be repeated due to high intrinsic HER2 expression of untreated cells. 
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6.1) Introduction 
In previous studies, the IgLON OPCML had been found to be frequently methylated and 
downregulated in epithelial ovarian cancer (EOC) as well as a broad range of other tumour 
types [Sellar et al., 2003; Cui et al., 2008]. Functional analyses suggested that the protein 
has tumour suppressor properties in vitro as transfection of the epithelial ovarian cancer cell 
line SKOV3 resulted in a significant reduction of proliferation rates [Sellar et al., 2003], while 
transfection of colorectal, oesophageal and prostate cancer cell lines with OPCML resulted 
in decreased colony growth [Cui et al., 2008]. More recently, our group showed that the 
growth-suppressing functions of OPCML are based on its direct interaction with and 
subsequent endocytotic downregulation of receptor tyrosine kinases (RTKs), both in vitro 
and in vivo [McKie et al., 2012]. 
As expression of two further members of the IgLON family, LSAMP and NEGR1, had 
previously been found to be downregulated in EOC at mRNA level in addition to OPCML 
[Ntougkos et al., 2005], the aim of this PhD project was to investigate if these proteins 
played similar tumour-suppressing cellular roles as OPCML, particularly with regards to RTK 
regulation. To our knowledge, this is the first study investigating the functional properties of 
LSAMP and NEGR1 in epithelial ovarian cancer. Based on the previous findings for OPCML, 
the main focus of this project lay in determining the effects of LSAMP/NEGR1 
overexpression or silencing on expression and phosphorylation levels of RTKs; furthermore, 
the impact of these alterations on cellular properties such as proliferation or migration was 
assessed. Due to the IgLON family members being extracellular proteins, and based on the 
immensely promising previous results for OPCML, investigation of the remaining family 
members in EOC has the potential to have hugely positive clinical implications.  
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6.2) Key Findings 
Initial bioinformatics analyses revealed that the IgLON family members overall share a high 
number of amino acid residues. Each member was found to exist in several different 
isoforms which mainly varied in their N-terminal signal sequence or exhibited C-terminal 
insertions. 
For LSAMP, the obtained results were largely conflicting and difficult to interpret due to lack 
of suitable resources such as reliable antibodies and successfully created transient or stable 
overexpression/knockdown clones. A potential association with RTK levels was observed in 
most experiments, but is likely attributable to transfection-induced side effects and not 
alterations in LSAMP expression. The discussion of the LSAMP results in the following 
chapter hence only represents a very preliminary evaluation which requires further 
validation. 
Results for NEGR1 were less conflicting. Stable overexpression of NEGR1 in SKOV3 cells 
could be achieved, which showed that presence of NEGR1 leads to downregulation of a 
broad array of RTKs at the protein level, presumably both via the proteasome and the 
lysosome. Furthermore, proliferation and spheroid-formation were reduced in NEGR1-
overexpressing clones. 
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6.3) In Silico Analyses 
6.3.1) IgLON Isoforms 
For each of the four IgLON family members, several isoforms could be identified through an 
online search. Some of these isoforms represent strongly truncated versions with significant 
N- or C-terminal deletions; it is therefore unlikely that they carry out the same physiological 
functions as full-length molecules. In most IgLONs, variations of the N-terminal signal 
peptide were observed, but it remains to be seen if these differences lead to altered 
distribution within the cell and on the cell membrane, or are responsible for tissue-specific 
expression. C-terminal deletions were also frequently observed, potentially resulting in loss 
of the GPI-anchor; it is therefore possible that these isoforms are located in the cytoplasm 
rather than on the membrane, or are secreted. Furthermore, several variants contained C-
terminal insertions of 9 (OPCML), 11 (neurotrimin) or 23 (LSAMP) amino acid residues 
between domain 3 and the propeptide. Similar insertions have been observed previously in 
chicken, both for neurotrimin [Struyk et al., 1995] and LSAMP [Spaltmann and 
Brümmendorf, 1996]; however, the functions of these different isoforms remain unknown. 
 
6.3.2) Whole Protein Sequence Alignments 
Sequence alignments of the four IgLON family members highlighted their similarity, 
supporting the hypothesis that they could be involved in related cellular processes. The 
highest sequence identity was observed between OPCML and neurotrimin with 76%, which 
is not surprising as both molecules are encoded closely together on the same chromosome 
(11q25). However, their gene expression levels had previously been found to differ strongly 
PhD Thesis – Sarah Christen – Imperial College London Discussion 
210 
from each other in EOC (expression of OPCML is downregulated in EOC compared to healthy 
ovarian tissue, while HNT (neurotrimin) is upregulated [Ntougkos et al., 2005]); despite their 
similarity, they may therefore carry out different cellular functions. It is hence possible that 
differences in IgLON function and physiological impact are mediated by single amino acid 
substitutions, such as the P95R loss-of-function mutation found in OPCML [Sellar et al., 
2003]; therefore, overall protein similarity may be high for OPCML and neurotrimin, but 
changes in key amino acids could result in different functions. Since the OPCML P95R 
substitution, which is present neither in its wildtype nor in its mutated form in any other 
IgLON, lies in a highly variable region within the IgLON protein sequences, it is plausible that 
this and other similarly low-conserved stretches of amino acid residues are the main 
determinants of IgLON functioning. Taken together, IgLON similarity might hence indicate 
that all four proteins are involved in similar cellular processes, such as RTK regulation, while 
single amino acid changes determine their functional outcome, i.e. the precise spectrum of 
affected RTKs. 
 
6.3.3) Domain Sequence Alignments 
Since it was found that the Ig domains within the same IgLON molecule only shared 6-22% 
of amino acid residues, it was investigated if domains at the same position across all four 
family members were more similar. This revealed that domains 1 shared 62.2% and domains 
2 61.2% sequence identity, while this percentage dropped to 51.0% for domains 3. These 
findings indicate that the IgLON family most likely evolved through gene duplication events 
and not domain shuffling, as domain order is clearly maintained in all four proteins. 
Furthermore, while it had previously been suggested that the majority of Ig domains, 
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particularly the region between the two cysteine residues forming the disulfide bond, are 
encoded in only one exon [Williams and Barclay, 1988], this was only found to be the case 
for domain 1 but not 2 or 3 in all four IgLONs. Domain shuffling therefore seems an unlikely 
mechanism for the formation of the IgLON family, while gene duplication represents a more 
probable alternative. 
The observation that the three Ig domains within the same protein only share a low degree 
of sequence identity points towards different functions for each domain. Indeed, previous 
studies on rat LSAMP found that while domain 1 mediates homophilic binding and can thus 
stimulate neurite outgrowth, domain 2 is responsible for heterophilic interactions and 
consequently inhibition of neurite outgrowth [Eagleson et al., 2003]. Although the precise 
functions of domain 3 remain to be elucidated, it might be the main determinant of 
differences in IgLON functioning due to its low degree of conservation – which was also 
observed in rats [Pimenta et al., 1995] – as well as its different pattern of glycosylation 
compared to the other domains [Itoh et al., 2008]. Furthermore, its presence seems to be 
crucial for IgLON functioning as an NEGR1 isoform lacking domain 3 was found to be 
biologically inactive [Marg et al., 1999]. Similar results have been obtained in our laboratory, 
which indicated that domain 3 of OPCML is crucial for binding to the RTK EphA2 (Elisa Zanini, 
unpublished data). 
 
6.3.4) Kaplan-Meier Survival Plots 
Association of IgLON expression levels with progression-free (PFS) and overall (OS) survival 
differed between the four family members. In this study, LSAMP was found to be negatively 
correlated with PFS but not OS; similar observations have been made in a previous study, 
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which identified LSAMP as a negative predictor for overall survival [Ntougkos et al., 2005]. 
As these findings are surprising for a putative tumour suppressor gene and in strong 
contrast with the observed downregulation of LSAMP expression in most of the ovarian 
cancer cell lines investigated here (see 6.4.1) as well as in the EOC tumour samples 
investigated in the study mentioned above, residual LSAMP in EOC cells might have a 
different function than in normal ovarian tissue and thus promote tumour progression. Due 
to the bifunctionality of LSAMP described in the previous section, this does not seem 
unlikely; LSAMP could function differently in tumours due to their strongly modified overall 
molecular background, for example due to altered availability of LSAMP interaction 
partners. The graph for LSAMP OS indicates that such a switch is possible as the curves for 
low and high LSAMP expression cross over several times. 
HNT (neurotrimin) was a second IgLON family member negatively associated with patient 
PFS and OS, which fits with its observed upregulation in ovarian cancer [Ntougkos et al., 
2005]. However, the precise cellular functions of neurotrimin are still to be determined; 
while LSAMP, NEGR1 and particularly OPCML have previously been shown to have tumour 
suppressor functions in vitro, no such studies have yet been carried out for neurotrimin, and 
it remains to be seen if the molecule has a similar positive cellular impact. If so, it is possible 
that expression of HNT in EOC is upregulated to compensate for loss of its closely related 
sister molecule OPCML – which showed an expected albeit non-significant positive 
correlation with both PFS and OS in this study – but may not be a prognostic factor in itself. 
While both PFS and OS were not significantly associated with either high or low expression 
of NEGR1, a clear positive trend for overall survival of patients with high NEGR1 expression 
could be observed from month 44 onwards. It is therefore possible that NEGR1 indeed has 
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tumour-suppressing functions, but similarly to LSAMP can only carry out these roles at later 
stages of cancerogenesis, when the tumours have evolved and exhibit a different molecular 
background particularly with regards to RTK expression. Since the functioning of IgLONs 
heavily depends on the availability of interaction partners, it is difficult to assess their role in 
isolation, which might be an explanation for the lack of significance in some of the Kaplan-
Meier plots presented here. 
 
6.3.5) IgLON Methylation Status 
While methylation was identified as the main mechanism of OPCML inactivation in several 
previous studies, it did not account for all cases with observed reduced gene expression 
[Sellar et al., 2003; Cui et al., 2008; Ye et al., 2008]. Furthermore, it has been suggested that 
expression of LSAMP and NEGR1 is regulated differently: while methylation was observed in 
some instances, genomic deletions seem to be the more common mechanism of 
inactivation in most investigated cancer types [Chen et al., 2003a; Kresse et al., 2009; Yen et 
al., 2009; Takita et al., 2011; Kühn et al., 2012]. 
It was therefore determined whether IgLON methylation played a role in our EOC dataset. 
Information was available for OPCML and NEGR1, revealing that while NEGR1 methylation in 
high-grade serous EOC (HGS) cases was significantly lower than in normal fallopian tube (FT) 
samples, no difference could be observed for OPCML. However, it has to be taken into 
account that only 10 fallopian tube samples were available for analysis; an increased sample 
size should therefore be studied to validate these findings. 
Overall, HGS methylation levels of NEGR1 (0.071) were significantly lower than for OPCML 
(0.398), confirming previous results suggesting that methylation plays a larger role in 
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OPCML inactivation than for the remaining IgLON family members. It therefore remains to 
be seen which other mechanisms, such as deletion, histone modification, or mutation (most 
likely in the promoter region, as mutations within the IgLON coding sequences – apart from 
the P95R substitution found in OPCML – have not been reported so far), are responsible for 
downregulation of NEGR1 expression in EOC. Additionally, coordinated transcriptional 
regulation of the entire IgLON family in EOC has previously been suggested [Ntougkos et al., 
2005], a hypothesis which is supported by the observation that the timing of IgLON 
expression was found to frequently overlap during rat and chick brain development [Miyata 
et al., 2003; McNamee et al., 2011]. Moreover, Kresse et al. observed co-deletion of the 
genomic regions encoding OPCML and LSAMP in osteosarcoma [Kresse et al., 2009]. 
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6.4) IgLON Protein Levels and Localisations 
6.4.1) IgLON Expression in Ovarian Cell Lines 
As in silico results indicated that LSAMP and NEGR1 are more likely than neurotrimin to 
behave like tumour suppressors similar to OPCML in EOC, these two molecules were 
selected for subsequent experiments. Since OPCML expression is frequently downregulated 
in EOC, it was initially examined if the same could be observed for LSAMP and NEGR1. 
Protein expression of LSAMP was assessed via Western blotting in 25 ovarian cancer cell 
lines as well as the immortalised normal surface epithelium cell line OSE-C2, both on 
medium containing 10% FCS as well as serum-free medium. LSAMP was found to be 
downregulated in the majority of samples (30 samples exhibited <50% expression, only 4 
>200%) compared to OSE-C2, a finding that supports its suggested role as a tumour 
suppressor in EOC. The observation that not all cell lines showed downregulation of LSAMP 
is in agreement with previous studies: while LSAMP gene expression in a study by Ntougkos 
et al. had overall been found to be reduced in EOC samples, several outliers with 
substantially higher expression in tumours than normal ovarian tissue could be observed 
here as well [Ntougkos et al., 2005]. Furthermore, while Pasic et al. reported LSAMP 
downregulation in 64.6% of investigated osteosarcoma samples, 16.7% of tumours however 
showed no difference compared to normal osteoblasts, and 18.8% even had increased 
LSAMP expression [Pasic et al., 2010]. Both results further underline the aforementioned 
suggested bifunctional activity of LSAMP. However, it has to be kept in mind that a) the 
studies quoted above focussed gene expression, not protein levels; and b) that the antibody 
employed in this project may recognise an immature form of the LSAMP protein. 
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NEGR1 expression was initially examined in OSE-C2 cells as well as SKOV3 and its 
derivatives, BKS2.1 (OPCML-transfected, 30x overexpression) and V1.2 (corresponding 
empty-vector control); however, no protein band could be detected on Western blots. 
NEGR1 expression was therefore also assessed via qRT-PCR; this revealed a significant 
downregulation of NEGR1 mRNA levels in SKOV3, V1.2 and BKS2.1 compared to OSE-C2, 
supporting a tumour-suppressive role for NEGR1 in EOC as well. Of note, qRT-PCR 
experiments generally yielded Ct values of approx. 24 for NEGR1 in OSE-C2 cells (approx. 19 
on average for the housekeeping genes ATP5B and CYC1); NEGR1 is therefore not 
particularly high expressed in OSE-C2 either, which may explain the lack of detectable 
protein expression in these cells on Western blots.  
 
6.4.2) Association of IgLON Expression with EOC Subtype 
As Ntougkos et al. had shown an association of IgLON gene expression levels with EOC 
histology – with LSAMP mainly being downregulated in endometrioid cancers [Ntougkos et 
al., 2005] – we determined if the same could be observed in EOC cell lines at the protein 
level. However, no obvious association was found for LSAMP in any EOC subtype; moreover, 
both assessed endometrioid cell lines showed clear expression of LSAMP at approximately 
the same levels as OSE-C2. These discrepancies may, asides from the antibody used for 
Western blotting, be due to differences in experimental setup; as mentioned above, the 
study by Ntougkos et al. investigated mRNA levels, while the data presented here focussed 
on protein expression. 
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6.4.3) Response to Growth Factors 
Comparison of several cell lines maintained on either full serum or serum-free medium 
showed that while expression of NEGR1 remained similar for both conditions, LSAMP 
protein levels may be decreased in full-medium samples across several cell lines. 
Furthermore, while stimulation of OSE-C2 and SKOV3 cells with EGF had virtually no 
influence on NEGR1 protein levels, LSAMP expression was potentially reduced in both cell 
lines, particularly SKOV3, and an equally strong effect could be observed upon stimulation 
of OSE-C2 cells with FGF. For the latter experiment, it should be noted that phosphorylation 
of FGFR1 was not detected; however, OSE-C2 cells endogenously express only very low 
levels of FGFR1, which may account for the observed lack of signal. Experiments using 
higher concentrations of FGF may validate this. Since these results are in contrast with 
previous findings for OPCML, which is upregulated upon stimulation with EGF and FGF 
[McKie et al., 2012], it seems possible that all three IgLON proteins may be regulated 
differently by growth factors. Due to their strong heterophilic interactions as DigLONs, 
difference in growth factor responses of the individual protein complex subunits could be 
beneficial as it leads to a broader array of possible cellular responses and enables a more 
precise regulation of IgLON functioning. However, it has to be noted that the observed 
effects were weak on Western blots for all three IgLONs and could only be detected in 
densitometry analyses; therefore, these results need to be validated in further experiments. 
 
6.4.4) IgLON Expression and Resistance to Platinum 
In previous experiments, OPCML was not found to be expressed in the isogenic PEO14/23 
and PEA1/2 (cisplatin-sensitive/-resistant) cell lines (unpublished data; Reut Porat, MRes 
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thesis “The Role of OPCML in Modulating the Akt-Dependent Response to Platinum 
Therapy”, Imperial College London, 2011). However, exogenous overexpression of the 
molecule in SKOV3 and PEO1 cells (both cisplatin-resistant) increased platinum sensitivity of 
these cells (as determined by increased caspase 3/7 activity), while knockdown in OSE-C2 
(cisplatin-sensitive) showed the opposite. 
As no LSAMP expression could be observed in any of the isogenic cell line pairs in the study 
presented here either, its role in cisplatin resistance would have to be further investigated 
as described for OPCML. For NEGR1 however, considerably reduced protein expression was 
observed in cisplatin-resistant cell lines PEO23 and PEA2 compared to their cisplatin-
sensitive counterparts PEO14 and PEA1, respectively. Together with OPCML, these results 
suggest the very interesting possibility of an involvement of the IgLON family in mediating 
the cellular response to cisplatin, and it will be of great interest to investigate the molecular 
mechanisms underpinning this. 
 
6.4.5) Subcellular IgLON Localisations and Relationships 
Using immunofluorescence microscopy, no colocalisation of LSAMP with phalloidin was 
observed, indicating that unlike other IgCAMs [Bombardelli and Cavallaro, 2010], it may not 
have a direct impact on the cytoskeleton. Furthermore, overexpression of OPCML, NEGR1 or 
LSAMP did not seem to affect the other family members’ cellular distribution, indicating a 
largely independent relationship between the IgLON family members at protein level; 
however, these results should be verified using more thoroughly validated antibodies. In 
support of this, overexpression and knockdown experiments only revealed weak 
associations between the molecules as well. These findings, which are in contrast with 
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previous reports highlighting the importance of IgLON dimers, could be explained by the 
technical issues mentioned before and described in more detail below (see also 6.7.2). 
Overall, distribution of OPCML was mainly concentrated at the periphery of the membrane, 
as would be expected for a membrane-bound protein. However, while both LSAMP and 
NEGR1 could be detected on the cells’ leading edges as well, an unexpectedly high degree of 
presence in the perinuclear area was observed. Distribution of LSAMP initially seemed 
broader in normal OSE-C2 cells than in SKOV3 and its derivatives, indicating different roles 
of the protein in healthy and cancerous tissues; however, this suggestion was not confirmed 
in subsequent experiments. Overexpression of NEGR1 resulted in higher presence of the 
protein in the cytoplasm, but overall the perinuclear area remained the main localisation 
site. Nuclear localisation has previously been observed for several IgCAMs such as EpCAM 
[Maetzel et al., 2009] and L1 [Riedle et al., 2009]; however, both EpCAM and L1 are 
transmembrane proteins, and only their cleaved intracellular domains are relocated to the 
nucleus. For LSAMP, the high variability within the signal sequence observed across its four 
isoforms could provide an explanation for different subcellular localisations of the mature 
protein. However, the previously mentioned technical issues with regards to the antibody 
must also be taken into account: as it was discovered in later experiments, the recognition 
sequence of the LSAMP antibody used for Western blotting and IFM experiments is half 
located in domain 1 and half located in the signal sequence of transcript 001, therefore 
presumably preferentially targeting the immature protein (for more details, see section 
6.7.2). A similar situation was observed for NEGR1; hence, the observed perinuclear 
localisation of both NEGR1 and LSAMP could be due to their respective primary antibodies 
preferentially binding to the immature protein forms. Since immature proteins are 
processed to their mature forms in the perinuclear area, mainly the endoplasmic reticulum, 
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increased signal intensity here is not surprising. Additionally, the reduced ability of the 
antibodies to target the mature, membrane-bound forms may also provide an explanation 
for the relatively low presence of NEGR1 and particularly LSAMP on the cell surface 
compared to OPCML. Conversely, the OPCML antibody was designed to only target the 
mature form, possibly explaining why this IgLON was much more frequently observed 
towards the cell membrane than LSAMP or NEGR1.  
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6.5) IgLON Overexpression and Silencing 
6.5.1) General Remarks on Transfections 
Based on the hypothesis that LSAMP and NEGR1 might act as tumour suppressors similar to 
OPCML, their functional properties were assessed in untransfected cells as well as in 
transient and stable overexpression/knockdown experiments. Initial investigation of EGFR 
and FGFR1 expression in relation to LSAMP expression across a panel of 25 ovarian cancer 
cell lines as well as the normal ovarian surface cell line OSE-C2 did not reveal a direct 
association of RTK expression with levels of LSAMP; however, this is not surprising due to 
the highly variable molecular backgrounds of the investigated cell lines. Therefore, 
transfected cell lines represent a much better resource for analysis and comparison of 
numerous cellular properties related to cancer, such as migration, proliferation, or response 
to drugs. If possible, stable clones were generated to allow for more recovery time after 
transfection, for use in long-term experiments such as proliferation assays, and to achieve 
increased experimental reproducibility. For LSAMP overexpression, an LSAMP expression 
vector was generated, while knockdown experiments were carried out using commercially 
available siRNA and shRNA sequences. Experiments with NEGR1 included overexpression of 
the molecule using a pre-constructed vector, as well as transient knockdown experiments. 
As this study hypothesised that the potential tumour suppressor functions of LSAMP and 
NEGR1 are mediated at the protein level, Western blot analysis was the main technique 
used to establish RTK presence and phosphorylation. 
As pointed out before, future experiments urgently require a more in-depth validation of 
the LSAMP expression vectors as well as siRNA sequences to allow for more reliable results 
and less challenging interpretation. 
PhD Thesis – Sarah Christen – Imperial College London Discussion 
222 
6.5.2) RTK Expression and Signalling in Transfected Cells 
6.5.2.1) Overexpression of LSAMP 
Overexpression of LSAMP in the non-expressing ovarian cancer cell lines PEO1 and OVCAR4 
was initially carried out transiently. However, both cell lines showed strong signs of stress 
and high levels of cell death after transfection, but no expression of LSAMP; therefore, 
stable overexpression was chosen for subsequent experiments. Still, as LSAMP could not be 
detected in stable PEO1 and OVISE clones via Western blotting either, qRT-PCR was carried 
out to verify success of transfection. However, this revealed that neither LSAMP-transfected 
clone showed increased expression of the molecule; hence, these models were not used in 
further experiments. 
 
To determine if the encountered issues were due to the construct itself, SKOV3 and OSE-C2 
were used cells for a final transfection attempt. These cell lines had previously proven to be 
comparably easy to transfect in experiments with OPCML; however, it has to be noted that 
both express a basal level of LSAMP endogenously and are therefore not the ideal choice to 
assess LSAMP functioning in vitro. 
In SKOV3 cells, the generation of an empty vector control clone with similar properties to 
untransfected cells, as well as the avoidance of transfection-induced off-target effects, 
represented major complications: both empty vector (EV4) and overexpressing clone (LS14) 
had lower LSAMP levels than untransfected SKOV3 cells, with EV4 not exhibiting any LSAMP 
expression at all. One potential explanation for these results is that overall protein levels in 
EV4 and LS14 were reduced compared to SKOV3 due to transfection-related cellular stress, 
and transfection with LSAMP merely reinstated LSAMP expression to similar levels as 
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observed in the parental SKOV3 cells (see 6.7.1). As mentioned above, using the previously 
employed vector pcDNA™3.1 instead of pcDNA™4/TO might have been a useful approach to 
determine if the observed effects were construct-related. 
Assessment of the association of LSAMP and RTK expression in these clones showed that 
presence of LSAMP in LS14 compared to EV4 resulted in downregulation of EGFR, HER2, 
pHER2, HER3 and pErk1/2 levels, while FGFR1 and – to a lesser degree – pAkt were 
upregulated, indicating that LSAMP could negatively regulate a similar but not identical 
spectrum of RTKs as OPCML. However, the differences in protein levels between SKOV3, 
EV4 and LS14 could also be due to the “bottleneck effect” described below (see 6.7.1), 
leading to overrepresentation of certain SKOV3 subpopulations in the transfected clones; 
this assumption is supported by the fact that EV4 are the only cells expressing HER3, 
therefore indicating enrichment of a HER3-positive SKOV3 subpopulation in this clone and 
making it a poor representative for wildtype attributes. 
 
The same issue encountered in SKOV3 cells was observed after transfection of OSE-C2 cells 
with LSAMP as well, with overall LSAMP levels being reduced after transfection and restored 
to wildtype levels in LSAMP-transfected LS2 cells. This again indicates that the vector itself 
may have led to the observed side effects and should have been replaced with pcDNA™3.1.  
Interestingly, transfection with LSAMP resulted in upregulation of EGFR, pEGFR, HER2, 
pHER2, and Akt; these findings were unusual for a putative tumour suppressor gene and in 
strong contrast to the observations made in SKOV3 cells. As suggested earlier, it is therefore 
likely that due to its bifunctionality, LSAMP plays a different role in a non-cancerous cellular 
context; however, the precise molecular causes for this bifunctionality remain to be 
PhD Thesis – Sarah Christen – Imperial College London Discussion 
224 
determined. Potential mechanisms include differences in stabilisation of the IgLON-RTK 
complex and thus altered signalling properties in cancerous and non-cancerous cells; 
modifications of endocytotic intake and subsequent processing of the complex; or 
compensatory mechanisms through other pathways which were not investigated here. 
Of note, RTK upregulation in LSAMP-transfected OSE-C2 cells did however not result in 
activation of downstream molecules such as Erk1/2 or Akt, and had no impact on 
proliferation either (see 6.5.4). This could be due to regulatory mechanisms downstream of 
RTKs, which inhibit aberrant signalling, remaining functional in non-cancerous OSE-C2 cells 
compared to cancerous SKOV3 cells.  
 
6.5.2.2) Silencing of LSAMP 
Knockdown of LSAMP expression was initially attempted transiently using six different 
siRNA constructs. However, neither transfection of SKOV3 or OSE-C2 yielded reproducible 
results despite various optimisation attempts regarding factors such as timing, cell 
confluency or siRNA concentration. As most employed siRNA sequences targeted the N-
terminal region of LSAMP, it was investigated if they potentially bound to only one of the 
four LSAMP transcript variants, particularly since all resulting protein isoforms have 
different N-terminal signal peptides (see section 6.3.1). This revealed that all six siRNA 
sequences targeted transcript variant 001, with sequences 2 and 3 not able to bind to any 
other variant; additionally, siRNA E could not target transcript 006. However, particularly 
sequences 2 and 3 yielded good results in OSE-C2 cells, possibly due to the fact that they 
solely target the putative main transcription variant 001. Additionally, it has to be kept in 
mind that half of the LSAMP antibody recognition sequence lies within the signal peptide of 
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transcript variant 001 (see 6.7.2); therefore, presumably neither normal expression nor 
downregulation of any other isoform would have been detectable. siRNA sequences binding 
to transcript variant 001 only are therefore most likely to produce a visible effect on 
Western blots. Ideally however, both siRNA sequences and antibodies should target all 
isoforms to ensure the broadest possible effect. 
Due to these technical issues, siRNA-treated cells were not analysed further, and LSAMP 
expression was silenced using shRNA in subsequent experiments. However, this approach 
revealed similar issues as encountered during stable overexpression of LSAMP: rather than 
observing downregulation in LSAMP-shRNA-transfected clones, cells transfected with the 
empty vector seemed to have increased LSAMP expression both in qRT-PCR and particularly 
Western blotting analyses. One potential reason behind these paradox findings across 
several cell lines could be that LSAMP expression is stress-responsive, as had previously 
been observed for OPCML, which was upregulated after exposure to extracellular stresses 
[Cui et al., 2008]. Hence, LSAMP could be upregulated in cells after transfection and 
subsequently reduced to wildtype levels in shRNA-treated clones. However, LSAMP protein 
levels in overexpression experiments had been reduced after transfection, not upregulated; 
this hypothesis can therefore not explain all observed issues, and the precise reasons 
remain unknown. 
As seen for LSAMP overexpression in OSE-C2 cells, presence of LSAMP was associated with 
increased levels of pEGFR; additionally, an upregulation of FGFR1 and pErk1/2 could be 
observed in LSAMP-expressing cells, while no relationship between LSAMP and the two 
proteins had been observed in overexpression experiments. These differences are most 
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likely due to the aforementioned difficulties associated with transfections (see 6.5.1), 
particularly the enrichment of minor subpopulations in selected clones. 
 
6.5.2.3) Overexpression of NEGR1 
Compared to experiments with LSAMP, transfection with NEGR1 was considerably more 
straightforward. In transient transfections of SKOV3 cells, which do not express NEGR1 
endogenously, overexpression of the molecule led to downregulation of a broad spectrum 
of RTKs and downstream molecules, most notably EGFR, FGFR2 and pAkt (but not HER2 or 
FGFR1). NEGR1 might therefore have a similar function as OPCML in RTK downregulation, 
albeit with a different target spectrum since OPCML overexpression led to reduced levels of 
HER2 and FGFR1, while EGFR and FGFR2 remained unchanged. In stable transfections, 
NEGR1 overexpression in A29 cells resulted in additional downregulation of HER2 and 
FGFR1 as well as HER4 and Akt; these differences between transient and stable cells are 
probably due to the fact that stable clones underwent a more thorough selection process, 
whereas transient experiments were carried out with polyclonal, pooled groups of cells. It is 
therefore possible that the presence of subgroups of unsuccessfully transfected SKOV3 cells, 
which still expressed high RTK levels, led to a background signal in transient experiments 
which was too strong to reveal the extent of downregulation in successfully transfected 
cells. Of note, the observed spectrum of protein downregulation in A29 cells was reflected 
in the weaker overexpression clone S6, albeit less pronounced than in A29, hence showing 
that the degree of RTK downregulation depends on the amount of NEGR1 present. 
Surprisingly, despite the broad range of downregulated RTKs in A29 cells, upregulation of 
pErk1/2 levels was observed in this clone, potentially indicating compensatory mechanisms; 
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EphA2, the only RTK which showed upregulation in transient experiments, could be a 
candidate for activation of this pathway. However, no consequences of increased Erk1/2 
activation with regards to proliferation could be observed (see 6.5.4). 
Overall, levels of RTK expression and phosphorylation could be reduced up to or beyond the 
levels observed in normal OSE-C2 cells, underlining the beneficial effects of IgLON 
overexpression. However, for these and other experiments it has to be kept in mind that 
OSE-C2 cells presumably do not represent an ideal control since recent years have seen 
many researchers advocating that the ovarian surface epithelium, from which OSE-C2 cells 
were derived, are not the source of origin for ovarian cancer, but that each EOC subtype has 
its own individual precursor cells (see 1.3.5.1). For example, in experiments using SKOV3 
(serous origin), a fallopian tube cell line may therefore represent a better control. 
 
6.5.2.4) Silencing of NEGR1 
Due to its low intrinsic expression in OSE-C2 cells, downregulation of NEGR1 in siRNA-
treated cells could not be verified via Western blotting as no signal was detected. However, 
the observation that treatment with siRNA, particularly with sequence 2, can lead to 
upregulation of HER2 protein levels indicates that NEGR1 negatively regulates RTKs in 
healthy cells as well, similar to the results observed for OPCML [McKie et al., 2012]. These 
preliminary results warrant the creation and investigation of stable NEGR1 knockdown 
clones in further experiments. 
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6.5.3) Colocalisation of IgLONs with RTKs 
Immunofluorescent staining of OSE-C2 cells for LSAMP and FGFR1 revealed a small degree 
of colocalisation between the two molecules, particularly around the nucleus and the cells’ 
leading edges. These results suggest that an association of FGFR1 and LSAMP might be 
possible; however, since the LSAMP antibody may also target immature forms of LSAMP, 
the observed costaining of the two proteins could rather reflect colocalisation during the 
maturation process than be a result of direct binding and subsequent downregulation of 
FGFR1 by the mature form of LSAMP. Using an antibody targeting only the mature form of 
LSAMP might therefore reduce intracellular detection of the immature protein and enhance 
membrane-associated staining, thus revealing the actual degree of LSAMP-FGFR1 
colocalisation. 
 
Colocalisation of NEGR1 was investigated with two RTKs it had been shown to 
downregulate, EGFR and HER2. Little colocalisation with HER2 could be observed in 
untransfected SKOV3 cells as well as the empty vector controls, with HER2 being mainly 
visible on the membrane, while NEGR1 staining was particularly strong around the nucleus. 
Overexpression of NEGR1 however led to a broader distribution of the molecule within the 
cells as well as a strong reduction of HER2 staining and an increased colocalisation of the 
two proteins. These results confirm the findings observed on Western blots, and underline 
direct interaction as a potential mechanism of NEGR1-mediated downregulation of HER2. 
Surprisingly, results for EGFR colocalisation with NEGR1 were less conclusive even though a 
striking downregulation of EGFR had been observed in NEGR1-overexpressing cells on 
Western blots. While NEGR1 was again mainly present around the nucleus, EGFR 
PhD Thesis – Sarah Christen – Imperial College London Discussion 
229 
distribution was very broad and not as membrane-specific as had been observed for HER2; 
furthermore, no reduction of signal strength was detected in NEGR1-overexpressing cells. It 
is possible that these results may reflect the experimental conditions: unlike all other 
antibodies used in immunofluorescence microscopy experiments, the primary antibody for 
EGFR was raised in goat; therefore, high background signalling may stem from the fact that 
the blocking step was carried out using goat serum. A different blocking approach may 
therefore yield better results for EGFR, with less background staining and a clearer 
difference between EGFR expression in untransfected/empty vector controls and NEGR1-
overexpressing cells. 
 
6.5.4) Proliferation of Transfected Cells 
Despite the fact that overexpression of LSAMP in SKOV3 cells generally led to decreased RTK 
protein and phosphorylation levels, while overexpression in OSE-C2 had the opposite effect, 
both LSAMP-transfected cell lines showed reduced proliferation rates compared to their 
respective untransfected counterparts. It is therefore possible that LSAMP has tumour 
suppressor-like functions in both cell lines, but these functions are mediated via different 
molecules/pathways depending on the molecular background of the respective cell type. A 
key switch in determining the physiological impact of LSAMP could be Erk1/2, a major 
determinant of cellular proliferation, since its phosphorylation levels are downregulated in 
LSAMP-transfected, slow-growing clones, regardless of RTK levels.  However, it has to be 
taken into account that both for SKOV3 and for OSE-C2, phosphorylation levels of Erk1/2 
and proliferation rates were significantly reduced in empty vector controls compared to 
untransfected cells as well, particularly in SKOV3. The possibility that transfection- or 
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selection-associated side effects are the main reason for the observed decreases in pErk1/2 
levels and proliferation can therefore not be excluded. 
Differences between untransfected and transfected SKOV3 cells became even more 
pronounced on serum-free medium, indicating that transfected cells are strongly growth 
factor-dependent, presumably due to their overall reduced RTK levels. 
As opposed to the results observed in overexpression experiments, silencing of LSAMP in 
OSE-C2 cells also resulted in reduced levels of pErk1/2 in LSAMP shRNA clones. 
Consequently, shRNA-treated cells showed reduced proliferation rates compared to 
untransfected cells and empty vector controls, which is in strong contrast with the 
aforementioned tumour suppressor function. However, due to the apparent transfection-
induced effects on the cells, these results should be validated using additional, improved 
models to determine the precise impact of LSAMP expression on cell proliferation. 
 
For NEGR1, results were more conclusive: stably transfected clones, which showed reduced 
levels of a broad repertoire of RTKs, grew significantly slower than untransfected SKOV3 
cells and empty vectors controls. This effect became even more pronounced on FCS-
reduced serum, indicating a strong serum dependence of NEGR1-overexpressing clones; as 
for LSAMP, this effect is probably due to the substantially reduced number of RTKs in 
NEGR1-transfected cells. However, it was observed that levels of Erk1/2 phosphorylation 
were actually increased in A29, the strongest NEGR1-expresser and slowest-growing clone. 
This indicates that as opposed to LSAMP (and OPCML [McKie et al., 2012]), the physiological 
impact of NEGR1 might be mediated through a different downstream molecule or pathway, 
and further experiments are needed to identify this alternative mechanism. 
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6.5.5) Migration of Transfected Cells 
Assessment of migration rates of stably LSAMP- and NEGR1-transfected cells was initially 
carried out using the xCELLigence system (Roche), due to its capability of long-term 
monitoring in short (15 min) time intervals. However, the observed results were rather 
unexpected: for LSAMP, LSAMP-transfected cells migrated faster than untransfected cells, 
while empty vector controls migrated slower; for NEGR1, the strong NEGR1-overexpressing 
clone A29 migrated faster than both empty vector controls, while the weak overexpressing 
clone S6 migrated slower, and all four transfected cell lines showed increased migration 
compared to untransfected SKOV3 cells. Therefore, apart from the fact that the two IgLON-
overexpressing cells exhibited the fastest migration rates both for LSAMP (LS14) and NEGR1 
(A29), no clear associations with transfection status, proliferation rate or RTK levels could be 
observed. The main reasons for these findings may lie within the setup of the assay. First of 
all, the xCELLigence system monitors migration of cells from serum-free towards serum-
containing medium; hence, cells which are strongly serum-dependent (as had been shown 
for LS14 and A29 in proliferation assays, see above) are likely to migrate faster. Secondly, 
the assay has no means to control for unequal loading of cells; this represents a major 
drawback particularly as counted cells could reattach during the time-intensive setup, thus 
reducing the number of suspended and subsequently seeded cells. Due to these limitations, 
a scratch migration assay was carried out additionally. Here, the influence of serum 
dependence is strongly reduced; furthermore, setup is facilitated and can also be visually 
controlled for inequalities in seeding densities or initial scratch width. These assays showed 
no increase in migration of IgLON-overexpressing cells; on the contrary, a slight decrease in 
IgLON-transfected cells was visible compared to untransfected SKOV3 cells and empty 
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vector controls after 24 h, although this could also be attributable to the slightly wider 
scratch in these clones. Overall, both assays have distinct advantages and disadvantages, 
and further optimisation is needed to clarify the results. 
 
6.5.6) Spheroid-Formation Ability of Transfected Cells 
Since the ability to grow anchorage-independently is a key feature of tumours, particularly 
in metastatic cells, it was investigated if overexpression of LSAMP or NEGR1 in SKOV3 cells 
reduces their ability to survive under low-adhesion conditions. Both transfection with 
LSAMP and NEGR1 led to substantially reduced number of colonies in LS14 and A29 clones, 
supporting the proteins’ proposed tumour-suppressing abilities. Furthermore, a marked 
reduction in colony size could be observed; however, since a similar decrease was seen in 
empty vector controls, this effect could also be a side effect of transfection and selection 
rather than a consequence of IgLON overexpression. Similar results had previously been 
observed for OPCML, which could reduce both anchorage-dependent and -independent 
formation of colonies in colorectal, oesophageal and prostate cancer cell lines [Cui et al., 
2008]; the results obtained here therefore again highlight the similar tumour suppressor 
functions of the members of the IgLON family.  
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6.6) Protein Interaction and Degradation 
6.6.1) LSAMP Pull-Down 
Since LSAMP and OPCML had previously been shown to interact heterophilically in chicken 
[Lodge et al., 2000], it was assessed if the same could be observed for human IgLONs. In an 
initial pull-down assay using recombinant GST-tagged LSAMP (GST-rLSAMP) to pull down 
previously generated recombinant His-tagged OPCML (His-rOPCML), presence of His-
rOPCML in the pull-down sample could be observed, indicating interaction; however, His-
rOPCML was also detected in the GST-only control. It is therefore not clear if His-rOPCML 
does interact with LSAMP, or was simply pulled down by binding to GST; however, since the 
Western blotting band for OPCML was stronger in the pull-down sample, interaction is 
likely. Additional washes or a different technique such as co-immunoprecipitation (see 
6.6.2) might lead to more conclusive results. 
 
6.6.2) NEGR1 Co-Immunoprecipitation 
Previous results have shown that OPCML is able to bind directly to the RTKs it 
downregulates, but not the ones it does not affect [McKie et al., 2012]; therefore, it was 
assessed if the same could be observed for NEGR1. 
Co-immunoprecipitation (co-IP) experiments were performed using lysates of PEO1 cells, an 
ovarian cancer cell line which had been found to express both NEGR1 as well as several 
RTKs. For EGFR and HER2, no direct interaction could be confirmed as no bands were visible 
in the IP samples. For HER3, a band was visible in the IP sample, indicating interaction even 
though no HER3 could be observed in the total PEO1 lysate; however, the lysate negative 
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control also showed HER3 presence, suggesting that HER3 might have bound directly to the 
Sepharose beads and thus been enriched throughout the procedure, explaining why a band 
was seen in the IP sample but not the full lysate. Therefore, it is possible that NEGR1 and 
HER3 interact, but direct binding of HER3 to the beads can not be excluded either and these 
data should be validated in further experiments. For FGFR1, both the full lysate as well as 
the IP sample contained bands, indicating direct interaction; however, the AB negative 
control contained a broad band as well, although this is probably rather due to unspecific 
binding of the FGFR1 secondary antibody (see below). 
Unexpectedly, presence of NEGR1 was mainly detected in the IP sample as well as the AB 
negative control. However, since both NEGR1 and Sepharose have a molecular weight of 55 
kDa, it is possible that the observed band rather represents detection of Sepharose-bound 
primary NEGR1 antibodies than NEGR1 itself. This hypothesis is supported by the fact that 
the only two samples exhibiting a 55 kDa band were also the only two samples containing 
NEGR1 primary antibodies; furthermore, the AB negative control does not contain any cell 
lysate and therefore no NEGR1 protein. To avoid such false detection, future validation 
experiments should be carried out by incubation of the Sepharose beads with a NEGR1 
primary antibody raised in a different species than the antibody used for detection on 
Western blots, thus avoiding interaction of the secondary Western blotting antibody with 
the primary Sepharose-bound antibody. However, for the purpose of this study, this setup 
was not possible as only one of the commercially available NEGR1 antibodies had been 
found to work reliably in previous experiments. 
As FGFR1 was the only other protein recognised by a primary antibody raised in rabbit, it 
was not surprising that the 55 kDa bands observed in NEGR1 samples were detected in 
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these samples as well, and resulted in a smear across the whole membrane up to the area 
of FGFR1 (100-110 kDa). The band visible in the FGFR1 AB negative control may therefore 
rather have appeared due to unspecific binding of the anti-rabbit secondary antibody, which 
was used to detect FGFR1 on Western blots, to the Sepharose-bound NEGR1 rabbit primary 
antibodies. Hence, interaction of NEGR1 with FGFR1 is certainly possible as it is highly likely 
that the observed band in the AB negative control represents an artefact. 
It has to be noted that NEGR1 could not be detected in the full PEO1 lysate despite previous 
experiments showing that this cell line expresses NEGR1. The reasons for this finding remain 
unclear but could explain the lack of binding observed between NEGR1 and EGFR/HER2 
even though both RTKs are clearly downregulated in NEGR1-overexpressing cells. 
 
6.6.3) Protein Degradation Assays 
Protein degradation assays were carried out using MG-132, a proteasomal inhibitor, as well 
as chloroquine (CQ), a lysosomal inhibitor, to determine if either pathway is used in NEGR1-
mediated downregulation of RTKs. Similar to previous results for OPCML [McKie et al., 
2012], treatment of NEGR1-overexpressing A29 cells with MG-132 led to inhibition of 
NEGR1-induced RTK downregulation, both for EGFR and HER2. Additionally, EGFR 
downregulation could also be inhibited using chloroquine, which had not shown an effect in 
experiments with OPCML-overexpressing cells. It is therefore possible that NEGR1 uses 
different or additional endocytotic mechanisms as OPCML, thus resulting in RTK degradation 
in different cellular compartments. 
For HER2, the effect of chloroquine could not be assessed as A29 cells showed surprisingly 
high levels of endogenous HER2 expression even if untreated. This may be due to the fact 
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that these experiments were carried out using cells at a slightly higher passage number 
(around 17) compared with all previous assays (7-13). As could be seen in 
immunofluorescence microscopy (see Figure 61, page 194), the A29 clone still contains a 
low number of HER2-positive cells, which had either not been transfected successfully or 
lost the insert/plasmid over time; since these cells would have a growth advantage, they 
may have reached a considerably higher percentage within the A29 population by the time 
the CQ assay was carried out, thus masking the NEGR1-induced downregulation of HER2 in 
the remaining A29 cells. To avoid these effects in the future, all experiments need to be 
carried out at low passage numbers; this seems to be particularly crucial for overexpression 
clones as similar effects were observed in OPCML-transfected BKS2.1 cells. Furthermore, 
selection of transfected clones might have to be carried out even more rigidly than 
performed here. While A29 cells were grown from a solitary colony of around 50-100 cells, 
generation of additional clones might have to be carried out using single cells to ensure a 
virtually identical genetic background in all cells (taking into account the high genetic 
variability of cancer cells which will inevitably lead to changes with increased passage 
numbers). However, it has to be considered that some cell lines, such as PEO1, do not grow 
very well if seeded singularly. 
 
6.6.4) Colocalisation of LSAMP with Caveolin-1 
Since OPCML had previously been found to colocalise with caveolin-1 and been implicated 
in clathrin-independent raft-mediated endocytotic downregulation of RTKs, it was 
investigated if the same could be observed for LSAMP. However, colocalisation of the two 
proteins was minimal. As observed for NEGR1, which does seem to be able to downregulate 
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RTKs through additional/alternative mechanisms than OPCML (see above), LSAMP might 
operate differently as well. 
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6.7) Experimental Difficulties 
6.7.1) Transfections 
One of the major challenges faced in this project, particularly with regards to LSAMP, was 
the issue that – across several separate experiments – no empty vector clone with protein 
levels comparable to untransfected cells could be generated. This is most likely due to three 
factors: transfection itself, isolation of transfected clones, and maintenance on selection 
antibiotics. First of all, transfection induces cellular stress, which might lead to alterations in 
gene expression. Secondly, isolation of transfected clones represents a “bottleneck” effect, 
potentially resulting in overrepresentation of a small minority of cells with a considerably 
different molecular background than the general untransfected cell population. And thirdly, 
maintenance of transfected clones on selection antibiotics can additionally lead to 
unwanted side effects and physiological differences between transfected and untransfected 
cells. Due to these reasons, both empty vector- and IgLON-transfected clones can therefore 
differ considerably from their parental cell line. Nonetheless, while the empty vector-
transfected cells in the experiments described here therefore often do not represent an 
exact replicate of untransfected cells, they are vital controls for transfection- and antibiotic-
induced side effects. However, to overcome these issues in future experiments, further 
optimisation is required (see 7.1). Since a different expression vector was used for LSAMP 
(pcDNA™4/TO) than for OPCML (pcDNA™3.1) or NEGR1 (pReceiver), it may be useful to 
subclone the LSAMP sequence into either of the other two vectors, to exclude construct-
related issues. 
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6.7.2) Antibodies 
During the production of recombinant LSAMP, it was observed that the employed LSAMP 
antibody was unable to bind to His-rLSAMP in Western blotting experiments, even though 
an anti-His antibody revealed presence of the protein in the samples. As mentioned 
previously, one potential reason for these findings could be the fact that the LSAMP 
antibody recognises an antigen sequence which is half located in domain 1 of LSAMP, and 
half in the adjacent N-terminal signal peptide (see Figure 47, page 170, and Figure 49, page 
172). Since primers for cloning of rLSAMP had been designed to include only the three Ig 
domains but not the N-terminal signal peptide, binding of the antibody to rLSAMP may 
hence be reduced; furthermore, the 6xHis/thioredoxin-tag is attached N-terminally, thus 
possibly making interaction of the two molecules additionally difficult due to steric 
hindrance. 
On Western blots of whole cell lysates, the mature glycosylated 55 kDa form of LSAMP was 
however still visible, probably since – unlike for rLSAMP – no tag-induced steric hindrance 
was present and the antibody could therefore still bind. Alternatively, it might have 
detected a semi-mature form of LSAMP, which is already fully glycosylated but still retains 
the signal sequence. Furthermore, it has to be considered that the LSAMP antibody used 
here is polyclonal and thus likely to contain a mixture of antibodies recognising different 
epitopes, some of which may lie within the signalling sequence, while others might be 
located in domain 1; therefore, detection of both the mature and immature form is likely. 
Indeed, a band at 37 kDa corresponding to the unglycosylated immature form of LSAMP 
(including N-terminal signal peptide and C-terminal propeptide) was frequently observed in 
Western blots as well, supporting the hypothesis that the LSAMP antibody used in this study 
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is able to bind to both forms of the protein. IFM experiments indicated that binding of 
immature LSAMP might occur preferentially as signal intensity was much higher around the 
cells’ nuclei, i.e. the expected localisation of maturing LSAMP (e.g. within the endoplasmic 
reticulum), than on the membrane.  
An additional drawback of the LSAMP antibody used in this study is that only one of the four 
protein isoforms identified for LSAMP (transcript 001) harbours the particular antigen 
sequence the antibody recognises, thus reducing the likelihood of it detecting the other 
variants as well. So far, it is unclear if transcript 001 represents the main form of LSAMP 
expressed in humans; based on previous studies in chicken, it is possible that different 
LSAMP signal peptides rather regulate correct timing of expression during development, but 
do not represent major or minor isoforms in adults [Brümmendorf et al., 1997]. Recognition 
of all variants therefore might be crucial. 
To overcome the issues described here, several other antibodies were investigated; 
however, they either did not detect the predicted 55 kDa band for LSAMP on Western blots, 
or showed strong cross-reactivity with OPCML. 
 
To ensure that the data obtained for the other IgLON family members was not affected by 
similar issues, the antibodies for OPCML and NEGR1 were investigated as well. This showed 
that although the precise antigen sequence of the OPCML antibody was not disclosed by the 
manufacturer, it should only bind within the three Ig domains, hence solely targeting the 
mature form. For NEGR1 however, the provided antigen sequence information revealed 
that the antibody recognises an area between mid-domain 1 and the C-terminus, thus 
covering not only domains 2 and 3 in full, but also the propeptide. Therefore, it may 
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potentially recognise an immature propeptide-containing form as well; however, since the 
propeptide only represents a small fraction of the quoted antigen sequence, this seems less 
likely than for LSAMP. Furthermore, no 37 kDa band corresponding to immature NEGR1 
could be observed on Western blots. Still, the employed NEGR1 antibody was polyclonal as 
well; recognition of an epitope within the protein’s propeptide by at least a fraction of the 
antibodies can therefore not be excluded and may account for the strong perinuclear 
NEGR1-staining observed in IFM experiments.  
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6.8) Summary 
The main aim of this PhD project was to investigate if LSAMP and NEGR1 exhibit similar 
tumour-suppressing functions as OPCML in EOC. Initial bioinformatic analyses showed that 
the four IgLON family members are highly similar to each other, making an involvement in 
related cellular processes likely. However, the precise function of each IgLON seems to 
strongly depend on the cell’s molecular background, presumably due to altered availability 
of interaction partners; this multifunctionality has been frequently documented in the 
literature and may explain why particularly the results for LSAMP presented here were 
somewhat conflicting. Additionally, it has to be taken into account that for LSAMP 
experiments, both transfections as well as analysis via Western blotting were hampered by 
unexpected technical difficulties, overall yielding few conclusive results. Nonetheless, since 
the protein was found to be downregulated in a broad range of ovarian cancer cell lines, a 
tumour-suppressing role in EOC is likely. Particularly overexpression experiments in SKOV3 
cells were promising, showing that LSAMP may function similarly to OPCML by inducing 
downregulation of RTKs, resulting in reduction of proliferation, colony formation and 
potentially migration. However, as overexpression and knockdown of LSAMP in OSE-C2 cells 
could not confirm these findings, further experiments are needed to provide a more 
detailed insight into the precise cellular roles of LSAMP. 
Results for NEGR1 were considerably less ambiguous. NEGR1 showed tumour-suppressing 
functions in SKOV3 overexpression experiments by downregulating a broad spectrum of 
RTKs, reducing proliferation rates, potentially decreasing migration, and substantially 
inhibiting anchorage-independent growth. While the suggested direct interaction of NEGR1 
with FGFR1 and possibly further RTKs needs to be validated as the results presented here 
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are only preliminary, initial protein degradation assays in NEGR1-overexpressing cells 
showed that both the proteasomal as well as the lysosomal pathway are used; therefore, 
NEGR1-mediated RTK downregulation seems to occur through a similar, albeit broader 
mechanism of direct binding and endocytotic uptake as observed for OPCML. 
Downregulation of HER2 could additionally be confirmed in IFM studies; furthermore, a 
potential role of NEGR1 in platinum resistance was observed, which should be addressed in 
more detail in future experiments. Overall, NEGR1 showed evidence of a variety of tumour 
suppressor functions in in vitro assays and therefore, in addition to OPCML and potentially 
LSAMP, represents a further IgLON family member which may play a crucial role in epithelial 
ovarian cancer. 
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6.9) Clinical Implications 
Due to the overall promising results for LSAMP and particularly NEGR1, the IgLON family 
could have immense clinical significance. As seen in in vivo experiments for OPCML, a 
recombinant version of the protein (rOPCML) has significant tumour-suppressing abilities 
[McKie et al., 2012]; it is therefore possible that mimetic molecules based on the other 
family members may induce similar effects. One of the main advantages of such 
recombinant IgLON (rIgLON) molecules would be their ease of administration: since IgLONs 
are extracellular tumour suppressors, no intracellular delivery or gene therapy would be 
necessary to restore their loss in tumours cells. Furthermore, the fact that they are 
expressed endogenously could indicate that patient intolerance might be minimal. 
As IgLONs act at the top of the RTK signalling cascade and affect several members from 
different RTK families, the risk of pathway redundancy – which is a major problem in cancer 
and a frequently observed mechanism of acquired drug resistance – is likely to be strongly 
decreased upon rIgLON treatment. Additionally, epithelial ovarian cancer represents a 
cancer type for which no frequently associated RTK has been identified so far (unlike breast 
cancer, which often shows strong amplification of HER2); therefore, targeting a broad range 
of receptors might be the most promising approach to combat EOC. Furthermore, 
recombinant IgLON molecules could not only be combined with each other to achieve a 
wider specificity, but may also act synergistically with existing RTK inhibitors. Such 
combinatorial approaches could not only increase the efficiency of treatments already in 
clinical use, but may also allow the reduction of applied doses, thus leading to reduced side 
effects. Combination particularly with small molecule TKIs might be required in tumours 
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with specific RTK aberrations such as deletion of the extracellular domain, which rIgLONs 
would be unable to target. 
In addition to RTK inhibitors, combination with cisplatin could prove to be particularly 
promising as both OPCML and NEGR1 are able to reduce phosphorylation of Akt, a molecule 
frequently associated with cisplatin resistance [Peng et al., 2010]; application of rOPCML or 
rNEGR1 may therefore resensitise resistant EOC cells to cisplatin. Since cisplatin resistance is 
frequently observed in EOC and ultimately one of the main reasons for the disease’s high 
mortality rate, the possibility to resensitise tumour cells to platinum would undoubtedly 
immensely benefit the majority of EOC patients.  
Whether the reduction of anchorage-independent growth seen in LSAMP- and NEGR1-
overexpressing clones represents an additional consequence of RTK downregulation or is 
mediated by other mechanisms remains to be seen. Nonetheless, anchorage-independent 
growth has previously been implicated in EOC tumour dissemination and metastasis 
[Mezzanzanica et al., 2008], suggesting that IgLONs could play a crucial role in advanced-
stage tumours, i.e. the stage at which most cases are diagnosed. 
Overall, due to their suggested broad spectrum of activity, the IgLON family holds immense 
clinical potential which may be of benefit to a large proportion of epithelial ovarian cancer 
patients. Furthermore, as aberrant RTK signalling is implicated in a vast number of other 
tumour types as well, rIgLONs could prove to be effective in not only EOC, but possibly a 
broad variety of cancers. 
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7.1) Creation and Validation of Additional Resources 
As discussed previously, a number of technical complexities should be addressed to validate 
the results of this study in future experiments; particularly the generation of stable LSAMP 
knockdown and overexpression clones requires further development. Likewise, stable 
NEGR1 knockdown clones should be created to provide a complementary model for A29 
and S6 overexpression clones. For the generation of additional cell models, a homogenous 
source population with a low passage number is crucial to avoid the aforementioned 
“bottleneck effect”, which posed a frequently observed problem in the experiments 
described here. Secondly, selection of stable clones should – cell line permitting – be carried 
out based on single cells instead of larger colonies, to avoid inclusion of untransfected cells. 
And thirdly, particularly for LSAMP, a different vector system should be assessed. Most 
importantly however, suitable antibodies to detect the mature forms of the IgLON proteins, 
particularly LSAMP, need to be identified and optimised to avoid cross-reactivity with other 
family members. 
 
7.2) Verification of Suggested Mechanisms 
To verify the suggested tumour-suppressing mechanism of IgLON-mediated RTK 
downregulation, each step in this process – from direct binding of IgLONs with RTKs on the 
cell surface to endocytosis and degradation – should be examined individually. 
Firstly, to complement previous IFM experiments and additionally assess if overexpressed 
IgLONs are truly located on the cell surface, a phosphatidylinositol-phospholipase C (PI-PLC) 
assay could be carried out. PI-PLC is capable of specifically removing GPI-anchored 
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molecules such as IgLONs from the cell surface; hence, PI-PLC treatment of IgLON-
overexpressing cells should significantly affect physiological properties such as aggregation 
or the ability to downregulate RTKs. Secondly, presence/absence of RTKs on the cell 
membrane should be assessed as well. Pulse-chase experiments, e.g. using biotin-labelling 
of RTKs, could be carried out to compare the amount of surface RTKs between 
overexpressing/knockdown clones and their respective parental cell lines.  
To verify the hypothesis that LSAMP and NEGR1 directly bind to the RTKs they regulate, the 
preliminary interaction assays presented here need to be validated and extended. Both co-
IP and pull-down assays represent suitable options, particularly since generation of 
recombinant NEGR1 should be completed for use in additional assays as well (see 7.3). 
Through collaborations, e.g. with the Imperial College Facility for Imaging by Light 
Microscopy (FILM), other techniques such as FRET (Förster resonance energy transfer) could 
be employed to further investigate and validate the suggested direct interaction between 
IgLON family members and selected RTKs. 
To verify that endocytosis is indeed the main mechanism of IgLON-mediated RTK 
downregulation, assays inhibiting endocytotic processes could be carried out analogous to 
the MG-132 and cloroquine experiments described in this study for NEGR1-overexpressing 
cells. Agents such as DynaminII-K44A could be used to inhibit overall endocytosis; 
furthermore, to differentiate between different endocytotic pathways, selective inhibition 
(e.g. of non-clathrin raft caveolar pathways by filipin or nystatin) could provide additional 
insights into IgLON functioning. Since clathrin-mediated endocytosis preferentially leads to 
receptor recycling while clathrin-independent mechanisms result in degradation [Sigismund 
et al., 2008], determination of the precise pathway is crucial. Additionally, previous studies 
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on endocytosis of EGFR have shown that lower concentrations of EGF lead to internalisation 
via clathrin-mediated pathways, while higher concentrations result in use of both clathrin-
dependent and -independent mechanisms [Sigismund et al., 2005]; therefore, endocytosis 
inhibition assays should be carried out both with and without the presence of growth 
factors. These experiments are particularly interesting since LSAMP, NEGR1 and OPCML 
were found to be differently regulated upon growth factor stimulation, and it is hence 
possible that their response to growth factors determines the precise pathway employed for 
RTK downregulation. 
IFM could provide a vital tool to assess the precise intracellular steps within the proposed 
pathway of IgLON-mediated endocytotic downregulation of RTKs. Costaining with cav-1 as a 
marker for caveolae, and clathrin/Rab5A as a marker for clathrin-coated vesicles, could be 
used to identify the initial mechanism of cellular uptake, while assessment of markers for 
specific stages of endocytosis (e.g. EEA1 for early endosomes, Rab7/9 for late endosomes, 
and Rab11 for recycling endosomes) could provide information on the subsequent steps. 
Ideally, such experiments should be carried out using a time-lapse imaging approach, as 
colocalisation might only be very brief due to rapid downregulation of RTKs; therefore, 
steady-state images might not be able to reveal the full extent of colocalisation. 
To assess if RTK downregulation ultimately occurs via polyubiquitin-tagging and subsequent 
degradation in the proteasome, an ubiquitination-assay could be carried out as described 
previously for OPCML [McKie et al., 2012]: in brief, IgLON overexpressing cells as well as 
untransfected and empty vector controls were transfected with a hemagglutinin(HA)-tagged 
ubiquitin vector followed by co-IP using a HER2 antibody, and Western blotting to 
determine HA presence. 
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In addition to the spectrum of IgLON-regulated proteins presented in this study, the 
identification of further target proteins is crucial to fully understand the complexity of IgLON 
functioning. Expression and phosphorylation of further RTKs as well as downstream 
molecules should initially be analysed via Western blotting of lysates from IgLON-
overexpressing cells. Particularly for NEGR1, which was found to increase phosphorylation 
of Erk1/2 despite downregulation of a broad range of RTKs, additional pathways seem to 
play a role; therefore, investigation of molecules upstream of Erk (such as Ras, Raf or 
MEK/MAPK) could provide important clues. However, to investigate activation of different 
cellular signalling pathways on a larger scale, a RPPA (reverse phase protein array) screen 
should be considered. Similarly to Western blotting, RPPA screens use antibodies to 
determine protein phosphorylation status, but in a high-throughput setup; thus, differences 
in several signal pathway activation between wildtype and IgLON-transfected cell lines could 
be assessed simultaneously. 
In order to determine further proteins which are potentially involved in IgLON functioning in 
addition to RTKs, a SILAC (stable isotope labelling by amino acids in cell culture) screen could 
be carried out. SILAC screens are able to detect differences in protein abundance between 
different cell types, e.g. IgLON-transfected clones and their respective untransfected 
parental cell line, by maintaining them on medium containing amino acids labelled with 
different isotopes. Therefore, this method could be used to both confirm the results 
obtained in this study as well as identify additional proteins with altered expression levels in 
NEGR1- or LSAMP-overexpressing/-silenced cells compared to untransfected controls. Such 
a screen has previously been undertaken for OPCML in collaboration with the University of 
Queensland (Brisbane, Australia) and predominantly identified lipid raft-associated proteins 
like flotillin-1 and -2 as well as caveolin-1 to be differentially regulated in OPCML-
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expressing/-nonexpressing cell lines, thus underlining the protein’s role in clathrin-
independent endocytosis (unpublished data; Emily Chater, MRes thesis “Investigating the 
role of membrane-associated proteins identified from lipid raft proteomics in the function 
of the OPCML tumour suppressor”, Imperial College London, 2012). It would be interesting 
to see if a similar spectrum of proteins is affected by overexpression or knockdown of the 
other IgLON family members. 
 
7.3) Investigation of Clinical Implications 
To address the potential clinical implications of the IgLON family in EOC, additional 
recombinant proteins should be produced analogous to rOPCML, which showed a similar 
degree of RTK downregulation as exogenously overexpressed OPCML both in vitro and in 
vivo. Initially, it should be assessed if rLSAMP and rNEGR1 proteins have similar effects on 
physiological properties such as proliferation, migration, or colony-formation as exogenous 
overexpression; furthermore, their impact on RTK expression and phosphorylation needs to 
be addressed. If promising results can be obtained, in vivo experiments similar to those 
described for rOPCML should be considered [McKie et al., 2012]. As NEGR1 seems to be able 
to downregulate EGFR – which has been shown to be unaffected by OPCML – recombinant 
NEGR1 could play a particularly important role not only in EOC but also in treating EGFR-
dependent tumours such as lung cancer or glioblastomas. 
In the context of platinum-resistance, IC50 assays should initially be used to assess if 
exogenous IgLON overexpression leads to an increase in platinum sensitivity compared to 
untransfected and empty vector control cells in vitro; previous results in our group have 
shown that this is the case for OPCML. It could then be determined if treatment of 
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untransfected ovarian cancer cells with a combination of rIgLON and cisplatin has a similar 
effect as transfection; if so, this would not only imply that simultaneous application of both 
agents could lead to reduction of the cisplatin dose used as first-line treatment in EOC 
patients, but also that treatment with an rIgLON/cisplatin combination could result in a 
significantly increased treatment success rate upon relapse. In addition to cisplatin, IC50 
values for RTK inhibitors frequently used in chemotherapy-resistant EOC should be 
determined with and without the presence of rIgLONs, to assess if a synergistic effect can be 
observed for this type of treatment as well. 
 
7.4) Further Assays 
To address other potential physiological functions of the IgLON family apart from their role 
in RTK regulation, a wide variety of additional assays could be employed. Since IgLONs are 
extracellular molecules and were initially implicated in cell adhesion and guidance, 
aggregation, adhesion and invasion assays should be carried out to gain a deeper 
understanding of the role of IgLONs in these processes in the context of cancer. 
Furthermore, IgLONs have frequently been shown to predominantly function as homo- or 
heterodimeric complexes termed DigLONs [Reed et al., 2004]; therefore, cell lines co-
transfected with two or more IgLONs (e.g. transfection of OPCML-overexpressing BKS2.1 
cells with NEGR1) should be generated to see if the observed effects on RTK regulation or 
physiological properties differ from singular IgLON overexpression. 
Additionally, one of the most surprising findings of this study was the frequently observed 
intracellular, sometimes even nuclear, localisation of LSAMP and NEGR1 in 
immunofluorescence microscopy experiments. While this might be due to the antibody 
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issue described for LSAMP, further investigation of these findings is nonetheless warranted 
as a previous study on renal carcinomas identified LSAMP presence within the cytoplasm as 
well [Chen et al., 2003a]. Additionally, relocation of ALCAM, another member of the IgCAM 
family, from the cell surface into the cytoplasm has been associated with reduced cell 
anchorage as well as tumour progression in EOC [Mezzanzanica et al., 2008]. 
Overexpression of tagged versions of LSAMP and NEGR1 could be suitable methods to 
validate the proteins’ precise cellular localisations in immunofluorescence microscopy 
experiments. 
Finally, the question of IgLON secretion could be addressed. In previous studies, several 
IgCAMs have been implicated in secretion, either through secretory vesicles or cleavage by 
ADAM17/TACE on the cell surface [Gutwein et al., 2005; Maetzel et al., 2009]. Furthermore, 
protein variants of CEPU-1 (neurotrimin) lacking the C-terminal section, therefore being 
secreted instead of attached to the cell surface via a GPI-anchor, have been identified in 
chicken [Lodge et al., 2001]; similar C-terminal deletions were observed in in silico analyses 
for neurotrimin in this project as well. Additionally, the reported differences in the IgLON 
signalling sequences between different isoforms could lead to secretion of a subset of IgLON 
proteins. Therefore it is possible that IgLONs represent a new group of biomarkers which 
could facilitate reliable and early detection of EOC. Thus far, these assumptions are highly 
speculative, but certainly worthy of further investigation. 
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Table 12: Description of cell lines. 
Information mainly retrieved from [Bartlett, 2000]. †: Cell lines were maintained in RPMI-1640 (10% FCS, 2 mM 
L-Glutamine added) at 37 °C and 5% CO2 unless indicated otherwise. #: Only protein lysates available. CCC: 
clear cell carcinoma; HGS: high-grade serous carcinoma; C = cisplatin; FU = 5-fluorouracil; CHL = chlorambucil; 
Pred = prednimustine; T = thiotepa; Cy = cyclophosphamide; Adr = adriamycin; Zeo: zeocin; P/S: 
penicillin/streptomycin. 
Cell line Histology Source Prior Treatment Cisplatin Maintenance† Remarks 
A2780     Serous  None Sensitive P/S optional   
ES2 CCC 
(endometrioid?) 
      McCoy's 5A + 10% FCS, 
1.5 mM L-G,P/S optional# 
  
IGROV1 Mainly 
endometrioid 
 None Sensitive P/S optional Tumour contained some undifferentiated 
and serous clear cells; [Benard et al., 1985]. 
KK CCC       P/S optional#   
KOC7C CCC       P/S optional#   
OSE-C2 Ovarian surface 
epithelium 
      33 °C SV40-transformed immortalised “normal” 
ovarian surface epithelium (OSE) cell line 
[Davies et al., 2003]. 
OV90 Serous       P/S optional   
OVCAR3 CCC (?) Ascites C/Cy/Adr Resistant P/S optional  [Hamilton et al., 1983] 
OVCAR4 Adenocarcinoma Ascites C/Cy/Adr   P/S optional   
OVCAR5 Endometrioid Ascites None   P/S optional   
OVISE CCC   Yes, unknown   P/S optional   
OVTOKO CCC       P/S optional#   
PEA1 Poorly 
differentiated 
adenocarcinoma 
(HGS) 
Pleural None Sensitive P/S optional Isogenic pair with PEA2; established before 
onset of platinum resistance [Langdon et al., 
1988]. 
PEA2 Poorly 
differentiated 
adenocarcinoma 
(HGS) 
Ascites C/Pred Resistant P/S optional Isogenic pair with PEA1; established 6 
months after PEA1 at relapse [Langdon et 
al., 1988]. 
PEO1 Serous (HGS) Ascites C/FU/CHL Sensitive P/S optional Isogenic pair with PEO4 and PEO6 [Langdon 
et al., 1988]. 
PEO14 Serous (HGS) Ascites None Sensitive P/S optional Isogenic pair with PEO23; established before 
onset of platinum resistance [Langdon et al., 
1988]. 
PEO23 Serous (HGS) Ascites C/CHL Resistant P/S optional Isogenic pair with PEO14; established 7 
months after PEO14 at relapse [Langdon et 
al., 1988]. 
PEO4 Serous (HGS) Ascites C/FU/CHL Resistant P/S optional Isogenic pair with PEO1 and PEO6; 
established 10 months after PEO1 [Langdon 
et al., 1988]. 
PEO6 Serous (HGS) Ascites C/FU/CHL Resistant P/S optional Isogenic pair with PEO1 and PEO4; 
established 3 months after PEO4 [Langdon 
et al., 1988]. 
RMG1 CCC       P/S optional   
SKOBS 3.5 see SKOV3       125 µg/ml Zeo SKOV3 cells stably transfected with 
OPCML/pcDNA3.1 vector; OPCML 
expression approx. 2-fold increased 
compared to OSE-C2. 
SKOBS 
BKS 2.1 
see SKOV3       125 µg/ml Zeo SKOV3 cells stably transfected with 
OPCML/pcDNA3.1 vector; OPCML 
expression approx. 30-fold increased 
compared to OSE-C2. 
SKOBS 
V1.2 
see SKOV3       125 µg/ml Zeo Empty vector (pcDNA3.1) control, OPCML 
expression negligible. 
SKOV3  Serous 
(endometrioid/ 
CCC?) 
Ascites T Resistant P/S optional  
SMOV2 CCC       P/S optional   
TOV21G CCC       1:1 of MCDB105 medium 
and Medium 199; 15% 
FCS; P/S optional# 
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Table 13: LSAMP siRNA information. 
For sequences, see Table 3, page 88. All sequences were purchased from Sigma. 
siRNA Catalogue Number 
MISSION® siRNA 1 SASI_Hs01_00225585 
MISSION® siRNA 2 SASI_Hs01_00225586 
MISSION® siRNA 3 SASI_Hs01_00225587 
siRNA P From Pasic et al. [Pasic et al., 2010] 
siRNA I Custom design 
siRNA E Custom design 
 
 
 
Table 14: NEGR1 siRNA information. 
For sequences, see Table 4, page 89. All sequences were purchased from Sigma. 
siRNA Catalogue Number 
MISSION® siRNA 1 SASI_Hs02_00368666 
MISSION® siRNA 2 SASI_Hs01_00235047 
MISSION® siRNA 3 SASI_Hs01_00235048 
 
 
 
 
Figure 70: pLKO.1 vector map. 
pLKO.1 vector (Sigma) was purchased both as an empty vector as well as constructs containing LSAMP shRNA 
sequences (see Table 5, page 90). pLKO.1 contains an ampicillin resistance gene (ampR) for bacterial, and a 
puromycin resistance gene (puroR) for mammalian selection. 
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Table 15: LSAMP shRNA information. 
LSAMP shRNA hairpin sequences (Sigma) were expressed from pLKO.1 vector (see Figure 70). For sequences, 
see Table 5, page 90. *: TRC number: unique library identifier assigned by The RNAi Consortium (TRC, 
www.broadinstitute.org/rnai/public/). 
siRNA TRC Number* Supplier 
33 TRCN0000063933 Sigma 
34 TRCN0000063934 Sigma 
35 TRCN0000063935 Sigma 
36 TRCN0000063936 Sigma 
37 TRCN0000063937 Sigma 
 
 
 
 
 
Table 16: 50X TAE buffer composition. 
TAE buffer was diluted to 1X prior to use in agarose gel electrophoresis. 
Volume Final concentration Reagent 
242.28 g 2 M Tris  
57.1 ml  5.71% Acetic Acid 
18.6 g 63.64 mM EDTA  
Adjust volume to 1 l with dH2O. 
 
 
 
 
 
              
Figure 71: NEGR1-pReceiver-M10 (A) and EX-NEG-pReceiver-M10 (B) vector maps. 
pReceiver-M10 vectors were used for transient and stable NEGR1 overexpression experiments, either in cells 
overexpressing NEGR1 (A) or as empty vector controls (B). Both contain an ampicillin resistance gene for 
bacterial, and a neomycin (geneticin) resistance gene for mammalian selection. 
A) B) 
pReceiver-M10 
6705 bp 
EX-NEG-pReceiver-M10 
5658 bp 
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Figure 72: pSecTag2 A,B,C vector map. 
pSecTag2 contains an ampicillin resistance gene for bacterial, and a zeocin resistance gene for mammalian 
selection. 
 
 
             
Figure 73: pGEM®-T Easy (A) and pcDNA™4/TO (B) vector maps. 
pGEM®-T Easy (A) was used for initial cloning and transformation experiments, while pcDNA™4/TO (B) was 
used for subcloning and DNA production. pGEM®-T Easy contains an ampicillin resistance gene for bacterial 
selection and the lacZ gene for expression of β-galactosidase. pcDNA™4/TO contains both an ampicillin 
resistance gene for bacterial selection, and a zeocin resistance gene for mammalian selection. 
 
 
 
5159 bp 
A) B) 
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Figure 74: pGEX-6P-2 (A) and pHisTrx (B) vector maps. 
pGEX-6P-2 (A) and pHisTrx (B) were used for recombinant protein production. pGEX-6P-2 attaches a GST tag to 
the expressed protein, while pHisTrx attaches a 6xHis/thioredoxin tag. 
 
 
Table 17: 2xYT medium composition. 
2xYT medium was used for incubation of bacterial cells after heat shock transformation or before IPTG-
induced protein overexpression. 
Volume Final concentration Reagent 
16 g 1.6% w/v Tryptone  
10 g 1% w/v Yeast Extract  
5 g 85.55 mM NaCl  
Dissolve in 800 ml dH2O and set pH to 7.0. Adjust volume to 1 l and autoclave. 
 
 
Table 18: LB-Broth composition. 
LB-Broth was used for general cultivation of bacterial cells, especially prior to DNA preparation. 
Volume Final concentration Reagent 
10 g 1% w/v Tryptone  
5 g 0.5% w/v Yeast extract  
10 g 171.11 mM NaCl  
Dissolve in 800 ml dH2O and set pH to 7.0. Adjust volume to 1 l and autoclave. 
 
 
 
A) B) 
 
pGEX-6P-2 
4985 bp 
pHisTrx 
3187 bp 
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Table 19: 1X co-IP lysis buffer composition. 
Co-IP lysis buffer was used to lyse cells prior to co-immunoprecipitation assays. 
Volume Final concentration Reagent 
1 ml 1% 10% Triton 
300 µl 150 mM 5 M NaCl 
500 µl 50 mM 1 M Tris, pH 8.8 
40 ul 2 mM 0.5 M EDTA, pH 8 
7.66 ml - dH2O 
Add 25x Complete Protease Inhibitor Cocktail (Roche) and 100x Phosphatase Inhibitor Cocktail 
(Calbiochem) fresh before use. 
 
 
 
Table 20: 1X SDS lysis buffer composition. 
SDS lysis buffer was used to harvest mammalian cells prior to Western blotting analysis. 
Volume Final concentration Reagent 
4 ml 66.67 mM 0.5 M Tris-HCl, pH 6.8  
6.4 ml 2.13% 10% SDS  
3.2 ml (4 g) 10.67% Glycerol  
16.4 ml - dH2O 
Pass through 0.2 µM filter. Add 25x Complete Protease Inhibitor Cocktail (Roche) and 100x 
Phosphatase Inhibitor Cocktail (Calbiochem) fresh before use. 
 
 
 
Table 21: SDS-PAGE gel composition. 
SDS-PAGEs were carried out using 10% resolving and 5% stacking gels. 
Stacking gel 
Volume Final concentration Reagent 
4.12 ml - dH2O 
1 ml 5% 30% Acrylamide (Acrylamide:Bis-Acrylamide 37.5:1) 
755 µl 126 mM 1 M Tris, pH 6.8 
60 µl 0.1% 10% SDS 
60 µl 0.1% 10% APS 
6 µl 0.1% TEMED 
Final volume for 2 gels: 6ml 
Resolving gel 
Volume Final concentration Reagent 
2.36 ml - dH2O 
1.6 ml 8% 50% sucrose (Sigma) 
3.33 ml 10% 30% Acrylamide (Acrylamide:Bis-Acrylamide 37.5:1) 
2.5 ml 375 mM 1.5 M Tris, pH 8.8 
100 µl 0.1% 10% SDS 
100 µl 0.1% 10% APS 
6 µl 0.06% TEMED 
Final volume for 2 gels: 10 ml 
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Table 22: 5X SDS-PAGE loading buffer composition. 
SDS-PAGE loading buffer was added to each sample to yield a final concentration of 1X. 
Volume Final concentration Reagent 
2.5 ml 0.25 M 1 M Tris, pH 6.8 
0.8 g  8% SDS 
5 ml 50% Glycerol 
4 mg 0.04% Bromophenol Blue 
0.62 g 0.2 M DTT 
Adjust volume to 10 ml with ddH2O 
 
 
 
Table 23: 10X SDS-PAGE running buffer composition. 
SDS-PAGE running buffer was diluted to 1X prior to use. 
Volume Final concentration Reagent 
30.2 g 250 mM Tris  
144.1 g 1.92 M Glycine  
100 ml 1% 10% SDS  
Adjust volume to 1 l with dH2O, adjust pH to 8.3. 
 
 
 
Table 24: 10X SDS-PAGE transfer buffer composition. 
SDS-PAGE transfer buffer was diluted to 1X and mixed with 20% methanol and 0.04% SDS prior to use. 
Volume Final concentration Reagent 
30.2 g 250 mM Tris  
144.1 g 1.92 M Glycine  
Adjust volume to 1 l with dH2O. After dilution to 1X, add 20% methanol and 0.04% SDS before use. 
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X. Appendix B: Supplementary Data for Introduction and Results 
Chapters 
 
 
OPCML         1 MGVC---GYLFLPWKCLVVVSLRLLFLVPTGVPV-RSGDATFPK-AMDNVTVRQGESATLRCTIDDRVT   64  
Neurotrimin   1 MGVC---GYLFLPWKCLVVVSLRLLFLVPTGVPV-RSGDATFPK-AMDNVTVRQGESATLRCTIDNRVT   64  
LSAMP         1 MVRR-----VQPDRKQLPLVLLRLLCLLPTGLPV-RSV--DFNR-GTDNITVRQGDTAILRCVVEDKNS   60  
NEGR1         1 MDMMLLVQGACCSNQWLAAVLLSLCCLLPSCLPAGQSV--DFPWAAVDNMMVRKGDTAVLRCYLEDGAS   67  
IgLON5        1 MPPP----APGARLRLLAAAALAGLAVISRGLLS-QSL--EFNS-PADNYTVCEGDNATLSCFIDEHVT   61  
 
Consensus     1 *             : *  . *    ::.  :   :*    *     **  * :*:.* * * :::  :   69  
 
 
OPCML        65 RVAWLNRSTILYAGNDKWSIDPRVIILVNTPTQYSIMIQNVDVYDEGPYTCSVQTDNHPKTSRVHLIVQ  133  
Neurotrimin  65 RVAWLNRSTILYAGNDKWCLDPRVVLLSNTQTQYSIEIQNVDVYDEGPYTCSVQTDNHPKTSRVHLIVQ  133  
LSAMP        61 KVAWLNRSGIIFAGHDKWSLDPRVELEKRHSLEYSLRIQKVDVYDEGSYTCSVQTQHEPKTSQVYLIVQ  129  
NEGR1        68 KGAWLNRSSIIFAGGDKWSVDPRVSISTLNKRDYSLQIQNVDVTDDGPYTCSVQTQHTPRTMQVHLTVQ  136  
IgLON5       62 RVAWLNRSNILYAGNDRWTSDPRVRLLINTPEEFSILITEVGLGDEGLYTCSFQTRHQPYTTQVYLIVH  130  
 
Consensus    70 : ****** *::** *:*  **** :      ::*: * :*.: *:* ****.** : * * :*:* *:  138  
 
 
OPCML       134 VPPQIMNISSDITVNEGSSVTLLCLAIGRPEPTVTWRHLSVKEGQGFVSEDEYLEISDIKRDQSGEYEC  202  
Neurotrimin 134 VSPKIVEISSDISINEGNNISLTCIATGRPEPTVTWRHISPK-AVGFVSEDEYLEIQGITREQSGDYEC  201  
LSAMP       130 VPPKISNISSDVTVNEGSNVTLVCMANGRPEPVITWRHLTPT-GREFEGEEEYLEILGITREQSGKYEC  197  
NEGR1       137 VPPKIYDISNDMTVNEGTNVTLTCLATGKPEPSISWRHISPS-AKPFE-NGQYLDIYGITRDQAGEYEC  203  
IgLON5      131 VPARIVNISSPVTVNEGGNVNLLCLAVGRPEPTVTWRQLRD----GFTSEGEILEISDIQRGQAGEYEC  195  
 
Consensus   139 *..:* :**. :::*** .:.* *:* *:*** ::**::       *  : : *:* .* * *:*.***  207  
 
 
OPCML       203 SALNDV-AAPDVRKVKITVNYPPYISKAKNTGVSVGQKGILSCEASAVPMAEFQWFKEETRLATG-LDG  269  
Neurotrimin 202 SASNDV-AAPVVRRVKVTVNYPPYISEAKGTGVPVGQKGTLQCEASAVPSAEFQWYKDDKRLIEG-KKG  268  
LSAMP       198 KAANEV-SSADVKQVKVTVNYPPTITESKSNEATTGRQASLKCEASAVPAPDFEWYRDDTRIN-S-ANG  263  
NEGR1       204 SAENDV-SFPDVRKVKVVVNFAPTIQEIKSGTVTPGRSGLIRCEGAGVPPPAFEWYKGEKKLFNG-QQG  270  
IgLON5      196 VTHNGVNSAPDSRRVLVTVNYPPTITDVTSARTALGRAALLRCEAMAVPPADFQWYKDDRLLSSGTAEG  264  
 
Consensus   208  : * * : .  ::* :.**:.* * . ..  .. *: . : **. .** . *:*:: :  :  .  .*  276  
 
 
OPCML       270 MRIENKGRMSTLTFFNVSEKDYGNYTCVATNKLGNTNASITLYGPGAVIDGVNSASRALACLWLSGTLL  338  
Neurotrimin 269 VKVENRPFLSKLIFFNVSEHDYGNYTCVASNKLGHTNASIMLFGPGAVSEVSNGTSRRAGCVWLLPLLV  337  
LSAMP       264 LEIKSTEGQSSLTVTNVTEEHYGNYTCVAANKLGVTNASLVLFRPGSVR-GINGSISLAVPLWLLAASL  331  
NEGR1       271 IIIQNFSTRSILTVTNVTQEHFGNYTCVAANKLGTTNASLPLNPPSTAQYGITGSADVLFSCWYLVLTL  339  
IgLON5      265 LKVQTERTRSMLLFANVSARHYGNYTCRAANRLGASSASMRLLRPGSLE---NSAPRPPGLLALLS-AL  329  
 
Consensus   277 : ::.    * * . **: ..:***** *:*:** :.**: *  *.:     ..:             :  345  
 
 
OPCML       339 AHF--------FIKF  345  
Neurotrimin 338 LHL--------LLKF  344  
LSAMP       332 LCL--------LSKC  338  
NEGR1       340 SSFTSIFYLKNAILQ  354  
IgLON5      330 GWL--------WWRM  336  
 
Consensus   346   :              360  
 
Figure 75: Amino acid sequence alignment of the IgLON family members including IgLON5. 
Alignment created using T-Coffee. Amino acid sequence alignment revealed a high degree of sequence 
similarity across the IgLON family. Conserved cysteine pairs, which form the Ig domains in all four molecules, 
are highlighted by arrows in blue (domain 1), green (domain 2), and red (domain 3). Consensus symbols: “*”: 
identical; “:”: conserved substitutions (same colour group); “.”: semi-conserved substitution (similar shapes).  
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 A) LSAMP 
LSAMP-002        ------------------------------LR------------LLCLLP--------TG 10 
LSAMP-201        ------------------------------MRTYWLHSVWVLGFFLSLFSL-------QG 23 
LSAMP-001        --------------------------MVRRVQPDRKQLPLVLLRLLCLLP--------TG 26 
LSAMP-006        MIVRLPQPCGTVSEKISSEVFSRNCAGGGSLRRKRKAGILEMVIFQLFHIHRSVSHGQQG 60 
                                               ::            :  :           * 
 
LSAMP-002        LPVRSVDFNRGTDNITVRQGDTAILRCVVEDKNSKVAWLNRSGIIFAGHDKWSLDPRVEL 70 
LSAMP-201        LPVRSVDFNRGTDNITVRQGDTAILRCVVEDKNSKVAWLNRSGIIFAGHDKWSLDPRVEL 83 
LSAMP-001        LPVRSVDFNRGTDNITVRQGDTAILRCVVEDKNSKVAWLNRSGIIFAGHDKWSLDPRVEL 86 
LSAMP-006        LPVRSVDFNRGTDNITVRQGDTAILRCVVEDKNSKVAWLNRSGIIFAGHDKWSLDPRVEL 120 
                 ************************************************************ 
 
LSAMP-002        EKRHSLEYSLRIQKVDVYDEGSYTCSVQTQHEPKTSQVYLIVQVPPKISNISSDVTVNEG 130 
LSAMP-201        EKRHSLEYSLRIQKVDVYDEGSYTCSVQTQHEPKTSQVYLIVQVPPKISNISSDVTVNEG 143 
LSAMP-001        EKRHSLEYSLRIQKVDVYDEGSYTCSVQTQHEPKTSQVYLIVQVPPKISNISSDVTVNEG 146 
LSAMP-006        EKRHSLEYSLRIQKVDVYDEGSYTCSVQTQHEPKTSQVYLIVQVPPKISNISSDVTVNEG 180 
                 ************************************************************ 
 
LSAMP-002        SNVTLVCMANGRPEPVITWRHLTPTGREFEGEEEYLEILGITREQSGKYECKAANEVSSA 190 
LSAMP-201        SNVTLVCMANGRPEPVITWRHLTPTGREFEGEEEYLEILGITREQSGKYECKAANEVSSA 203 
LSAMP-001        SNVTLVCMANGRPEPVITWRHLTPTGREFEGEEEYLEILGITREQSGKYECKAANEVSSA 206 
LSAMP-006        SNVTLVCMANGRPEPVITWRHLTPT----------------------------------- 205 
                 *************************                                    
 
LSAMP-002        DVKQVKVTVNYPPTITESKSNEATTGRQASLKCEASAVPAPDFEWYRDDTRINSANGLEI 250 
LSAMP-201        DVKQVKVTVNYPPTITESKSNEATTGRQASLKCEASAVPAPDFEWYRDDTRINSANGLEI 263 
LSAMP-001        DVKQVKVTVNYPPTITESKSNEATTGRQASLKCEASAVPAPDFEWYRDDTRINSANGLEI 266 
LSAMP-006        ------------------------------------------------------------ 
                                                                             
 
LSAMP-002        KSTEGQSSLTVTNVTEEHYGNYTCVAANKLGVTNASLVLFKRVLPTIPHPIQEIGTTVHF 310 
LSAMP-201        KSTEGQSSLTVTNVTEEHYGNYTCVAANKLGVTNASLVLFKRVLPTIPHPIQEIGTTVHF 323 
LSAMP-001        KSTEGQSSLTVTNVTEEHYGNYTCVAANKLGVTNASLVLFR------------------- 307 
LSAMP-006        ------------------------------------------------------------ 
                                                                             
 
LSAMP-002        KQKGPGSVRGINGSISLAVPLWLLAASLLCLLSKC 345 
LSAMP-201        KQKGPGSVRGINGSISLAVPLWLLAASLLCLLSKC 358 
LSAMP-001        ----PGSVRGINGSISLAVPLWLLAASLLCLLSKC 338 
LSAMP-006        ----------------------------------- 
 
 B) NEGR1 
NEGR1-001        MDMMLLVQGACCSNQWLAAVLLSLCCLLPSCLPAGQSVDFPWAAVDNMMVRKGDTAVLRC 60 
NEGR1-201        --MMLLVQGACCSNQWLAAVLLSLCCLLPSCLPAGQSVDFPWAAVDNMMVRKGDTAVLRC 58 
NEGR1-002        ------------------------------------------------------------ 
                                                                             
 
NEGR1-001        YLEDGASKGAWLNRSSIIFAGGDKWSVDPRVSISTLNKRDYSLQIQNVDVTDDGPYTCSV 120 
NEGR1-201        YLEDGASKGAWLNRSSIIFAGGDKWSVDPRVSISTLNKRDYSLQIQNVDVTDDGPYTCSV 118 
NEGR1-002        ------------------------------------------------------------ 
                                                                             
 
NEGR1-001        QTQHTPRTMQVHLTVQVPPKIYDISNDMTVNEGTNVTLTCLATGKPEPSISWRHISPSAK 180 
NEGR1-201        QTQHTPRTMQVHLTVQVPPKIYDISNDMTVNEGTNVTLTCLATGKPEPSISWRHISPS-- 176 
NEGR1-002        --------MQVHLTVQVPPKIYDISNDMTVNEGTNVTLTCLATGKPEPSISWRHISPSAK 52 
                         ************************************************** 
 
NEGR1-001        PFENGQYLDIYGITRDQAGEYECSAENDVSFPDVRKVKVVVNFAPTIQEIKSGTVTPGRS 240 
NEGR1-201        ------------------------------------------VAPTIQEIKSGTVTPGRS 194 
NEGR1-002        PFENGQYLDIYGITRDQAGEYECSAENDVSFPDVRKVKVVVNFAPTIQEIKSGTVTPGRS 112 
                                                            ***************** 
 
NEGR1-001        GLIRCEGAGVPPPAFEWYKGEKKLFNGQQGIIIQNFSTRSILTVTNVTQEHFGNYTCVAA 300 
NEGR1-201        GLIRCEGAGVPPPAFEWYKGEKKLFNGQQGIIIQNFSTRSILTVTNVTQEHFGNYTCVAA 254 
NEGR1-002        GLIRCEGAGVPPPAFEWYKGEKKLFNGQQGIIIQNFSTRSILTVTNVTQEHFGNYTCVAA 172 
                 ************************************************************ 
 
NEGR1-001        NKLGTTNASLPLNPPSTAQYGITGSADVLFSCWYLVLTLSSFTSIFYLKNAILQ 354 
NEGR1-201        NKLGTTNASLPLNPPSTAQYGITGSADVLFSCWYLVLTLSSFTSIFYLKNAILQ 308 
NEGR1-002        NKLGTTNASLPLNPPSTAQYGITGSADVLFSCWYLVLTLSSFTSIFYLKNAILQ 226 
                 ****************************************************** 
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 C) OPCML 
OPCML-001        MGVCGYLFLPWKCLVVVSLRLLFLVPTGVPVRSGDATFPKAMDNVTVRQGESATLRCTID 60 
OPCML-201        MGVCGYLFLPWKCLVVVSLRLLFLVPTGVPVRSGDATFPKAMDNVTVRQGESATLRCTID 60 
OPCML-002        -----------------------------------------MDNVTVRQGESATLRCTID 19 
OPCML-003        ------MYHPAYWVVFSATTALLFIP-GVPVRSGDATFPKAMDNVTVRQGESATLRCTID 53 
                                                          ******************* 
 
OPCML-001        DRVTRVAWLNRSTILYAGNDKWSIDPRVIILVNTPTQYSIMIQNVDVYDEGPYTCSVQTD 120 
OPCML-201        DRVTRVAWLNRSTILYAGNDKWSIDPRVIILVNTPTQYSIMIQNVDVYDEGPYTCSVQTD 120 
OPCML-002        DRVTRVAWLNRSTILYAGNDKWSIDPRVIILVNTPTQYSIMIQNVDVYDEGPYTCSVQTD 79 
OPCML-003        DRVTRVAWLNRSTILYAGNDKWSIDPRVIILVNTPTQYSIMIQNVDVYDEGPYTCSVQTD 113 
                 ************************************************************ 
 
OPCML-001        NHPKTSRVHLIVQVPPQIMNISSDITVNEGSSVTLLCLAIGRPEPTVTWRHLSVKEGQGF 180 
OPCML-201        NHPKTSRVHLIVQVPPQIMNISSDITVNEGSSVTLLCLAIGRPEPTVTWRHLSVKEGQGF 180 
OPCML-002        NHPKTSRVHLIVQVPPQIMNISSDITVNEGSSVTLLCLAIGRPEPTVTWRHLSVKEGQGF 139 
OPCML-003        NHPKTSRVHLIVQVPPQIMNISSDITVNEGSSVTLLCLAIGRPEPTVTWRHLSVKEGQGF 173 
                 ************************************************************ 
 
OPCML-001        VSEDEYLEISDIKRDQSGEYECSALNDVAAPDVRKVKITVNYPPYISKAKNTGVSVGQKG 240 
OPCML-201        VSEDEYLEISDIKRDQSGEYECSALNDVAAPDVRKVKITVNYPPYISKAKNTGVSVGQKG 240 
OPCML-002        VSEDEYLEISDIKRDQSGEYECSALNDVAAPDVRKVKITVNYPPYISKAKNTGVSVGQKG 199 
OPCML-003        VSEDEYLEISDIKRDQSGEYECSALNDVAAPDVRKVKITVNYPPYISKAKNTGVSVGQKG 233 
                 ************************************************************ 
 
OPCML-001        ILSCEASAVPMAEFQWFKEETRLATGLDGMRIENKGRMSTLTFFNVSEKDYGNYTCVATN 300 
OPCML-201        ILSCEASAVPMAEFQWFKEETRLATGLDGMRIENKGRMSTLTFFNVSEKDYGNYTCVATN 300 
OPCML-002        ILSCEASAVPMAEFQWFKEETRLATGLDGMRIENKGRMSTLTFFNVSEKDYGNYTCVATN 259 
OPCML-003        ILSCEASAVPMAEFQWFKEETRLATGLDGMRIENKGRMSTLTFFNVSEKDYGNYTCVATN 293 
                 ************************************************************ 
 
OPCML-001        KLGNTNASITLY---------GPGAVIDGVNSASRALACLWLSGTLLAHFFIKF 345 
OPCML-201        KLGNTNASITLYEISPSSAVAGPGAVIDGVNSASRALACLWLSGTLLAHFFIKF 354 
OPCML-002        KLGNTNASITLY---------GPGAVIDGVNSASRALACLWLSGTLLAHFFIKF 304 
OPCML-003        KLGNTNASITLY---------GPGAVIDGVNSASRALACLWLSGTLLAHFFIKF 338 
                 ************         ********************************* 
 
 D) Neurotrimin 
NTM-009        ------------------------------------------------------------ 
NTM-202        MKTIQPKMHNSISWAIFTGLAALCLFQGVPVRSGDATFPKAMDNVTVRQGESATLRCTID 60 
NTM-002        MKTIQPKMHNSISWAIFTGLAALCLFQGVPVRSGDATFPKAMDNVTVRQGESATLRCTID 60 
NTM-001        MGVCGYLFLPWKCLVVVSLRLLFLVPTGVPVRSGDATFPKAMDNVTVRQGESATLRCTID 60 
NTM-003        MGVCGYLFLPWKCLVVVSLRLLFLVPTGVPVRSGDATFPKAMDNVTVRQGESATLRCTID 60 
NTM-008        MGVCGYLFLPWKCLVVVSLRLLFLVPTGVPVRSGDATFPKAMDNVTVRQGESATLRCTID 60 
NTM-201        ---------MNGKRNGEGGKRWKWKGTGVPVRSGDATFPKAMDNVTVRQGESATLRCTID 51 
NTM-014        ------------------------------------------------------------ 
NTM-020        ------------------------------------------------------------ 
NTM-013        ------------------------------------------------------------ 
                                                                             
 
NTM-009        ------------------------------------------------------------ 
NTM-202        NRVTRVAWLNRSTILYAGNDKWCLDPRVVLLSNTQTQYSIEIQNVDVYDEGPYTCSVQTD 120 
NTM-002        NRVTRVAWLNRSTILYAGNDKWCLDPRVVLLSNTQTQYSIEIQNVDVYDEGPYTCSVQTD 120 
NTM-001        NRVTRVAWLNRSTILYAGNDKWCLDPRVVLLSNTQTQYSIEIQNVDVYDEGPYTCSVQTD 120 
NTM-003        NRVTRVAWLNRSTILYAGNDKWCLDPRVVLLSNTQTQYSIEIQNVDVYDEGPYTCSVQTD 120 
NTM-008        NRVTRVAWLNRSTILYAGNDKWCLDPRVVLLSNTQTQYSIEIQNVDVYDEGPYTCSVQTD 120 
NTM-201        NRVTRVAWLNRSTILYAGNDKWCLDPRVVLLSNTQTQYSIEIQNVDVYDEGPYTCSVQTD 111 
NTM-014        ------------------------------------------------------------ 
NTM-020        ------------------------------------------------------------ 
NTM-013        ------------------------------------------------------------ 
                                                                             
 
NTM-009        ------------------------------------------------------------ 
NTM-202        NHPKTSRVHLIVQVSPKIVEISSDISINEGNNISLTCIATGRPEPTVTWRHISPKAVGFV 180 
NTM-002        NHPKTSRVHLIVQVSPKIVEISSDISINEGNNISLTCIATGRPEPTVTWRHISPKAVGFV 180 
NTM-001        NHPKTSRVHLIVQVSPKIVEISSDISINEGNNISLTCIATGRPEPTVTWRHISPKAVGFV 180 
NTM-003        NHPKTSRVHLIVQVSPKIVEISSDISINEGNNISLTCIATGRPEPTVTWRHISPKAVGFV 180 
NTM-008        NHPKTSRVHLIVQVSPKIVEISSDISINEGNNISLTCIATGRPEPTVTWRHISPKAVGFV 180 
NTM-201        NHPKTSRVHLIVQVSPKIVEISSDISINEGNNISLTCIATGRPEPTVTWRHISPKAVGFV 171 
NTM-014        ------------------------------------------------------------ 
NTM-020        ------------------------------------------------------------ 
NTM-013        ------------------------------------------------------------ 
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NTM-009        ------------------------------------------------------------ 
NTM-202        SEDEYLEIQGITREQSGDYECSASNDVAAPVVRRVKVTVNYPPYISEAKGTGVPVGQKGT 240 
NTM-002        SEDEYLEIQGITREQSGDYECSASNDVAAPVVRRVKVTVNYPPYISEAKGTGVPVGQKGT 240 
NTM-001        SEDEYLEIQGITREQSGDYECSASNDVAAPVVRRVKVTVNYPPYISEAKGTGVPVGQKGT 240 
NTM-003        SEDEYLEIQGITREQSGDYECSASNDVAAPVVRRVKVTVNYPPYISEAKGTGVPVGQKGT 240 
NTM-008        SEDEYLEIQGITREQSGDYECSASNDVAAPVVRRVKVTVNYPPYISEAKGTGVPVGQKGT 240 
NTM-201        SEDEYLEIQGITREQSGDYECSASNDVAAPVVRRVKVTVNYPPYISEAKGTGVPVGQKGT 231 
NTM-014        ------------------------------------------------------------ 
NTM-020        ------------------------------------------------------------ 
NTM-013        ------------------------------------------------------------ 
                                                                             
 
NTM-009        --------XSAEFQWYKDDKRLIEGKKGVKVENRPFLSKLIFFNVSEHDYGNYTCVASNK 52 
NTM-202        LQCEASAVPSAEFQWYKDDKRLIEGKKGVKVENRPFLSKLIFFNVSEHDYGNYTCVASNK 300 
NTM-002        LQCEASAVPSAEFQWYKDDKRLIEGKKGVKVENRPFLSKLIFFNVSEHDYGNYTCVASNK 300 
NTM-001        LQCEASAVPSAEFQWYKDDKRLIEGKKGVKVENRPFLSKLIFFNVSEHDYGNYTCVASNK 300 
NTM-003        LQCEASAVPSAEFQWYKDDKRLIEGKKGVKVENRPFLSKLIFFNVSEHDYGNYTCVASNK 300 
NTM-008        LQCEASAVPSAEFQWYKDDKRLIEGKKGVKVENRPFLSKLIFFNVSEHDYGNYTCVASNK 300 
NTM-201        LQCEASAVPSAEFQWYKDDKRLIEGKKGVKVENRPFLSKLIFFNVSEHDYGNYTCVASNK 291 
NTM-014        ----------------MNGKRNGEGGKRWKWKGT-------------------------- 18 
NTM-020        ----------------MNGKRNGEGGKRWKWKGTGVPVRSGDATFPKAMDNV-------- 36 
NTM-013        ----------------MNGKRNGEGGKRWKWKGTGVPVRSGDATFPKAMDNVTVRQGESA 44 
                                :.**  ** *  * :.                            
 
NTM-009        LGHTNASIMLFELNEPTSSTLLQEVKTTALTPWKGPGAVSEVSNGTSRRAGCVWLLPLLV 112 
NTM-202        LGHTNASIMLF------------EVKTTALTPWKGPGAVSEVSNGTSRRAGCVWLLPLLV 348 
NTM-002        LGHTNASIMLF-----------------------GPGAVSEVSNGTSRRAGCVWLLPLLV 337 
NTM-001        LGHTNASIMLF-----------------------GPGAVSEVSNGTSRRAGCVWLLPLLV 337 
NTM-003        LGHTNASIMLF-----------------------GETVL--------------------- 316 
NTM-008        LGHTNASIMLF------------EVKTTALTPWKGPGAVSEVSNGTSRRAGCVWLLPLLV 348 
NTM-201        LGHTNASIMLF------------EVKTTALTPWKGPGAVSEVSNGTSRRAGCVWLLPLLV 339 
NTM-014        ------------------------------------------------------------ 
NTM-020        ------------------------------------------------------------ 
NTM-013        TLRCTIDNRVTRVAWLNRSTILYAGNDKWCLDPRVVLLSNTQTQYSIEIQNVDVYDEGPY 104 
                                                                             
 
NTM-009        LHLLLKF----------------------------------------------------- 119 
NTM-202        LHLLLKF----------------------------------------------------- 355 
NTM-002        LHLLLKF----------------------------------------------------- 344 
NTM-001        LHLLLKF----------------------------------------------------- 344 
NTM-003        ------------------------------------------------------------ 
NTM-008        LHLLLKF----------------------------------------------------- 355 
NTM-201        LHLLLKF----------------------------------------------------- 346 
NTM-014        ------------------------------------------------------------ 
NTM-020        ------------------------------------------------------------ 
NTM-013        TCSVQTDNHPKTSRVHLIVQVSPKIVEISSDISINEGNNISLTCIATGRPEPTVTWRHIS 164 
                                                                             
 
NTM-009        --------------------------- 
NTM-202        --------------------------- 
NTM-002        --------------------------- 
NTM-001        --------------------------- 
NTM-003        --------------------------- 
NTM-008        --------------------------- 
NTM-201        --------------------------- 
NTM-014        --------------------------- 
NTM-020        --------------------------- 
NTM-013        PKAVGFVSEDEYLEIQGITREQSGDYE 191 
 
Figure 76: Amino acid sequence alignments of IgLON isoforms. 
IgLON isoforms were identified using the Ensembl database (www.ensembl.org) and aligned using ClustalW2 
(www.ebi.ac.uk/Tools/msa/clustalw2). Signal peptides (yellow), domains (1: green; 2: grey; 3: pink) and 
propeptides (blue) were assigned based on the UniProt database (www.uniprot.org). Signal peptide 
modifications and C-terminal insertions represented the most frequent variations. Consensus symbols: “*”: 
identical; “:”: conserved substitutions (same colour group); “.”: semi-conserved substitution (similar shapes). 
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Table 25: Alignment scores for full-length IgLON protein sequences. 
Scores determined using ClustalW2. Amino acid sequences of all four IgLON family members were aligned, 
revealing the highest identity score for OPCML and neurotrimin, and the lowest score for NEGR1 and 
neurotrimin. 
Sequence A Length [amino acids] Sequence B Length [amino acids] Score [%] 
OPCML 345 Neurotrimin 344 76 
LSAMP 338 NEGR1 354 55 
LSAMP 338 Neurotrimin 344 55 
OPCML 345 LSAMP 338 53 
OPCML 345 NEGR1 354 46 
NEGR1 354 Neurotrimin 344 45 
 
 
Table 26: Alignment scores for IgLON protein domain sequences. 
Scores determined using ClustalW2. Alignment of the three Ig domains of all four IgLONs revealed that 
sequence identity is much higher between domains at the same position (top of the table, grey) than between 
domains at different positions (bottom of the table, white). Numbers in brackets represent domain position, 
numbers behind brackets represent amino acids corresponding to the respective domain. 
Sequence A Length [amino acids] Sequence B Length [amino acids] Score [%] 
OPCML(1)39-126 88 HNT(1)39-126 88 90 
OPCML(2)136-219 84 HNT(2)136-218 83 69 
OPCML(3)223-310 88 HNT(3)222-309 88 69 
OPCML(2)136-219 84 LSAMP(2)132-214 83 62 
LSAMP(2)132-214 83 HNT(2)136-218 83 60 
NEGR1(2)139-221 83 HNT(2)136-218 83 60 
OPCML(1)39-126 88 LSAMP(1)29-122 94 59 
LSAMP(1)29-122 94 HNT(1)39-126 88 59 
LSAMP(2)132-214 83 NEGR1(2)139-221 83 59 
LSAMP(1)29-122 94 NEGR1(1)38-134 97 58 
OPCML(2)136-219 84 NEGR1(2)139-221 83 57 
OPCML(1)39-126 88 NEGR1(1)38-134 97 55 
LSAMP(3)219-304 86 NEGR1(3)225-313 89 55 
NEGR1(1)38-134 97 HNT(1)39-126 88 52 
LSAMP(3)219-304 86 HNT(3)222-309 88 48 
OPCML(3)223-310 88 LSAMP(3)219-304 86 46 
OPCML(3)223-310 88 NEGR1(3)225-313 89 44 
NEGR1(3)225-313 89 HNT(3)222-309 88 44 
OPCML(1)39-126 88 NEGR1(2)139-221 83 22 
OPCML(2)136-219 84 HNT(1)39-126 88 22 
LSAMP(2)132-214 83 LSAMP(3)219-304 86 22 
LSAMP(2)132-214 83 NEGR1(3)225-313 89 22 
OPCML(1)39-126 88 OPCML(3)223-310 88 21 
OPCML(2)136-219 84 LSAMaP(3)219-304 86 21 
OPCML(2)136-219 84 NEGR1(3)225-313 89 21 
OPCML(2)136-219 84 HNT(3)222-309 88 21 
LSAMP(3)219-304 86 NEGR1(2)139-221 83 21 
OPCML(3)223-310 88 LSAMP(2)132-214 83 20 
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Sequence A Length [amino acids] Sequence B Length [amino acids] Score [%] 
OPCML(3)223-310 88 HNT(1)39-126 88 20 
LSAMP(1)29-122 94 NEGR1(3)225-313 89 19 
LSAMP(2)132-214 83 HNT(1)39-126 88 19 
LSAMP(3)219-304 86 HNT(2)136-218 83 19 
NEGR1(2)139-221 83 NEGR1(3)225-313 89 19 
NEGR1(2)139-221 83 HNT(1)39-126 88 19 
NEGR1(3)225-313 89 HNT(2)136-218 83 19 
OPCML(1)39-126 88 LSAMP(2)132-214 83 18 
OPCML(3)223-310 88 LSAMP(1)29-122 94 18 
LSAMP(1)29-122 94 LSAMP(2)132-214 83 18 
LSAMP(1)29-122 94 HNT(3)222-309 88 18 
LSAMP(2)132-214 83 HNT(3)222-309 88 18 
NEGR1(2)139-221 83 HNT(3)222-309 88 18 
HNT(2)136-218 83 HNT(3)222-309 88 18 
OPCML(1)39-126 88 OPCML(2)136-219 84 17 
OPCML(2)136-219 84 OPCML(3)223-310 88 17 
OPCML(2)136-219 84 LSAMP(1)29-122 94 17 
OPCML(1)39-126 88 LSAMP(3)219-304 86 16 
OPCML(3)223-310 88 NEGR1(2)139-221 83 16 
LSAMP(3)219-304 86 HNT(1)39-126 88 16 
OPCML(2)136-219 84 NEGR1(1)38-134 97 15 
OPCML(3)223-310 88 HNT(2)136-218 83 15 
LSAMP(1)29-122 94 HNT(2)136-218 83 15 
NEGR1(1)38-134 97 NEGR1(2)139-221 83 15 
HNT(1)39-126 88 HNT(2)136-218 83 15 
OPCML(1)39-126 88 NEGR1(3)225-313 89 14 
OPCML(1)39-126 88 HNT(2)136-218 83 14 
OPCML(3)223-310 88 NEGR1(1)38-134 97 14 
NEGR1(1)38-134 97 HNT(2)136-218 83 14 
NEGR1(1)38-134 97 HNT(3)222-309 88 14 
NEGR1(3)225-313 89 HNT(1)39-126 88 12 
OPCML(1)39-126 88 HNT(3)222-309 88 11 
NEGR1(1)38-134 97 NEGR1(3)225-313 89 11 
HNT(1)39-126 88 HNT(3)222-309 88 11 
LSAMP(3)219-304 86 NEGR1(1)38-134 97 9 
LSAMP(1)29-122 94 LSAMP(3)219-304 86 8 
LSAMP(1)29-122 94 NEGR1(2)139-221 83 7 
LSAMP(2)132-214 83 NEGR1(1)38-134 97 6 
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Table 27: Alignment scores for IgLON protein domain sequences 1, 2 and 3 separately. 
Comparing the three Ig domains of all four molecules separately, domains 1 and 2 showed a significantly 
higher average sequence identity across the whole family than domain 3. Numbers in brackets represent 
domain position, numbers behind brackets represent amino acids corresponding to the respective domain. 
 Sequence A 
Length 
[amino acids] 
Sequence B 
Length 
[amino acids] 
Score 
[%] 
Average 
Score [%] 
D
o
m
ai
n
 1
 
OPCML(1)39-126 88 HNT(1)39-126 88 90 
62.2 
OPCML(1)39-126 88 LSAMP(1)29-122 94 59 
LSAMP(1)29-122 94 HNT(1)39-126 88 59 
LSAMP(1)29-122 94 NEGR1(1)38-134 97 58 
OPCML(1)39-126 88 NEGR1(1)38-134 97 55 
NEGR1(1)38-134 97 HNT(1)39-126 88 52 
D
o
m
ai
n
 2
 
OPCML(2)136-219 84 HNT(2)136-218 83 69 
61.2 
OPCML(2)136-219 84 LSAMP(2)132-214 83 62 
LSAMP(2)132-214 83 HNT(2)136-218 83 60 
NEGR1(2)139-221 83 HNT(2)136-218 83 60 
LSAMP(2)132-214 83 NEGR1(2)139-221 83 59 
OPCML(2)136-219 84 NEGR1(2)139-221 83 57 
D
o
m
ai
n
 3
 
OPCML(3)223-310 88 HNT(3)222-309 88 69 
51.0 
LSAMP(3)219-304 86 NEGR1(3)225-313 89 55 
LSAMP(3)219-304 86 HNT(3)222-309 88 48 
OPCML(3)223-310 88 LSAMP(3)219-304 86 46 
OPCML(3)223-310 88 NEGR1(3)225-313 89 44 
NEGR1(3)225-313 89 HNT(3)222-309 88 44 
 
 
